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 Cascade radical cyclizations have been employed in the synthesis of several novel 
analogs of camptothecin and luotonin A. The mild conditions of the cyclization allowed for the 
synthesis of a wide variety of analogs with high functional group tolerance in a modular fashion. 
 The asymmetric synthesis of a pyridone lactone, a key intermediate in Lavergne and 
Bigg’s synthesis of (R)-hCPT, is described. The synthesis furnished the product in good 
enantiopurity (96% ee) in eleven synthetic steps starting from commercially available 2-
methoxypyridine. The key reactions in this synthesis are Sharpless asymmetric epoxidation and 
Corey-Stille coupling.  
Attempts towards a more efficient synthesis of the DE-fragment of (R)-hCPT which were 
not successful, but led to the synthesis of novel non-lactone analogs of camptothecin are 
discussed. These non-lactone analogs contain either a cyclic ether or an α,β-unsaturated lactone 
in place of the α-hydroxy-δ-lactone as the E-ring of camptothecin. Despite possessing interesting 
structural features, these analogs were shown to be biologically inactive in the topo I inhibition 
assays as well as cell growth inhibition studies. 
 The semi-synthesis and biological evaluation of E-ring open form analogs of 
camptothecin was developed. This analog synthesis evolved from an interesting report by 
Stewart and coworkers of the X-ray crystal structure of topo I-DNA-topotecan ternary complex. 
Amongst the six open form analogs synthesized, the hydrazides showed activity comparable to 
 iv
that of camptothecin in the DNA cleavage assays. This activity may be due to the reclosure to 
camptothecin under the assay conditions.  
 20-Fluorocamptothecin was accidentally discovered upon fluorination of the tertiary 
alcohol of CPT with DAST at −78 °C. This discovery led to the stereoselective total synthesis of 
racemic, 20R- and 20S-fluorocamptothecin. It was concluded from the biological data that the 
fluorination occurred with inversion of configuration. 
 The total synthesis of luotonin A, a recently isolated topo I poison, and its analogs using 
the radical cascade cyclization strategy, was accomplished. A concise, modular approach was 
undertaken for the synthesis of all the analogs of luotonin A. This exercise would provide more 
insight into the structure-activity relationships of this new drug candidate. 
 The development of camptothecin analogs with interesting biological properties and 
differing mainly in the D, E rings was the central theme of the research work described in this 
thesis. Knowledge acquired from this research can be used for future discovery and development 
of potential drug candidates. 
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1. BACKGROUND 
 
1.1. Camptothecin 
One of the primary causes for deaths in many parts of the world is cancer.1 “Cancer” is a 
general name for a condition in which abnormal cells grow in an uncontrolled manner. Cancer 
can invade and destroy healthy tissues and spread via the bloodstream and lymphatic system to 
other parts of the body. One of the efficient ways to treat cancer is by chemotherapy in which 
anti-cancer drugs are used to treat cancerous cells. Chemotherapy either kills or arrests the 
growth of cancerous cells by targeting specific parts of the cell growth cycle. A wide variety of 
compounds possessing chemotherapeutic properties have been isolated from natural substances 
like plants, fungi etc. Taxol is an excellent example of a plant-derived anticancer drug that has 
achieved tremendous success in cancer chemotherapy. Another important family of plant-derived 
anticancer drugs that has been the subject of considerable attention is that of the camptothecins 
(Figure 1.1). 
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Figure 1.1 Structure of (S)-Camptothecin 
 
Camptothecin (CPT) was isolated by Monroe Wall and Mansukh Wani in 1966 from the 
extracts of the Chinese tree Xi Shu (Camptotheca acuminata of the Nyssaceae family) and its 
1 
 chemical structure was established.2 Camptothecin exhibited promising antitumor activity 
against a wide range of solid tumors and this led to widespread attention.3 Camptothecin soon 
entered into clinical trials (Phase I and partially Phase II) in the late ‘60s. However, the clinical 
development of CPT was halted because of certain severe and unpredictable side effects such as 
haemmorhagic cystitis and myelosuppression.4 It was later learned that CPT failed because it 
was administered as the water-soluble sodium carboxylate form rather than the water-insoluble 
camptothecin itself. Unfortunately, this ring-opened carboxylate form of CPT is biologically 
inactive5 (Scheme 1.1). 
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Scheme 1.1 Hydrolysis of camptothecin at physiological pH 
 
In 1985, the molecular target of CPT, human DNA topoisomerase I, was identified.6 This 
result, coupled with the understanding of the failure of clinical trials of CPT, led to a dramatic 
increase in research efforts aimed at development of various analogues of CPT which would 
possess improved water solubility yet retain CPT’s unique mechanism of action. 
 
 
 
2 
 1.2. Mechanism of Action 
Topoisomerase I (topo I) is an enzyme that catalyzes the various topoisomerization 
reactions of DNA (e.g., relaxation/supercoiling, catenation/decatenation) by transient enzyme-
linked single-strand breaks.7 The primary function of topo I is believed to be the removal of 
excessive supercoils generated during processes like transcription, replication etc. 
DNA relaxation reaction by topo I occurs in three steps. First, a nucleophilic attack by the 
tyrosine hydroxyl group (#723 of human DNA topo I) on the 3′-phosphate of the phosphodiester 
linkage gives rise to an enzyme-linked single-strand break. Second, the phosphodiester linkage 
opposite to the transient break is believed to turn around to undergo the religation reaction. 
Third, the 5′-hydroxyl group nucleophilically attacks the tyrosyl phosphate to release the tyrosine 
residue from the phosphate. This constitutes the religation reaction. 
Biochemical studies have shown that CPT binds at the interface between the DNA and 
topo I and inhibits specifically the religation step in the cleavage/religation reaction. It has been 
learned that CPT binds neither the DNA nor the topo I alone,6 but rather interacts with the DNA-
topo I complex to form a reversible ternary complex termed as the “cleavable complex”. Based 
on the studies in a cell-free SV40 replication system by Hsiang and Liu, a replication fork 
collision model8 was proposed for the cytotoxicity of CPT as shown in Scheme 1.2. 
      3 
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Scheme 1.2 Mechanism of Action of Camptothecin (adapted from ref. 8) 
 
The reversible topo I-DNA-CPT ternary complexes are not lethal by themselves.  
However, collision occuring between this complex and the advancing replication fork leads to 
apoptosis.  Three biochemical events have been identified as occuring soon after the collision 
occurs. These are (a) formation of a double-strand break, (b) irreversible arrest of the replication 
fork, and (c) formation of topo-I linked DNA break at the site of collision. 
It has also been shown that this collision is potentially lethal only if the cleavable 
complex is formed on the strand complementary to the leading strand of DNA synthesis.9
 
4 
 1.3. Structure-Activity Relationships 
While efforts to elucidate the mechanism of action of CPT and its binding in the 
cleavable complex are important to understand its cytotoxicity, it is equally crucial to acquire 
knowledge about the various structure-activity relationships associated with CPT. CPT itself is 
not used as a drug for chemotherapy due to its poor blood stability and solubility resulting in loss 
of activity. Hence it was of considerable importance to determine if substitutions by various 
hydrophilic and lipophilic groups at different positions on the CPT structure would lead to 
suitable drug candidates.   
Considerable efforts of various research groups around the world have thrown light on 
the structure-activity relationships in CPT. It is now known that: 
• Only the 20S enantiomer is active.5a,6b,6d 
• The lactone form of E-ring in the CPT structure is crucial for activity. The open hydroxy-
carboxylate form of CPT is inactive (see Scheme 1.1). 
• Changes in the E-ring, for example, replacing lactone by lactam, removal of the 20-
hydroxy group, substituting a lactol for the lactone etc., resulted in inactivity with respect 
to topo I inhibition.5b 
Analogs bearing substituents at positions 7, 9, 10 and to some extent 11 either retained the 
activity of or showed enhanced activity than the parent CPT. Figure 1.2 proposed by Sawada and 
coworkers summarizes the overall understanding of structure-activity relationships of CPT.10
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Figure 1.2 Structure-Activity Relationships of various CPT derivatives (adapted from ref. 10) 
 
Two analogs of CPT, topotecan (Hycamptin®, Smithkline Beecham) and irinotecan 
(Camptosar®, Pharmacia-Upjohn), have been approved by the Food and Drug Administration 
(FDA) for clinical use in the United States. Topotecan is used for the treatment of cisplatin-
refractory ovarian carcinoma and for second-line therapy in small-cell lung cancer (SCLC) and 
irinotecan is used for the treatment of colorectal cancer.11
Recently, Stewart and co-workers reported the X-ray crystal structure of human 
topoisomerase I covalently joined to double-stranded DNA and bound to topotecan, a clinically 
approved analog of camptothecin (Figure 1.3).12 This crystal structure explains a number of 
structure-activity relationships of the camptothecin family of anticancer drugs. The ternary 
complex demonstrated that topotecan intercalates at the site of DNA cleavage and is stabilized 
by base-stacking interactions with both the upstream and the downstream base pairs. The 
6 
 topotecan, in effect, mimics a DNA base pair and occupies the same space as a base pair in the 
structure without the drug bound. 
   
   
Figure 1.3 Topotecan Binding as the (A) Closed Lactone and (B) Open Carboxylate (reproduced from ref. 12) 
   
The high functional group tolerance demonstrated at positions 7, 9 and 10 positions of 
CPT could also be explained because these positions face into the major groove of the DNA and 
modifications that improve solubility, stability etc. would not sterically interfere with the binding 
of the drug. Also, only one direct hydrogen bonding (20S hydroxyl hydrogen bonds to Asp 533) 
between the enzyme and topotecan was predicted by the structure model. The SAR studies have 
7 
 also concluded that 20R enantiomer was biologically inactive in vitro. This is because, according 
to the model, the 20R-hydroxyl would not be able to contact Asp 533 to participate in the 
hydrogen bonding and the 20R-ethyl group would create a steric hindrance with Asp 533 and 
Lys 532. 
The substitution of hydroxyl group with hydrogen atom (20-deoxy analog) would 
eliminate hydrogen bonding thus making the analog biologically inactive. Chloro or bromo 
substitution at the C20 position only partially eliminates the biological activity unlike the case of 
20-deoxy analog. This is because the E-ring opening to the carboxylate form is still allowed in 
the halocamptothecins and therefore water-bridged contacts of the 22-hydroxyl to Asn-722 and 
21-carboxylate oxygen to the P-Tyr-723 in the carboxylate model are still allowed. The lactam 
modification is also inactive due to the change in the hydrogen bond acceptor (OH) to a 
hydrogen bond donor (NH). Homocamptothecins are potent topo I poisons because the model 
reveals that there is sufficient space within the binding pocket to accommodate the slightly larger 
E-ring and the 20S-hydroxyl and the hCPT could maintain the critical Asp 533:20S hydroxyl 
hydrogen bonding. 
Several novel analogs of CPT have promising activity and are presently undergoing 
preclinical development. Some of them include exatecan (DX-8951f), rubitecan (9-NC), 9-
aminoCPT, lurtotecan (Figure 1.4).11,3e,h,i,j
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Figure 1.4 Various clinically relevant CPT analogs 
 
1.4. Various Total Syntheses of CPT 
Owing to the promising antitumor activity of CPT, many synthetic strategies have 
evolved over the last 3 decades aimed at preparing camptothecin.3i The total syntheses published 
thus far have focussed mainly on the synthesis of camptothecin itself, in both racemic and 
enantiopure forms. While several research groups have contributed to the synthesis of racemic 
CPT,13 the first synthesis of (S)-CPT was reported by Corey in 1975.14 This was followed by a 
host of total syntheses of (S)-CPT by Vollhardt, Wani and Wall, Tagawa, Comins and Ciufolini 
involving either a resolution strategy or an asymmetric synthesis.15 In 1996, Fortunak reported a 
novel intramolecular [4+2] cycloaddition strategy for the synthesis of (S)-CPT.15f More recently, 
Snieckus and coworkers reported a convergent synthesis of the ABCD ring system of 
camptothecin using a combination of directed ortho metalation and Negishi cross-coupling 
reactions.15g
9 
 Most of these syntheses are not amenable to the preparation of a wide variety of known 
and new CPT analogs. The radical cascade cyclization strategy in the synthesis of CPT 
developed in the Curran group16 (Scheme 1.3) stands as an elegant example in overcoming this 
problem. This strategy, in addition to being modular in nature, is tolerant to a variety of 
functional groups present in the molecule. 
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Scheme 1.3 [4+1] Radical Cascade Cyclization Strategy 
 
The key [4+1] radical annulation step is interesting because the pentacyclic skeleton in 
CPT is assembled in this step by the coupling of DE fragment (iodopyridone) 1 and the A-ring 
(isonitrile) 4 in one single reaction by a tandem radical cyclization. The accepted mechanism of 
this [4+1] radical annulation/cyclization reaction is shown below (Scheme 1.4). 
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Scheme 1.4 Mechanism of the cascade radical cyclization 
 
Pyridonyl radical 3 is formed upon irradiation of 1 in the presence of hexamethylditin 2. 
Addition of 3 to the isonitrile 4 gives the corresponding iminoyl radical 5. This iminoyl radical 
undergoes a 5-exo radical cyclization to give the vinyl radical 6. Radical 6 adds on to the 
aromatic ring to give the cyclohexadienyl radical 7, which oxidatively rearomatizes to give the 
CPT skeleton. The synthesis of several analogs by this radical cascade cyclization approach is a 
testimony to the mildness and generality of the strategy. 
Shibasaki and coworkers have shown that the key iodopyridone intermediate in the 
Curran synthetic strategy of CPT could be obtained via an enantioselective cyanosilylation of a 
suitable ketone.17 More recently, Hecht and coworkers reported water-soluble camptothecin 
derivatives, 20-O-phosphate and phosphonates, that have inhibited topo I in an enzyme-
dependent fashion.18 Husson and coworkers synthesized racemic 17-methylcamptothecins by a 
partial synthesis starting from ajmalicine via a sequential oxidation steps and E-ring 
functionalization.19
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 1.5. Silatecans 
Originally, camptothecins were administered in vitro necessitating the water solubility of 
the drug. However, Knight and coworkers have shown that certain drugs delivered to the 
respiratory tract in a liposome formulation may have significant advantages over other modes of 
administration.6f Also, Burke and coworkers found out that increased lipophilicity of the analogs 
reduces the in vivo hydrolysis of the lactone form of CPT, leading to its improved blood stability 
without any loss in activity.6e This is thought to be due to a rapid intracellular drug accumulation 
and tissue distribution that favors lactone stabilization. Hence, in search of better drug 
candidates, it might prove to be beneficial to test for lipophilic analogs of CPT. 
 To test the effect of lipophilic analogs, a project aimed at developing various lipophilic 
analogs of CPT was undertaken in the Curran group in mid 1990s. During the course of these 
collaborative investigations with the late Prof. T. G. Burke and coworkers (University of 
Kentucky), it was found that silyl substitution at the 7-position of CPT increased the lactone 
concentration in the blood.20 This family of camptothecin analogs is now commonly referred to 
as silatecans. 
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Figure 1.5 Structure of DB-67 
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 Amongst all the silatecans synthesized, DB-67 showed the most promise. DB-67 (Figure 
1.5) displayed superior human blood stability when compared to topotecan, irinotecan and many 
other clinically relevant CPT analogues. DB-67 showed 25-fold increase in lipophilicity 
compared to CPT and is incorporated quite readily as the lactone form into cellular and 
liposomal bilayers. Accordingly it was found to possess comparable potency relative to CPT, 
topotecan and irinotecan. 
 More recently, work by Merlini and Zunino shows that lipophilicity is the main 
parameter correlated to cytotoxicity in the QSAR analysis of novel 7-oximinomethyl substituted 
camptothecins.21
1.6. Homocamptothecin and Homosilatecans 
The α-hydroxy-δ-lactone functionality in the E-ring was thought to be crucial for the 
activity of camptothecins. However, the discovery of homocamptothecin by Lavergne and Bigg 
in early 1997 (Figure 1.6) showed that alteration of the E-ring is possible while still maintaining 
the biological activity.22
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Figure 1.6 Structure of Homocamptothecin 
 
Homocamptothecin (hCPT) is an E-ring expanded analog of CPT. Structurally, this is the 
result of homologation of the α-hydroxy-δ-lactone of CPT by one methylene group thereby 
13 
 converting it into a β-hydroxy-δ-lactone. The advantage of hCPT over CPT is that the lactone is 
much less reactive (although not completely unreactive) due to the methylene spacer and hence 
less prone to any nucleophilic attack that might lead to the formation of the inactive open 
carboxylate form. 
 Homocamptothecin was synthesized by Lavergne and Bigg by a semi-synthetic approach 
(Scheme 1.5).22 Commercially available (S)-CPT was reduced with NaBH4 to the corresponding 
hydroxy lactol followed by an oxidative cleavage of the 1,2-diol with NaIO4 to give achiral 
ketone 8. This was subjected to a Reformatsky reaction with tert-butyl bromoacetate to give 
racemic 9 after an aqueous workup. Finally, 9 was converted to racemic hCPT (BN 80245) by 
treatment with TFA at room temperature. 
During the biological evaluation, hCPT was found to inhibit topo I mediated DNA 
relaxation with an activity comparable to that of CPT and, in addition, proved to be considerably 
more active (IC50 = 16.2 nM) in cell growth inhibition than both CPT (IC50 = 126 nM) and 
topotecan (IC50 = 601 nM) in the MTT assay.
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Scheme 1.5 Lavergne and Bigg’s semisynthetic approach to racemic hCPT 
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 Hence, on the one hand, CPT analogues with more lipophilic character (the silatecans, 
e.g., DB-67) help increase its potency and, on the other hand, homologation of the E-ring in CPT 
also leads to a more potent system than the parent CPT itself. It could be surmised that 
incorporation of both these features in an analog could lead to greater activity. This led to the 
development of 7-silylhomocamptothecins or homosilatecans. 
 Indeed, the homosilatecans have displayed markedly enhanced human blood stabilities 
relative to clinically relevant CPT analogs and are the most blood stable camptothecins to date.20 
The homosilatecans showed greater than 80% lactone levels following three hours of incubation 
in the human blood which is much greater than those exhibited by CPT (~5%) under the same 
conditions. Also the IC50 cytotoxicity values of the homosilatecans against MDA-MB-435 
tumorigenic metastatic human breast cancer cells were in the range of 20-100 nM.23
 Recent work in the Curran group focused on the development of new non-lactone analogs 
of CPT that might potentially be active and better drug candidates. As part of this work, a novel 
α-hydroxy keto-ether E-ring analog of CPT and hCPT, Du1441, was synthesized and 
biologically evaluated (Figure 1.7).24
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Figure 1.7 Structure of Du1441 
 
This analog combines the α-hydroxy carbonyl moiety of CPT with the seven-membered 
E-ring of hCPT. Despite these similarities, Du1441 was inactive in the preliminary biological 
15 
 studies. However, the search for non-lactone analogs continues because it has been suggested by 
current biological and computational studies that the lactone moiety is not opened during the 
binding of CPT to the topo-I-DNA complex leading to loss of any activity. 
 Homocamptothecin can be prepared by semi-synthetic approaches starting from 
commercially available (S)-CPT. However, these approaches are limited to the synthesis of the 
parent hCPT and a limited set of analogs. In contrast, a total synthesis broadens the scope in 
preparing a wider variety of analogs. A total synthesis of racemic hCPT was accomplished in late 
1990s by Lavergne and Bigg and coworkers.25 An asymmetric total synthesis of (R)-hCPT was 
developed recently in the Curran group which provided access to many of its analogs. In an 
effort to develop an asymmetric strategy to the synthesis of the key DE-fragment in the 
Lavergne-Bigg synthesis of hCPT, the Curran asymmetric strategy of synthesis of (R)-hCPT was 
employed successfully. The following chapter describes this synthesis after an introduction to the 
Lavergne-Bigg synthesis of racemic hCPT. 
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 2. ASYMMETRIC SYNTHESIS OF LAVERGNE-BIGG DE FRAGMENT OF (R)-
hCPT 
 
2.1. Introduction 
Homosilatecans have showed markedly enhanced human blood stabilities and cell growth 
and topo I inhibitory activity compared to CPT, topotecan and irinotecan. This biological activity 
is exhibited by only one enantiomer of hCPT. The absolute configuration of this enantiomer was 
initially postulated to be R on the presumption that CPT and hCPT have the same spatial 
arrangement of atoms at the stereocenter based on the stereospecific Topo I inhibition and 
positive rotation of polarized sodium D light. This postulate was later confirmed by the X-ray 
crystal structure analysis of the quinidium salt of (R)-23 (see Scheme 2.4).27 The biologically 
active counterpart of (S)-CPT is therefore (R)-hCPT, because homologation of the lactone 
changes the substituent priority according to the CIP nomenclature. 
Lavergne and Bigg achieved a concise semi-synthesis of racemic hCPT from CPT (see 
Scheme 1.5, Chapter 1). Following this, they disclosed the total synthesis of racemic hCPT in 
1998.20 The construction of the hCPT skeleton in this synthesis was based on Comins’ strategy 
of CPT synthesis:11e N-alkylation of 11 with bromide 10 with tBuOK/DME and subsequently 
closing the C ring in 12 by a Heck coupling reaction to give camptothecin (Scheme 2.1). 
Comins’ strategy was attractive because of the convergent nature of the synthesis and the ready 
access to various substituted quinolines.26
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Scheme 2.1 Comins’ strategy of synthesis of the CPT skeleton 
 
The Lavergne-Bigg synthesis of the DE-fragment 19 in the synthesis of hCPT is shown in 
Scheme 2.2. Protection of the pyridine ketone 13 as a ketal (not shown) followed by treatment 
with NaOMe in acetonitrile under reflux conditions gave substitution product 14. 
Methoxypyridine 14 was formylated by treatment with mesityllithium, followed by trapping of 
the resultant anion with DMF. The resulting aldehyde (not shown) was subsequently reduced by 
NaBH4 to the primary alcohol 15. This was then protected as the benzyl ether and the ketone was 
deprotected with TFA to afford 16. Reformatsky reaction of ketone 16 with t-butylbromoacetate 
under reflux conditions gave 17, which was debenzylated by catalytic hydrogenolysis and the 
resulting primary alcohol was subsequently lactonized by treatment with TFA to afford 18. The 
pyridine lactone 18 was finally demethylated in HCl under reflux conditions to give the desired 
DE pyridone-lactone 19 in 13% overall yield. 
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Scheme 2.2 Lavergne-Bigg synthesis of DE fragment of racemic hCPT22 
 
To make hCPT AB-ring analogs, various substituted quinolines were prepared by the 
Meth-Cohn protocol (Scheme 2.3).21 Acetanilides 20 were subjected to Vilsmeier conditions to 
give the intermediate 2-chloro-3-quinolinecarboxaldehydes (not shown). These aldehydes were 
reduced with NaBH4 to give AB quinolines 21. DE fragment 19 and the AB quinolines 21 were 
coupled together by a Mitsunobu reaction to give 22. Finally an intramolecular Heck reaction of 
22 afforded the pentacyclic racemic homocamptothecins. 
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Scheme 2.3 Final steps in the Lavergne-Bigg synthesis of racemic hCPT 
 
Lavergne and Bigg subsequently reported a total synthesis of (R)-hCPT by using a 
chemical resolution strategy (see Scheme 2.4).27 The Reformatsky adduct 17 was converted to 
the acid 23 by treatment with TFA (not shown). β-Hydroxy acid 23 was resolved with quinidine 
to give the desired (R)-enantiomer (R)-23 in 70% ee. This was subsequently converted to the 
pyridone (R)-19 in two steps (Scheme 2.4). Recrystallization of (R)-19 increased the ee to >99% 
which in 4 steps gave (R)-hCPT. 
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Scheme 2.4 Resolution strategy in Lavergne-Bigg synthesis of (R)-hCPT 
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 A major drawback of a resolution strategy in the preparation of enantiomerically pure 
compounds is that the maximum chemical yield cannot exceed 50%. This is unattractive from a 
practical standpoint especially when large quantities of the compound are required for biological 
evaluation. An efficient asymmetric total synthesis could surpass the limitations posed by both 
the semi-synthetic as well as the resolution strategies. 
Recently, the first asymmetric synthesis of (R)-hCPT developed in the Curran group by 
Dr. A. E. Gabarda provided access to a number of its analogs in >90% ee (see Schemes 2.7 & 
2.9: b series).28 The key bond constructing steps involved Corey modified Stille coupling 
reaction29 and Sharpless asymmetric epoxidation.30 Thus iodopyridine 30b was treated with vinyl 
stannane 31 in the presence of LiCl, CuCl and Pd(PPh3)4 in DMSO and the reaction mixture 
heated to 60oC to afford the Stille product 32b in 80% yield. The α,β-unsaturated ester 32b was 
readily reduced to the allylic alcohol 33b by treatment with LAH. Stoichiometric Sharpless 
asymmetric epoxidation on 33b gave the epoxide 34b in 79% yield and 90% ee. No reaction was 
observed when catalytic amounts of Ti(OiPr)4 and diethyltartrate were used. Epoxide 34b was 
then converted to lactone (R)-39 in 6 steps. 
 We set out to apply the asymmetric approach to the preparation of the key DE-fragment 
of the Lavergne-Bigg synthesis of (R)-hCPT in a highly enantiopure form. 
 
2.2. Asymmetric Synthesis of the Lavergne-Bigg DE Fragment 
In accordance with Dr. Gabarda’s strategy, the asymmetric synthesis of the Lavergne-
Bigg DE fragment commenced with the iodoformylation of 2-methoxypyridine 24a (Scheme 
2.5). Iodoformylation was performed following Comins’ ortho-directed metallation protocol.11e 
For this, pyridine 24b was ortho-lithiated by t-BuLi. Then addition of the formamide 26 followed 
21 
 by addition of n-BuLi and subsequently I2 gave aldehyde 28b. However, this procedure cannot 
be used with pyridine 24a because of the likelihood of competitive lithiation with butyllithium at 
the 6-position of the pyridine ring.31 This was not a concern with pyridine 24b because of the 
blocking provided by the TMS group at the 6-position. 
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Scheme 2.5 Initial iodoformylation reactions with 24a and 24b 
 
Quéguiner and coworkers have reported the selective ortho lithiation of 2-
methoxypyridine at the 3-position by using methyllithium in the presence of catalytic amounts of 
diisopropylamine.32 Scheme 2.6 shows the proposed roles of LDA and methyllithium in this 
reaction.. 
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Scheme 2.6 Quéguiner’s strategy of selective ortholithiation of 2-methoxypyridine 
 
Reaction of 2-methoxypyridine 24a with 1.8 equiv of MeLi in the presence of catalytic 
amounts of diisopropylamine results in a fast overall deprotonation to give 25a. The small 
amount of diisopropylamine generated reacts irreversibly with MeLi allowing constant 
regeneration of a small concentration of LDA, which shifts the equilibrium in favor of the lithio 
derivative 25a. This leads to an accumulation in the concentration of 25a before the electrophile 
is added.  
Based on this literature precedent, we treated 2-methoxypyridine 24a with methyllithium 
in the presence of 5 mol% of diisopropylamine. The resultant 3-lithio derivative was quenched 
with the formamide 26 to afford only the 3-formyl derivative (not shown). We then attempted the 
one-pot iodoformylation via this strategy as shown in Scheme 2.5.  
Treatment of 2-methoxypyridine 24a with methyllithium in the presence of 5 mol% of 
diisopropylamine was followed by addition of formamide 26. nBuLi was then added to this 
followed by addition of I2 to afford iodo aldehyde 28a. On a 1 mmol scale, 28a was obtained in 
73% yield after purification by column chromatography. The yield suffered, however, when the 
scale was raised to 19 mmol when only 40% product was isolated. Trapping of the initial lithio 
derivative 25a with the formamide 26 gave the α-amino alkoxide in situ (not shown). This, on 
addition of n-BuLi, resulted in the dianion 27a which on reaction with I2 gave the iodo aldehyde 
28a. Aldehyde 28a was reduced by NaBH4 to the corresponding alcohol 29a in 97% yield 
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 (Scheme 2.7). This was subsequently protected as a MOM ether using the standard protocol33 to 
afford 30a in quantitative yield. Intermediates 29a and 30a were used crude in the subsequent 
reactions. 
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Scheme 2.7 Preparation of the Sharpless asymmetric epoxidation precursor 
 
The necessary (E)-vinylstannane 31 for the Stille coupling was prepared by the procedure 
previously published by Piers and coworkers34 (Scheme 2.8). Reaction of the 
lithium(tributylstannyl)cyanocuprate (formed from treatment of Bu6Sn2 with n-BuLi  followed 
by addition of CuCN) with commercially available ethyl 2-pentynoate at –78 oC in THF gave the 
vinylstannane 31 in 85% yield after distillation at 140 oC under a pressure of 0.06 mm Hg. 
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Scheme 2.8 Preparation of ethyl (E)-3-(tributylstannyl)-2-pentenoate 
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 Stille coupling was achieved by first degassing the reaction vessel containing the mixture 
of LiCl, Pd(PPh3)4 and CuCl under high vacuum followed by an Ar purge (Scheme 2.7). Then 
DMSO, iodopyridine 30a and the vinylstannane 31 were added and the resulting mixture was 
degassed by the freeze-thaw process. The mixture was stirred at room temperature for 1 h and 
then at 60oC for 17 h to afford the Stille product 32a in 82% yield after column chromatography. 
The α,β-unsaturated ester 32a was readily reduced to the allylic alcohol 33a in 81% yield by 
treatment with LAH. 
 Sharpless asymmetric epoxidation (SAE) was successfully carried out on the allylic 
alcohol 33a (Scheme 2.9). Keeping in mind the poor results with catalytic SAE during the 
epoxidation studies in the preparation of (R)-hCPT and the subsequent success with the 
stoichiometric version, only the stoichiometric SAE was attempted.  
Thus, tBuOOH was added to a mixture of the allylic alcohol 33a, 4Å molecular sieves, 
diethyl-L(+)-tartrate and Ti(OiPr)4 at –20 oC in CH2Cl2. After 24 h at room temperature, the 
reaction was worked up, giving the epoxide 34a in 84% crude yield. The racemic epoxide was 
simultaneously prepared from reaction of the allylic alcohol 33a with mCPBA (not shown). 
Chiral HPLC analysis (using Chiralcel-OD column) of the epoxide 34a, with the racemate as the 
standard, showed the enantiomeric excess to be 96%. 
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Scheme 2.9 Completion of the asymmetric synthesis of (R)-19 and (R)-39 
 
Epoxide 34a was then converted the β-hydroxy carboxylic acid 37a in three steps with no 
purification of the intermediates. Reaction of epoxide 34a with LAH resulted in the 
regioselective opening of the epoxide to give 35a in 76% yield. Diol 35a was then oxidized to 
the aldehyde 36a with Dess-Martin periodinane.35 The resultant aldehyde was further oxidized to 
the β-hydroxy carboxylic acid 37a using NaClO2 in t-BuOH, buffered with an aqueous solution 
of NaH2PO4 in the presence of 2-methyl-2-butene in 75% crude yield (for 2 steps). 
 Treatment of this crude acid with TFA at room temperature resulted in an in situ 
deprotection of the MOM group followed by lactonization to give the pyridine lactone (R)-18 in 
80% yield. The crude product was used for the subsequent reaction. 
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  Completion of the synthesis was effected by the demethylation of the pyridine lactone 
(R)-18 by TMSI generated in situ, by the reaction of TMSCl and NaI in acetonitrile, at 65oC. The 
product, pyridone lactone (R)-19, was obtained in a low yield of 16%. No attempts of improving 
the reaction yield were made.  
 The enantiomeric excess of the lactone (R)-19 was presumed to be 96% since no 
synthetic steps affecting the stereocenter at C20 were involved after the Sharpless asymmetric 
epoxidation step. 
 
2.3. Summary 
The asymmetric synthesis of the pyridone lactone (R)-19, a key intermediate in Lavergne 
and Bigg synthesis of (R)-hCPT, was described. The synthesis furnished the product in an 
overall yield of 2.9% and with 96% ee in 11 steps starting from 2-methoxypyridine 24a. 
Sharpless asymmetric epoxidation and Corey-Stille coupling reactions, developed during the 
synthesis of (R)-hCPT, were utilized here for key bond constructions. The chemistry described in 
this chapter provides an easy access to the DE fragment thus establishing a direct route to the 
desired R enantiomer without having to resort to resolution strategies. 
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 3. NEW ASYMMETRIC APPROACHES TO THE DE-FRAGMENT OF (R)-hCPT 
AND SYNTHESIS OF NON-LACTONE E-RING ANALOGS OF CPT 
 
3.1. Introduction 
The first asymmetric synthesis of (R)-hCPT developed in the Curran group has been used 
to produce several analogs in highly enantioenriched form (ee > 90%).23 However, the synthesis 
employs stoichiometric quantities of the tartrate and Ti(OiPr)4 for the Sharpless asymmetric 
epoxidation to establish the requisite stereocenter. This might be a drawback for large scale 
preparation of the epoxide. Furthermore, sixteen steps are required to synthesize (R)-hCPT and 
its analogs starting from 2,6-dibromopyridine and the overall yield is about 0.6%. Realizing the 
need for improvement, we decided to look for a practical alternative route to the synthesis of (R)-
hCPT. 
An attractive approach to synthesize the DE-fragment of (R)-hCPT (R)-39 is to install the 
β-hydroxy carboxylic group via an asymmetric nucleophilic addition to the ketone 40 (Scheme 
3.1). This approach is more direct and addresses the problems raised by the current synthesis. 
The synthesis of enantioenriched tertiary alcohols by the addition of an organometallic 
reagent to prochiral ketones in the presence of a chiral catalyst is a formidable challenge. Several 
examples of preparing chiral tertiary alcohols in an indirect fashion (opening of an epoxide, C-H 
insertion into a secondary alcohol, etc.) are known.36 Diastereo- and enantioselective 
nucleophilic additions to ketones and pyruvate esters to generate chiral tertiary alcohols have 
been reported.37
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Scheme 3.1 Asymmetric Nucleophilic Addition Approach to Ketones Towards the DE-fragment of (R)-hCPT 
 
We initially attempted two strategies to access 43: (a) asymmetric allylation route, or (b) 
asymmetric enolate addition via the Reformatsky routes. Unfortunately, after considerable 
experimentation (Scheme 3.1) with the above methods following literature precedents, we failed 
to achieve satisfactory results.38 This chapter deals with the variety of alternatives we attempted 
to achieve a more efficient synthesis of the DE fragment of (R)-hCPT and the unexpected results 
leading to the synthesis of a small assortment of non-lactone analogs of CPT. 
 
3.2. Homologation Approaches to the Synthesis of the DE-Fragment of (R)-hCPT 
Asymmetric cyanosilylation reactions of ketones to give TMS-protected cyanohydrins 
have been studied by many research groups with Belokon, Deng, Hoveyda and Snapper making 
important contributions in this field.39 Shibasaki and coworkers had recently reported an 
asymmetric cyanosilylation of ketones in the presence of catalytic amounts of the bifunctional 
catalyst 44 and Ti(OiPr)4.40 The reaction is general and affords TMS-protected cyanohydrins in 
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 good enantioselectivities. An example of this reaction using Shibasaki’s conditions is shown in 
Scheme 3.2.  
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Scheme 3.2 Shibasaki's catalytic enantioselective cyanosilylation of ketones 
 
Following this work, Shibasaki and coworkers, in collaboration with Prof. Curran and Dr. 
Du, published the enantioselective synthesis of (S)-camptothecin with a modified version of the 
enantioselective cyanosilylation strategy13 (Scheme 3.3). 
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Scheme 3.3 Shibasaki's Enantioselective Eyanosilylation of Ketone 45 
 
Ketone 45 was reacted with TMSCN in the presence of the ligand 44 (9 mol%, see 
Scheme 3.2) and Sm(OiPr)3 (5 mol%) in propionitrile. The nitrile 46 was obtained in 98% yield 
and 84% ee.  
In considering ways to synthesize the DE-fragment of (R)-hCPT, we realized that nitrile 
46 could be used as an important intermediate. We envisioned a synthetic sequence in which 46 
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 or a derivative could be homologated by one carbon to the compound with the desired oxidation 
state 47, which could then be carried forward to make the DE lactone of (R)-hCPT (Scheme 3.4). 
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Scheme 3.4 Envisioned Synthesis of (R)-38 from Nitrile 46 
 
A few methods have been reported to homologate niriles to esters or other carboxylic 
acid derivatives (see Section 3.2.1.). Aldehyde 49 (Scheme 3.5) was determined to be best suited 
for the one-carbon homologation studies. We screened some of these known methods for 
reaction with the aldehyde 49. 
 
3.2.1. Synthesis of the Substrate 49 for Homologation Studies 
 
The synthesis of the homologation precursor 49 was accomplished according to some of 
the methods developed in the Curran group. Reduction of aldehyde 28b (Scheme 3.5, see also 
Scheme 2.7, Chapter 2) by NaBH4 gave the alcohol 29b in 89% yield. Protection of the crude 
alcohol 29b as a TBS ether with Corey’s procedure29 gave 48 in quantitative yield. Iodopyridine 
48 was then converted to the corresponding cuprate by treatment with iPrMgCl followed by 
addition of LiCl and CuCN.41 The cuprate was quenched with propionyl chloride to provide the 
TBS-ketone 45 in 71% yield after purification by column chromatography. 
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Scheme 3.5 Synthesis of the Homologation Substrate 49 
 
This TBS-ketone was transformed to the corresponding TMS-protected cyanohydrin rac-46 
in 87% yield with TMSCN in the presence of KCN and 18-crown-6. Reduction of the nitrile rac-
46 to the aldehyde 49 took place upon reaction with DIBAL at −30 °C to afford 49 in 55% yield. 
Aldehyde 49 was used as the substrate for all the subsequent homologation studies. 
 
3.2.2. Attempted Homologation of 49 with 1,3-Dithiane derived Phosphonate 
 
In the late 1970s, Jacobine and coworkers reported a procedure for one-carbon 
homologation of benzaldehyde by a modified Wittig reaction.42 Phosphonate esters were 
prepared by treatment of active methylene compounds with a suitable base and diethyl 
phosphorochloridate to form the corresponding olefins. We envisioned the use of 1,3-dithiane as 
the active methylene compound to afford our desired olefin 52 (Scheme 3.6), which upon acid 
treatment could be transformed to lactone 38 (see Scheme 3.4). 
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Scheme 3.6 Proposed Homologation of 49 with 1, 3-Dithiane Derived Phosphonate 51 
 
Accordingly, 1,3-dithiane 50 was treated with 2 equiv of LDA at −78 °C. The resulting 
anion was treated with diethyl phosphorochloridate at the same temperature to presumably afford 
the phosphonate anion 51. It was determined that 2 equiv of LDA was necessary since the 
product phosphonate is more acidic than the starting material 50. The phosphonate anion 51 was 
then trapped with aldehyde 49 at −40 °C. Unfortunately, the Wittig olefination product 52 was 
not observed as indicated by 1H NMR analysis; instead, ketone 45 was formed. The structure of 
the product 45 was confirmed by spectroscopic techniques. A plausible mechanism for the 
formation of the ketone 45 is shown in Scheme 3.7. 
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Scheme 3.7 Proposed Mechanism for the Generation of 45 in the Homologation of 49 with 51 
  
The addition of phosphonate anion 51 (see Scheme 3.6) to the aldehyde 49 results, 
presumably, in the formation of adduct 53. This is expected to undergo a regular Wittig 
olefination by extruding the corresponding phosphate to give 52. However, 53 undergoes a 1,4-
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 silyl shift to form the tertiary oxyanion 54. This can now undergo a sequence of steps, as shown 
by the movement of arrows, to liberate ketone 45 and β-phosphato acetaldehyde (not shown).  
Unfortunately, attempts to use a different base (e.g. nBuLi) or conduct the aldehyde 
addition at different temperatures (e.g. −40 °C, −15 °C) resulted in the formation of 45 and not 
52. We therefore decided to abandon this strategy in favor of a new one. 
 
3.2.3. Attempted Homologation using α-Aminoacetonitriles 
 
Takahashi and coworkers reported an interesting procedure for homologation of 
aldehydes to carboxylic acids in the early 1980s43 employing α-(N-methylanilino)acetonitrile 55. 
We expected that the reaction of 49 with 55 under Takahashi’s reaction conditions would 
produce 56 (Scheme 3.8). 
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Scheme 3.8 Proposed Homologation of 49 with an Aminoacetonitrile 55 
 
Potassium hydride was added to a mixture of the aldehyde 49 and the α-aminoacetonitrile 
5544 in THF at room temperature. However, no reaction occurred even after stirring overnight for 
14 h as indicated by TLC. In this case, both the starting materials remained unaffected (Table 
3.1). In an attempt to promote the addition, the reaction mixture was heated to 40 °C. This 
resulted in decomposition as indicated by TLC and 1H NMR analysis.  
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 Similar results were obtained when LDA or KHMDS in the presence of 18-crown-6 (1 
equiv or 2 equiv) was used as the base at room temperature. When nitrile 55 was treated with 
LDA and the resulting anion was quenched with D2O, a clean incorporation of deuterium in the 
alpha position of the nitrile was observed by 1H NMR spectrum. This indicates that the anion 
addition of 55 to the aldehyde 49 is the problematic step. 
 
3.2.4. Attempted Homologation using Tosylmethyl Isocyanide (TosMIC) 
 
The chemistry of tosylmethyl isocyanide (TosMIC) is well documented in the synthesis 
of heterocycles.45 In 1977, van Leusen and coworkers used TosMIC as a homologating agent 
from carbonyl compounds to nitriles.46
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Scheme 3.9 Reaction of Adamantanone with TosMIC 
 
For example, adamantanone 57 was reacted with 1.3 equiv of TosMIC in the presence of 
a strong base such as tBuOK to yield cyanoadamantane 58 in 93% yield. The proposed 
mechanism of the homologation of an aldehyde 59 with TosMIC is shown in Scheme 3.10. The 
key step of this reductive cyanation mechanism is the formation of the oxazoline anion 60 
following by the opening of the rearranged oxazoline 61 to 62. Formation of 63 from 62 is 
accompanied by the precipitation TosK. Hydrolysis of 63 with an alcohol leads to the cyano 
anion 64 along with the loss of formate ester and the resulting anion 64 is protonated to give the 
homologated nitrile 65. 
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Scheme 3.10 Proposed Mechanism of Reaction of TosMIC with an Aldehyde 
 
The proposed homologation procedure is shown in Scheme 3.11. Aldehyde 49 was added 
to the anion of TosMIC, generated by the treatment of TosMIC with a strong base such as 
tBuOK (1M solution in THF), and the reaction mixture was stirred at room temperature. 
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Scheme 3.11 Proposed Homologation of Aldehyde 49 with TosMIC 
 
However, no conversion of the starting material 49 was observed as shown by TLC 
(entry 1, Table 3.2). Instead, some unidentifiable material was observed in the 1H NMR 
spectrum. Suspecting the purity of tBuOK solution, we employed solid tBuOK under the same 
reaction conditions (entry 2). However, the result was identical to the previous case in that the 
same unidentifiable material was obtained. 
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Table 3.1 Homologation of Aldehyde 49 with TosMIC - Reaction Conditions 
 
  
 
 
  
 
   
 
 
 
 
 
 
 
*
 a) These reactions were done using recrystallized TosMIC. 
S. No. Reagents Solvent Temp. Comments 
1. 
2. 
3. 
4. 
 
5. 
6.a) 
7. a) 
8. a) 
tBuOK (liq) 
tBuOK (solid) 
tBuOK (solid) 
tBuOK (solid) 
+ H2O 
NaOEt 
tBuOK (solid) 
tBuOK (solid) 
tBuOK (solid) 
DMSO 
DMSO 
DME 
DME 
 
DME 
DME 
DME 
DME 
rt 
rt 
rt 
rt 
 
rt 
rt 
0oC 
-20oC 
Unidentified material 
Unidentified material 
45 (<10%) + unidentified mat. 
No intermediate trapped 
 
Multiple spots on TLC 
45 
45 
45 
 
We next decided to explore the solvent conditions. van Leusen and coworkers used 
DMSO, DME and HMPT in the reaction. Using DME as the solvent (entry 3), we were surprised 
to observe ketone 45 by 1H NMR, albeit in small amounts (<10%), along with a majority of 
unidentifiable material. In an effort to determine whether any intermediate compounds could be 
trapped, the reaction was repeated under the same conditions but quenched with H2O (entry 4) 
which could, in principle, trap the oxazoline or any one of the intermediates formed. 
Unfortunately, the 1H NMR spectrum of the crude product indicated the formation of multiple 
products and was not very informative. Changing the base to NaOEt (entry 5) resulted only in 
multiple products as indicated by TLC.  
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 Suspecting the quality of TosMIC, we recrystallized it from MeOH. The recrystallized 
TosMIC was had a sharp melting point at 112oC (lit. 116o-117oC).45 The purity of TosMIC was 
also confirmed by reacting cycloheptanone with TosMIC in the presence of tBuOK to afford 
cyanocycloheptane in 80% yield as reported.46
The initial reaction of TosMIC with 49 in the presence of tBuOK was repeated with the 
purified TosMIC at room temperature, 0 °C and −20 °C (entries 6, 7 and 8). In all the three cases, 
ketone 45 was the sole product of the reaction.  
The mechanism of the formation of 45 is presumed to be akin to that of the side reaction 
observed for the reaction of the 1,3-dithiane derived phosphonate 51 (see Schemes 3.6 & 3.7) 
with the aldehyde 49. This proposed mechanism is shown below in Scheme 3.12. 
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Scheme 3.12 Proposed Mechanism of Formation of 45 by Reaction of TosMIC with 49 
 
After the addition of the anion of TosMIC to the aldehyde 49, adduct 67 is presumably 
formed (Scheme 3.12). This adduct undergoes a TMS exchange reaction (as shown in Scheme 
3.10) to form the tertiary oxy anion 68 instead of forming the usual oxazoline. This can now 
undergo a sequence of steps, as shown by the movement of arrows, with the elimination of the 
tosyl group to liberate ketone 45 and α-isocyanoaldehyde (not shown).  
We suspected that this fragmentation behavior was exhibited often by aldehydes with an 
α-quaternary center bearing a TMS-protected tertiary alcohol, such as 49. To confirm this, 
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 aldehyde 70 was synthesized by treatment of tetralone 69 with TMSCN in presence of KCN and 
18-crown-6 followed by reduction of the resulting nitrile with DIBAL in an overall yield of 60% 
for two steps (Scheme 3.13). This aldehyde was then subjected to the TosMIC reaction 
conditions. As expected, the sole product of the reaction was α-tetralone 69, isolated in 
quantitative yield. 
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Scheme 3.13 Reaction of TosMIC on Test Substrate 70 
 
Other strategies such as the Wittig olefination of the aldehyde 49 have also yielded 
results similar to previously discussed examples and hence not discussed. However, one general 
observation was that the aldehyde 49 was too hindered and prone to undesirable side reactions 
which arose from the TMS group migration as discussed in Schemes 3.7 & 3.12. These 
discouraging results prompted us to abandon the homologation strategy in favor of an entirely 
new approach towards making the DE fragment of (R)-hCPT. 
 
3.3. Epoxidation/Dihydroxylation Approaches to the Synthesis of the DE Fragment of 
(R)-hCPT 
Synthesis of tertiary alcohols in good to excellent enantioselectivities, by Sharpless 
asymmetric epoxidation (SAE) or Sharpless asymmetric dihydroxylation (SAD) of olefins, is 
well documented.47 Accordingly, we decided to explore these Sharpless protocols to set the 
tertiary alcohol stereocenter (Scheme 3.14). 
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Scheme 3.14 Proposed Synthetic Routes to (R)-38 via Asymmetric Epoxidation or Dihydroxylation of 71 
 
Thus, enelactone 71 could be envisioned to undergo an SAE with a suitable chiral ligand 
to provide the epoxylactone 72 and the epoxide could be opened by SmI2 to afford the β-
hydroxylactone (R)-38. Alternatively, 71 could be enantioselectively dihydroxylated to give diol 
73, which could be deoxygenated using a literature protocol48 to give (R)-38. 
Previous research efforts in the Curran group directed towards the study of Sharpless 
asymmetric dihydroxylation of the enelactone 71 with commercially available AD-Mix reagents 
indicated modest yields and enantioselectivities.49 For example when 71 was subjected standard 
Sharpless conditions using DHQD-PYR as the chiral ligand, diol 73 was obtained in 48% yield 
and 67% ee as indicated by analysis by HPLC. On the other hand, the asymmetric epoxidation 
route was never previously attempted with 71. 
 
 
 
 
40 
 3.3.1. Synthesis of the Enelactone 71 
 
Enelactone 71 was previously prepared44 by the dehydration of racemic 38 with Burgess 
reagent (not shown). However, this procedure involves the synthesis of the racemic lactone first 
in several steps. To quickly access 71, we explored a metathesis approach, radical addition to an 
alkyne, Heck cyclization onto an alkene and Ni(II)/Zn catalyzed cyclization chemistry. We 
finally successfully utilized the Stille coupling in synthesizing 71.  
 
3.3.1.1. Attempted Synthesis of 71 by Metathesis Approach 
 
Olefin metathesis has evolved into a versatile and an important tool in synthetic organic 
chemistry.50 In particular, metathesis of enones to access α,β-unsaturated lactones was first 
reported by Fürstner and coworkers in 2000.51 They reported the synthesis of enelactones of ring 
sizes 5, 6 and 7 in good to excellent yields. 
Attempts to synthesize the trisubstituted olefin 71 by a metathesis of the corresponding 
acrylate and 1,1-disubstituted olefin 76 is shown in Scheme 3.15. The suitable substrate for the 
Grubbs metathesis, 76, was easily synthesized from the known ketone 45 by first methylenation 
with the commercially available Tebbe reagent to give the 1,1-disubstituted olefin 74 in 65% 
yield. Deprotection of the TBS group reveals the benzyl alcohol 75 in 60% yield. The alcohol 75 
was treated with acryloyl chloride in the presence of DMAP to obtain 76 in 68% yield. The other 
two metathesis substrates, 77 and 78, were also synthesized in a similar fashion using the 
appropriate acylating agent in 40% and 30% yields, respectively. 
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Scheme 3.15 Attempted Synthesis of 71 by Metathesis Approach 
 
We first conducted a control reaction to verify the purity and efficacy of the catalyst. 
Thus, 4-pentenyl ester of acrylic acid was treated with the Grubbs catalyst 79 under the standard 
metathesis reaction conditions (not shown). The product olefin was obtained in 44% yield with 
no other product derived from the starting ester validating the reagent purity. 
Acrylate 76 was treated with the 2nd generation Grubbs catalyst 79 in refluxing toluene 
(0.04 M) to effect an intramolecular metathesis reaction. However a TLC analysis showed 
predominantly the starting acrylate. No desired enelactone was detected either by TLC or 1H 
NMR spectroscopy. A number of reaction conditions, by varying the concentration and the 
temperature, were tested with 76, 77 and 78 to effect this transformation. 
Following the initial failure, we attempted the same metathesis conditions for the 
substrates 77 and 78. In both the cases, the substrates remained unreactive under these conditions 
presumably due to the increase in substitution on the olefins. Increasing the amount of the 
catalyst used with 78 resulted only in the recovery of the starting acrylates. 
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 We hypothesized that the presence of basic nitrogen in the pyridine ring inhibits the 
reaction to proceed. It is documented that free amines are incompatible with metathesis reactions 
owing to the inhibition of the catalyst by basic nitrogen.52 In order to circumvent a similar 
problem in their synthesis of halichlorine, Wright and coworkers conducted their metathesis 
reactions in the presence of p-toluenesulfonic acid to protonate the basic nitrogen in situ and 
allow the reaction to proceed. When olefin 76 was reacted with catalyst 79 in the presence of 
pTsOH, the reaction was messy with the starting material, an unidentified compound and a new 
compound (which was later identified as 80) as the major products. Since the catalyst was not 
inactivated in this reaction, we concluded that our initial hypothesis of catalyst inhibition by the 
pyridine nitrogen was false. 
We next changed the concentration of the reaction. Increasing the concentration of the 
reaction of 76 to 0.2 M with 20 mol% of the Grubbs catalyst in toluene at room temperature 
resulted in a new product. However, 1H NMR analysis revealed that this product was not the 
desired enelactone 71. Instead, we obtained the cinnamate ester 80, which is the metathesis 
product of the starting enone 76 and styrene, in 28% yield. Presumably, the catalyst 79, after 
forming the carbene with the α,β-unsaturated olefin, undergoes metathesis with the styrene that 
was released in the initial carbene formation (not shown) to form the cinnamate ester. The low 
yields of the cinnamate ester could be explained by the use of only 20 mol% of the catalyst. 
Increasing the concentration of the reaction mixture to 0.5 M, however, resulted in the same 
undesired product 80 in similar yields as above.  
Changing reaction conditions in the reaction with the Grubbs catalyst did not yield any 
desired olefin 71. We next employed the Schrock catalyst with our substrate 76. Although no 
reports of Schrock catalyst used for the metathesis of electron-deficient olefins have been 
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 documented, we decided to apply to our system. Accordingly, substrate 76 was reacted with 
Schrock catalyst (30 mol%) at 0.04 M concentration in toluene (entry 8). However, only the 
starting material remained completely unreactive to these conditions. Increasing the 
concentration to 0.1 M under identical conditions did not improve the reaction outcome either 
(entry 9). 
After these unsuccessful attempts to install the olefin by using the metathesis approach, 
we decided to abandon this strategy and investigate alternative methods for the preparation of the 
desired enelactone.  
 
3.3.1.2. Synthesis of 71 by Ni (II)/Zn Catalyzed Cyclization 
 
During the course of this work, Cheng and Rayabarapu described a one pot synthesis of 
7-membered α,β-unsaturated lactones by a Ni/Zn catalyzed regioselective cyclization of 2-
iodobenzyl alcohols with alkyl propiolates.53 The authors reported several examples of 
trisubstituted olefin products although no heteroaromatic substrates have been examined. 
We first checked the quality of our nickel catalyst in a control reaction of 2-iodobenzyl 
alcohol 81 and methyl 2-octynoate 82 with Ni(dppe)Cl2 complex in the presence of zinc powder 
at 80 °C. The product enelactone 83 was isolated in 82% yield (reptd. 81%) after 
chromatography. 
Iodoalcohol 29b and ethyl 2-pentynoate are the suitable substrates to access to 71 
(Scheme 3.16). Accordingly, 29b and ethyl 2-pentynoate were treated with Ni(dppe)Cl2 complex 
in the presence of zinc powder and the reaction mixture was heated in acetonitrile at 80 °C. The 
reaction mixture showed multiple products as observed by TLC. The desired compound 71 was 
isolated in a yield of 10% after a difficult column chromatography.   
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Scheme 3.16 Ni(II)/Zn Catalyzed Regioselective Cyclization of 29b 
 
The reaction parameters that were varied included the solvent, temperature and 
equivalents of the nickel catalyst. Since acetonitrile was the optimum solvent, we decided to 
change the solvent to propionitrile which can be used to conduct the reaction at higher 
temperatures as well. The temperature was varied between 80 °C and 110 °C. The catalyst 
equivalents were varied between 5 mol% and 1 equiv. Unfortunately, in all the cases, we 
observed multiple products as indicated by TLC. The 1H NMR spectra of the crude reaction 
mixtures (after workup) were identical to each other as well.  
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Scheme 3.17 Intramolecular Ni(II)/Zn Catalyzed Cyclization of 84 
 
An alternative to the above reaction conditions is the intramolecular variant shown in 
Scheme 3.17. We reasoned that predisposition of the second substrate would favor the product 
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 formation. Hence alkynyl ester 84 was subjected to the standard reaction conditions. The 
reaction mixture showed multiple products, as indicated by TLC, none of which was the desired 
product. Increasing the amount of the nickel catalyst added did not affect the outcome of the 
reaction.  
Failing Cheng’s cyclization protocol, we attempted other intramolecular strategies that 
can allow access to 71 such as intramolecular radical addition to 84 under Bu3SnH/AIBN 
conditions, Pd(0) promoted intramolecular Heck reaction conditions of the olefin variant of 84 
(not shown) etc. Unfortunately, none of these methods provided us the desired olefin 71 in any 
reasonable quantities.  
 
3.3.1.3. Synthesis of 71 using Stille Coupling 
 
Faced with multiple failures to synthesize 71, we decided to explore the Stille reaction. 
We had earlier made use of the Stille reaction in the total synthesis of (R)-hCPT (see Chapter 2). 
Iodopyridine 30b (Scheme 3.19, see also Scheme 2.7) was subjected to the Stille conditions in 
the presence of the vinyl stannane 31 as the coupling partner. A similar type of coupling can be 
envisioned en route to synthesize 71, albeit with the Z-variant of 31. 
The requisite vinyl stannane 85 was synthesized by the procedure that was previously 
published by Piers and coworkers (Scheme 3.18).34 The lithium(tributylstannyl)cyanocuprate, 
prepared from treatment of Bu6Sn2 with BuLi followed by the addition of CuCN, was reacted 
with commercially available ethyl 2-pentynoate at -78 °C in THF. The vinyl stannane 85 was 
obtained in 61% yield after distillation at 95-100 °C under a pressure of 0.7 mm of Hg. 
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Scheme 3.18 Preparation of Ethyl (Z)-3-(Tributylstannyl)-2-pentenoate 
 
The Stille coupling was conducted with iodopyridine 30b in moisture- and oxygen-free 
conditions. The reaction vessel was degassed under high vacuum followed by Ar purge after all 
the solid reagents (Pd(PPh3)4, LiCl and CuCl) were added and by the freeze-thaw process after 
the liquid reagents, DMSO and (Z)-vinylstannane 85, were added. The reaction mixture was 
heated to 60 °C under these Corey-modified conditions of reaction with 1,1-disubstituted 
vinylstannanes.29 The Stille product 86 was obtained in 90% yield after column chromatography. 
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Scheme 3.19 Synthesis of 71 by Stille Coupling 
 
With the α,β-unsaturated ester 86 in hand, the next step was lactonization with 
concomitant deprotection of MOM group to give the enelactone 71. Based on previous 
experience, our first choice of reagent for this transformation was TFA. Hence, an 0.4 M solution 
of ester 86 was treated with TFA and stirred at room temperature. This resulted in multiple 
products as detected by TLC. The desired enelactone 71 could be fished out of the crude reaction 
mixture in 15% yield after a difficult chromatography. Two other reactions of 86 with TFA were 
attempted in a similar fashion in higher and lower concentrations compared to the first reaction. 
Whilst the concentration variation did have an effect, it resulted only in poor yields of 71.  
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 We next conducted the reaction in the presence of camphor sulfonic acid. Unfortunately, 
only the starting material was recovered. When the ester 86 was reacted with Bu2BOTf, TLC 
indicated the presence of multiple products. Gratifyingly, however, when 86 was stirred for 30 
min with 1.5 equiv of pTsOH•H2O, the product enelactone 71 was obtained in a 63% yield after 
purification by flash column chromatography.  
We noticed that if the reaction time exceeds 30 min, we observed progressive decrease of 
reaction yields with time and also contamination of the reaction mixture with methyl 
toluenesulfonate (TsOMe). The by-product TsOMe was found to co-elute with the enelactone 71 
in many solvent combinations. The presence of TsOMe was confirmed by 1H NMR analysis 
combined with GC-MS analysis which clearly showed m/z peak corresponding to TsOMe. If the 
acid catalyzed cyclization is carried out for a period of 12 h or more, the reaction led to complete 
decomposition of the starting material and no desired product could be detected. 
 
3.3.1.4. Modeling and Variable Temperature NMR Studies of 71 
 
Spectroscopic analysis of the enelactone 71 revealed some interesting dynamic behavior. 
The two methylene protons on the lactone ring appeared as a broad peak at room temperature 
centered at 5.14 ppm in the 1H NMR spectrum. This indicated that the methylene protons are 
positioned in different chemical environments compared to one another giving rise to two 
individual resonances at low temperature and at room temperature, the methylene protons 
resonances average out and coalesce to form one broad peak. This behavior can also be observed 
with enelactone 83 from the supporting information of the report by Cheng and Rayabarapu53 
(see Scheme 3.16). We then decided to study this interesting behavior of 71 by modeling and 
variable temperature NMR studies.  
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Figure 3.1 MOE Images of the Predicted Lowest Energy Conformer of 71 (A) Front view (B) Side view 
 
To construct a model of 71, an in vacuo conformational search using the MMFF94x force 
field within the molecular mechanics package MOE54 was carried out. Two images of the 
predicted lowest energy conformer from this study are shown in Figure 3.1. The conformational 
search revealed a cluster of six lowest energy conformations (representing the different 
positioning of the groups TMS, ethyl and methoxy in space) all separated from the next highest 
energy cluster by a gap of 0.8 kcal.mol. This low energy conformation showed that the lactone 
portion of 71 is puckered (see Figure 3.1B). As a consequence, the two methylene protons are 
diastereotopic if the interconversion is slow on the NMR time scale. 
In order to quantitate this dynamic NMR behavior, we conducted variable temperature 
NMR studies on 71. Accordingly 1H spectra of a CDCl3 solution of 71 were recorded at 
temperatures ranging from −40 °C to 50 °C in increments of 10°. The spectra are shown in 
Figure 3.2. 
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Figure 3.2 Variable Temperature Proton NMR Studies of 71 
 
We observed that as the temperature was raised to 50 °C from room temperature, the 
broad peak corresponding to the methylene protons at 25 °C gradually sharpened to a singlet at 
5.13 ppm. Similarly when the temperature was decreased to −40 °C, the broad peak separates 
into two doublets at -10 °C (which are coupling partners with J = 12.4 Hz) at 5.51 and 4.78 ppm 
respectively.  
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 The coalescence temperature is the temperature at which the two doublets merge to 
become a broad singlet and this was estimated by inspection to be 15 °C. The rate of site 
exchange between the two conformations, kcoal, can be determined by the following equation,55
kcoal = ½ π √2 √(ν1 – ν2)2 + 6J2 
where J is the coupling constant of the two methylene protons with chemical shifts ν1 and ν2 
recorded in the units of Hz. Inserting the values of the variables in the equation above with the 
average coupling constant J = 12.4 Hz, the rate constant kcoal was determined to be 491 s-1 at the 
coalescence temperature of 15 °C. From this information, the free energy of activation for this 
exchange was calculated from the Eyring equation shown below,  
∆G‡ = RTc ln (hkcoal/kBTc) 
where Tc is the coalescence temperature, h is Planck’s constant and kB is Boltzmann’s constant. 
Plugging in the appropriate values into the above equation, the free energy of activation, ∆G‡, 
was determined to be −13.3 kcal mol-1. Thus the enelactone 71 was found to display the 
interesting behavior of conformational equilibrium with averaging of the two conformers at room 
temperature. 
With the desired enelactone 71 in hand, we next proceeded to explore the dihydroxylation 
and the epoxidation approaches to make the DE fragment (R)-38 (see Scheme 3.14). 
 
3.3.2. Dihydroxylations and Epoxidations of Olefin 71 
 
Investigations in the Curran group in the past have shown that the catalytic Sharpless 
asymmetric dihydroxylations of endocyclic α,β-unsaturated lactones were marred either with 
poor reactivity of the olefin or with good conversion but low enantioselectivities. In contrast, 
Sharpless dihydroxylations of exocyclic electron-deficient olefins have shown better selectivities 
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 and good conversions and yields. With this as the background, we first decided to investigate the 
reactivity with dihydroxylation of racemic 71. 
 
3.3.2.1. Dihydroxylation Studies of Olefin 71 
 
Several protocols were attempted to synthesize the racemic diol 73 with different Os 
sources, bases, oxidants etc. including OsO4/pyridine, KMnO4, OsO4/NMO etc. But in our 
hands, none of these well established reaction conditions were successful. We observed either 
the starting material or traces of the desired diol product 73. We then attempted conditions that 
mimic those of Sharpless asymmetric dihydroxylation reaction using the combination 
K2OsO2(OH)4/DABCO instead of the chiral ligand. This reaction showed traces of product rac-
73 along with large amounts of the starting material. 
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Scheme 3.20 Racemic and Asymmetric Dihydroxylation of 71 
 
Sharpless and coworkers reported in late ‘70s a dihydroxylation procedure that works 
even for trisubstituted and hindered olefins.47a Accordingly, 71 was reacted with OsO4 in the 
presence of Et4NOAc and t-butyl hydroperoxide at room temperature to afford the corresponding 
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 diol rac-73 in 75% yield after the usual workup followed by filtration through a pad of celite 
(Scheme 3.20). 
We then investigated the asymmetric dihydroxylation reaction of 71. Under standard 
Sharpless conditions along with different commercially available chiral ligands (DHQD)2-
PHAL, (DHQD)2-AQN gave unreacted starting material back (Scheme 3.20). Reaction with the 
ligand (DHQD)2-PYR gave a 16% yield of (S,S)-73 after 48 hours along with large amounts of 
starting material left unconsumed as indicated by the TLC. Increase in the amounts of the ligands 
or the Os source or using different Os sources did not improve the result. In conclusion, 
dihydroxylation strategy failed to provide a practical means to access lactone (R)-38. 
 
3.3.2.2. Epoxidation Studies of Olefin 71 
 
We decided to first investigate the reactivity pattern of our olefin 71 by studying the 
racemic epoxidation of this substrate. Olefin 71 was accordingly reacted with 30% H2O2 in the 
presence of 6N NaOH (Scheme 3.21). TLC analysis indicated the complete consumption of the 
starting olefin and the appearance of an intense polar product observed under a UV lamp. 
Unfortunately, none of the desired epoxide rac-72 was observed in the product mixture as 
analyzed by 1H NMR. Instead, the polar spot proved to be the rearranged acid 87 which was 
isolated in 88% yield after acidification of the crude reaction mixture with 1N HCl followed by a 
standard aqueous workup. The structure of 87 was confirmed by NMR and MS techniques. 
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Scheme 3.21 Racemic Epoxidation of 71 
 
We also observed that the same product 87 was obtained even in the absence of 30% 
H2O2 in otherwise identical reaction conditions. These two observations led us to propose the 
plausible mechanism for this unexpected rearrangement involving the hydroxide (Scheme 3.22). 
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Scheme 3.22 Plausible Mechanism of the Unexpected Rearrangement during Epoxidation of 71 
 
Thus, under the basic conditions the lactone is converted to the tetrahedral intermediate 
71a, which breaks down to give rise to the alkoxide 71b. This alkoxide undergoes a conjugate 
addition to the α,β-unsaturated acid and the resulting carboxylate dianion, after workup, gives 
the rearranged product 87. Other known procedures of epoxidation of electron-deficient olefins 
involving the use of NaOCl/neutral Al2O3, tBuOOH/DBU did not proceed well in our hands. In 
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 these cases either the unreacted starting material was obtained or the crude reaction mixture 
displayed an indiscernible 1H NMR spectrum.  
Knowing that the structure of 71 is puckered and that the olefin is slightly out-of-
conjugation with the lactone carbonyl moiety, we reasoned that 71 might behave more like a 
simple, unconjugated olefin. Hence we attempted reaction with mCPBA, DMDO to effect the 
epoxidation. However, in both the cases, only the starting olefin remained unreacted and none of 
the desired epoxide rac-72 was observed.  
In spite of the failure with the epoxidation strategy, we identified an interesting 
rearrangement occurring with the olefin 71. Capitalizing upon this unexpected result, we turned 
our attention to developing compounds such as 87 into novel non-lactone analogs of 
camptothecin. 
 
3.3.3. Novel Non-Lactone Analogs of Camptothecin – Synthesis 
 
Our interest in the development of non-lactone analogs of camptothecin arises from the 
recent interest shown in the area of E-ring modified camptothecin analogs. Lavielle and 
coworkers reported the synthesis and pharmacological evaluation of the first biologically active 
non-lactone analogs of camptothecin (Figure 3.3).56
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Figure 3.3 Novel Non-Lactone Analogs Reported by Lavielle 
 
They described a series of two different kinds of E-ring ketone derivatives 88 and 89 as 
shown in Figure 3.3. The topoisomerase inhibitory assay (with CPT and SN-38 as standards) and 
the cell-growth inhibitory assay (with L1210 leukemia cells) both indicated that the compounds 
showed reasonable activity (0.06-1.0 µM). In particular, the methylenedioxy derivative (R1, R2 = 
OCH2O) showed activity that was comparable to topotecan. 
With reference to non-lactone E-ring analogs, the Curran group had also reported the 
synthesis and biological evaluation of the keto-ether Du1441.24 Unfortunately, Du1441 did not 
show promise as a topo I poison. We carried through 87 into E-ring modified cyclic ether CPT 
derivatives (Figure 3.4). 
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Figure 3.4 Development of Cyclic Ether Analogs to Camptothecin Derivatives 
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 We planned to synthesize four non-lactone analogs with modifications on the 7 and 10 
positions of the A & B rings of the final derivatives. Our choices of substitution at the 7-position 
were H and TBS and at the 10-position were H and F. This selection for the initial set of 
compounds was based on previous knowledge in the Curran group in this area. Silyl substitution 
on the 7-position has been shown to increase blood stability of the derivatives and result in an 
enhanced activity.57 In particular, 7-TBS substitution has been very beneficial. Similarly 10-F 
substitution allows to study effect a hydrogen-bond acceptor while still retaining the size of the 
group at that position compared to the parent 10-H substituted compound. The synthesis of these 
analogs is shown in Scheme 3.23. 
The synthesis commences with the esterification of the carboxylic acid 87 upon treatment 
with TMSCHN2 at room temperature to afford the corresponding methyl ester58 (not shown). 
This protection as the ester ensures that no complications arise due to the free carboxylic acid. 
This ester is then iododesilylated under standard ICl conditions. The iodine atom in this 
iodopyridine acts as the radical precursor. Next, the reaction of this methoxy pyridine with in situ 
generated TMSI affords the demethylated iodopyridone 90 in a combined three-step yield of 
25%. 
Compound 90 was divided into two portions and propargylated with the two propargyl 
bromides in the presence of NaH and LiBr to give the corresponding N-propargylated pyridones 
91a and 91b in 54% and 45% yield, respectively. Each of these propargylated pyridones was 
further divided into two portions and reacted with two p-substituted isonitriles under 
photoirradiation conditions to afford the four camptothecin analogs 92a-d in 30-71% yield after 
purification by flash column chromatography. The structures of 92a-d were confirmed by NMR 
and MS analysis. 
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Scheme 3.23 Synthesis of Four Cyclic Ether Analogs of CPT 
 
We realized that E-ring modified analogs without a stereocenter would also be interesting 
to understand the significance of the tertiary alcohol in CPT and hCPT. To access such type of 
analogs, we identified the enelactone 71 as a good starting point and decided to develop analogs 
with the E-ring containing an olefin in the place of the tertiary stereocenter. The synthesis, which 
closely follows the synthesis of the cyclic ether analogs, is described in Scheme 3.24. 
Four analogs with identical substitution patterns to those of the cyclic ethers were 
synthesized. Thus, enelactone 71 was iododesilylated with ICl and following that it was 
demethylated with in situ generated TMSI to afford iodopyridone 93 in 12% for the two steps. 
Compound 93 was divided into two portions for the propargylation reaction and then the N-
propargylated iodopyridones 94a and 94b, obtained in 37% and 43% yield respectively, were 
further divided into two portions each to be reacted with two isonitriles under photoirradiation 
conditions to give the final enelactone derivatives 95a-d in about 34-55% yields after 
purification by column chromatography. The structures of the four enelactones were confirmed 
by NMR and MS techniques. 
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Scheme 3.24 Synthesis of Four Enelactone Analogs of CPT 
 
 
3.3.4. Novel Non-Lactone Analogs of Camptothecin – Biological Evaluation 
 
Eight E-ring modified CPT analogs, four cyclic ethers and four enelactones, were tested 
by Drs. Y. Pommier, B. Anderson and their coworkers for biological activity in two assays: 
topoisomerase inhibitory assay and cell growth inhibitory assay. The results from the 
electrophoresis experiments in the topoisomerase inhibitory assay are shown in Figure 3.5. 
The first two lanes in the gel display show the controls DNA and topo I in the absence of 
CPT or hCPT. As expected, no cleavage products were observed. The third lane shows CPT 
control and cleavage products are clearly observed. The next two sets of lanes show the hCPT 
controls, the first set indicates hCPT synthesized by French researchers and the second set hCPT 
synthesized by our group. Each set is divided into four lanes, represented by concentrations 0.1 
µM, 1 µM, 10 µM and 100 µM respectively. The final two sets of lanes show the assay results of 
analogs 95a and 95b. The DNA cleavage products are indicated by arrows in Figure 3.5. 
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Figure 3.5 Topoisomerase Inhibitory DNA Cleavage Assay Results for Non-lactone Analogs 95a,b 
 
For topo I cleavage assays, labeled DNA (~50 fmole/reaction) was incubated with 5 ng of 
recombinant topo I with or without the drug at 25 °C in 10µL reaction buffer (10 mM Tris-Cl pH 
7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 15 µg/mL BSA, final concentrations) for 20 
min. Reactions were stopped with SDS (0.5 %). Samples were denatured by the addition of 3.3 
volumes of Maxam Gilbert loading buffer (80% formamide, 10 mM sodium hydroxide, 1 mM 
sodium EDTA, 0.1% xylene cyanol and 0.1% bromophenol blue, pH 8.0). Aliquots were 
separated in 16% denaturing polyacrylamide gels (7M urea) in 1 X TBE (45 mM Tris, 45 mM 
60 
 Boric acid, 1 mM EDTA) for 2 h at 40 V/cm at 50 °C. Imaging and quantitation were performed 
using a Phosphorimager. 
The electrophoresis experiments have led to the following results. First, the cyclic ether 
analogs 92a-d have shown no activity compared to the standard samples of hCPT. Second, the 
enelactones 95a-d showed that the 20-OH group is not absolutely required for topoisomerase I 
poisoning. However, in the absence of the 20-OH group, the drug activity was reduced by abolut 
100-fold. And third, due the low activity of the parent enelactone 95a, effects of the substitution 
could not be assessed accurately. 
 
3.4. Summary 
This chapter described our initial efforts to investigate new approaches towards the 
efficient synthesis of the DE-fragment of (R)-hCPT. Our efforts in using different homologation 
approach to achieve this goal were described. When many of the tested homologation protocols 
either failed to succeed or furnished unsatisfactory results, we turned our attention to the 
epoxidation and dihydroxylation procedures in accessing the desired DE-fragment. These 
procedures have not afforded the desired results. However, an unexpected rearrangement in an 
epoxidation protocol led us to the synthesis of novel non-lactone analogs of camptothecin which 
can be classified into two categories – cyclic ether analogs and enelactone analogs. Despite the 
interesting synthetic sequence, these analogs have not showed much promise in the biological 
activity studies. The development of non-lactone analogs with promising biological activity 
continues to be of interest in our group and other research laboratories. Further studies in this 
area may reveal such analogs possessing interesting modifications in the E-ring without 
compromising the biological activity. 
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 4. E-RING OPEN-FORM ANALOGS OF CAMPTOTHECIN  
 
4.1. Introduction 
Recently, Stewart and co-workers reported the X-ray crystal structure of human 
topoisomerase I covalently joined to double-stranded DNA and bound to topotecan, a clinically 
approved analog of camptothecin.12 This crystal structure sheds light on the mechanism of 
topoisomerase I poisoning by the CPT derivatives. Prior to the disclosure of this report, it had 
been difficult to study the mechanism of action of CPT because the drug acts as an 
uncompetitive inhibitor at the binding site and binds only the transient covalent enzyme-substrate 
complex.59
It was reported that topotecan mimics a DNA base pair and binds at the site of DNA 
cleavage by intercalating between the upstream and downstream base pairs. One of the most 
striking findings of this report was that the electron density allowed the positioning of both the 
closed lactone and the open carboxylate conformers of topotecan. An unrestrained full matrix 
refinement of occupancy factors for both these conformers converged to an occupancy of 37% 
open carboxylate and 63% closed lactone forms. Fluorescence spectrophotometric measurements 
of topotecan as a function of pH revealed a similar ratio between the closed (75%) and open 
(25%) forms. The observed ternary crystal structure also demonstrates that both the closed 
lactone and the open carboxylate conformers can bind within the same intercalation pocket and 
presumably prevent the religation reaction. These findings are surprising because they contradict 
conventional wisdom that the ring-opened carboxylate is detrimental to the drug’s biological 
activity (see Scheme 1.1, Chapter 1). 
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 The binding interactions of topotecan within the intercalation pocket (Figure 1.3, Chapter 
1) in both the closed and the open forms explain the results of various E-ring modifications 
reported in literature. The crystal structure model shows that in the closed lactone there is only 
one direct hydrogen bond between the enzyme and topotecan: the 20(S)-hydroxy group hydrogen 
bonds to Asp533. This stabilizing hydrogen bond interaction is intact in the open carboxylate 
form arguing against the belief that the open form inactivates the drug. In addition, the open form 
enjoys two other stabilizing interactions: the water-bridged contacts of the free primary hydroxyl 
group to Asn722 and the carboxylate oxygen to the P-Tyr723. 
This report of the crystal structure opens up new avenues in the field of camptothecin 
analog synthesis: E-ring open form analogs. Based on the conclusions described above, we 
initiated a project aimed at the synthesis and biological evaluation of derivatives which resemble 
the open carboxylate form of camptothecin. 
 
4.2. Synthesis of the E-ring Open Form Analogs of CPT 
The two points of modification in the synthesis of open form analogs that we made are 
shown in Figure 4.1. One of the key features of the open form is the extent to which it can 
participate in hydrogen bonding. Excluding the tertiary alcohol which is involved in a key 
stabilizing interaction, we varied the primary hydroxyl group and the carboxylate such that the 
resulting modifications may enhance or diminish the hydrogen bond interactions. 
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Figure 4.1 Structural Modifications in Synthesis of E-ring Open Form Analogs 
 
The first type of modification we made was to substitute the acid for a hydrazide (X = 
NHNH2). The hydrazide can retain the hydrogen bond donor capacity while remaining in the 
same oxidation state as the parent carboxylate. Secondly, the acid was substituted by the 
Weinreb amide that will remove the hydrogen bonding interactions due to the lack of donors. 
This change will help us understand the significance of the hydrogen bonding interactions of the 
carboxylate. 
The synthesis of these analogs is shown in Scheme 4.1. Camptothecin (CPT) was treated 
with an excess of hydrazine monohydrate in methanol at room temperature60 to effect the 
opening of the lactone and form hydrazide 96 in quantitative yield. DB-67 was subjected to 
identical reaction conditions affording hydrazide 97, also in near quantitative yield. Both the 
hydrazides did not require further purification after the workup. The structures of 96 and 97 were 
confirmed by NMR and MS techniques. 
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Scheme 4.1 Synthesis of the Hydrazides 96, 97 and Weinreb Amide 99 
 
For the synthesis of the Weinreb amide 98, CPT was added to a mixture of Me3Al and 
N,O-dimethylhydroxylamine hydrochloride at room temperature to afford 98 in 77% yield.61 
Weinreb amide 98 was quite unstable on standing at room temperature (displayed multiple 
products as indicated by TLC). However, when the free alcohol in 98 was protected as the TBS 
ether on treatment with TBSCl and imidazole, the product 99 (obtained in 92% yield) was found 
to be stable on the bench top as indicated by TLC. 
The second point of modification was at the primary alcohol position. We synthesized 
two derivatives lacking a hydrogen bond donor group i.e., a 17-deshydroxy derivative (Y = H in 
Figure 4.1) as shown in Scheme 4.2. 
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Scheme 4.2 Synthesis of 17-Deshydroxy Open-form Analogs 
 
We were particularly interested in the 17-deshydroxy substrate 101 because it combines 
the structural features of camptothecin and the related mappicine 100.62 A report by the 
researchers at the Smithkline Beecham Corporation63 describes a semi-synthetic route to 101. 
However, no information regarding the biological activity was reported. Employing this 
procedure, camptothecin (CPT) was subjected to hydrogenolysis reaction using palladium on 
carbon in the presence of Et3N and DMF to afford the acid 101 in 40% yield after purification by 
semi-preparative HPLC using a reverse phase C18 column. DB67 was also submitted to identical 
reaction conditions but substituting the solvent DMF with MeOH because of better solubility and 
ease of workup. The product 102 was isolated in a 83% yield after column chromatography. The 
presence of a carboxylic acid moiety in 101 was confirmed by esterification with trimethylsilyl 
diazomethane to the corresponding methyl ester 103 in 76% yield. 
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 4.3. Biological Evaluation of the E-ring Open Form Analogs of CPT 
All the open-form derivatives of CPT were sent for a preliminary evaluation for any 
biological activity as shown by the topoisomerase inhibitory assay. The assay conditions were 
identical to those described in Chapter 3. Figure 4.2 shows an electrophoresis gel display of CPT, 
the hydrazides 96 and 97 and the acids 101 and 102. The first two lanes in the gel display show 
the controls DNA and topo I in the absence of CPT. As expected, no cleavage products were 
observed. The third set of four lanes shows CPT control and the cleavage products are clearly 
observed. Each of these four lanes refers to the concentrations 0.1 µM, 1 µM, 10 µM and 100 
µM respectively. The next four sets of lanes show the assay results of 101, 96, 97 and 102 
respectively. The DNA cleavage products are indicated by arrows in Figure 3.5. 
The topo I assay shows that the hydrazides 96 and 97 display promising activity that is 
comparable to that of camptothecin (CPT). One can also note that the hydrazide 97 shows 
slightly better activity as indicated by the intensity of the cleavage products in the electrophoresis 
gel display. Unfortunately, the acids 101 and 102 showed no activity at all as indicated by the 
empty lanes 2 and 5 (Figure 4.3). Weinreb amide 99 also exhibited no activity. 
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Figure 4.2 Results of Topo I Inhibitory Assay of Derivatives 96, 97, 101 & 102 
  
We next studied the stability of the hydrazides at room temperature. Two portions (of 
arbitrary amounts) of hydrazide 96, one as a solution in DMSO and the other as a solid sample, 
were allowed to stand at room temperature. It was learned that 96, as a solution of DMSO, closes 
to the lactone generating camptothecin. However, it is quite stable on the bench top as a solid 
sample as indicated by 1H NMR spectrum. When the 1H NMR spectrum of 96 was recorded after 
it was present as a solution in DMSO for 20 days, the spectrum showed a complete conversion of 
the hydrazide to camptothecin. The hydrazide 96 is, however, stable as a solid at room 
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 temperature for at least six months with no traces of camptothecin formed as indicated by 1H 
NMR. 
The hydrazide samples were checked for conversion to CPT after they had been tested for 
topo I inhibitory activity. The 1H NMR spectrum showed a ratio of 2:1 of CPT/hydrazide 96. It is 
still unclear if the activity displayed by the hydrazides originates from the in situ generated CPT 
in DMSO. More experimentation is required to confirm unambiguously the nature of the species 
in the assay contributing to the biological activity. If CPT is determined responsible for the 
observed activity, then these hydrazides can serve as prodrug analogs that can potentially 
undergo reconversion to CPT in vivo. 
The open form analogs of CPT were also studied in a cell growth inhibition assay. The 
plot of the percentage of cells remaining (y-axis) versus the concentration of the CPT analog (x-
axis) is shown in Figure 4.3. The first two entries are the CPT (blue) and DB67 (pink, see Figure 
1.5, Chapter 1) controls. The other four entries are 101 (green), 96 (cyan), 97 (purple) and 102 
(brown). The SRB assay, done in the cell growth inhibition studies, measures the amount of 
protein attached to a well. This amount is proportional to the number of cells still attached to the 
well. The cells used, MDA-MB-435S+ are no longer viable if they lose their attachment after 
exposure to CPT or its analogs. 
The cells were plated onto 24 well plates 24 h before they were exposed to CPT analogs. 
After the CPT derivative was added, cells were allowed to grow for 72 h (full cell cycle arrest 
was observed around 48 h after exposure to CPT analog). Thus the cells grew for 96 h, with CPT 
analog present for 72 h. The cells were then gently washed with PBS buffer and fixed with 
trichloracetic acid. The plates were dried and stained with sulforhodamine blue (SRB) and excess 
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 dye was washed off with 1% acetic acid. Plates were dried again. SRB dye was then mobilized 
with 10 mM tris base and measured with a spectrophotometer set at 490 nm. 
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Figure 4.3 Results of the Cell Growth Inhibition SRB Assay of Derivatives 96, 97, 101 and 102 
 
The results of the SRB assay were in agreement with those of the topo I inhibitory assay 
(see Figure 4.2). Hydrazides 96 and 97 inhibited the growth of cells with an approximate GI50 = 
20 nM and 100 nM respectively. These values are comparable to those of CPT and DB67 which 
are in the 10 nM range. Acids 101 and 102, on the other hand, showed no growth inhibition of 
cells. 
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 4.4. Summary 
This chapter described the synthesis of a small assortment of E-ring open form analogs of 
camptothecin. This analog synthesis evolved from an interesting report of the X-ray crystal 
structure of the topo I-DNA-topotecan ternary complex by Stewart and co-workers which 
revealed that the open carboxylate form of CPT contributed to its biological activity. The analogs 
were synthesized using semi-synthetic approaches commencing from CPT and DB67, a well-
studied CPT analog. The different substitution patterns of the analogs were designed based on 
the findings of the report. All the analogs synthesized were biologically tested and the hydrazides 
showed good activity in the topoisomerase inhibitory assay. Additional experimentation is 
needed to confirm that these hydrazides remain in the open form under the assay conditions. 
Further development in this nascent field of open form CPT analogs is necessary to understand 
the implications of this report. 
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 5. 20-FLUOROCAMPTOTHECINS: AN ACCIDENTAL DISCOVERY 
 
5.1. Introduction 
During the course of our studies of E-ring open form derivatives of CPT, we became 
interested in studying open form analogs which have fluorine incorporated such as 104 (Scheme 
5.1). We envisioned that such primary fluorides could be synthesized in a semi-synthetic fashion 
starting from CPT or its analog using diethylamine sulfurtrifluoride (DAST). Based on a related 
literature precedent by Kirihara and coworkers,64 we envisioned a plausible mechanism for the 
desired transformation as shown in Scheme 5.1.  
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Scheme 5.1 Proposed Synthesis of 104 from CPT 
 
Thus, CPT could react with DAST via the nucleophilic displacement of the fluorine on 
sulfur by the oxygen of the 3° alcohol in CPT to afford 105. Intermediate 105 could then 
displace a second fluoride in an intramolecular fashion to give the oxonium ion intermediate 106. 
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 Attack of fluoride ion at the benzylic position in 106 could afford the desired fluorinated 
derivative 104. 
When CPT was treated with DAST at −78 °C and the reaction mixture was stirred 
overnight followed by an aqueous workup, a clean monofluorinated product was isolated in 54% 
yield after purification by flash column chromatography (99.0:0.5:0.5 
dichloromethane/methanol/acetonitrile). Based on a detailed spectroscopic analysis, we 
concluded that the product was not the fluorinated derivative 104 but rather 20-
fluorocamptothecin 107 (Scheme 5.2). The best precedent for this fluorination was reported by 
Takeuchi and coworkers65 where ethyl 2-hydroxy-2-phenylpropionate was reacted with DAST to 
the corresponding fluorinated derivative (boxed in Scheme 5.2). 
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Scheme 5.2 Reaction of CPT with DAST 
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 The 1H NMR spectrum of 107 showed a doublet of quartets (J = 7.4 Hz, 22.2 Hz) for the 
C19 methylene protons of the ethyl chain. The large 22 Hz coupling constant for the doublet 
indicated that the methylene protons were coupled to a fluorine atom consistent with a 
CH3CH2CFR2 fragment. The product shows a triplet at −163 ppm (J = 22.6 Hz) in 19F NMR 
spectrum, which is consistent with a fluorine atom with no geminal protons rather than the 
expected primary fluoride 104 with two geminal protons. An HMBC (1H – 13C correlation, 
greater than one bond coupling) spectrum of the product displayed crosspeaks between the C19 
methylene protons and the carbon bearing the fluorine atom. In addition, no crosspeaks between 
the benzyl protons (protons geminal to F in 104 in Scheme 5.1) and F were observed. The 13C 
NMR spectrum showed a doublet at 89.5 ppm with a coupling constant of 193.7 Hz consistent 
with a C-F one bond coupling. MS analysis showed an m/z value of 350 also consistent with a 
monofluorinated product. All these data support structure 107. 
The proposed mechanism of the formation of 20-fluroocamptothecin 107 is shown in 
Scheme 5.2. The formation of the intermediate 105 is followed a nucleophilic substitution of the 
oxygen leaving group by a fluoride ion to give a tertiary fluoride 107. 20-Chloro and 20-
bromocamptothecins have been reported66 to stabilize the covalent topo I-DNA binary complex 
fully despite lacking hydrogen bond donors. Interestingly, 20-fluorocamptothecin contains a 
hydrogen bond acceptor (a fluorine atom) in place of a hydrogen bond donor (a hydroxy moiety) 
at the C20 position. Also from the standpoint of the importance of fluorine functionality in 
medicinal chemistry,67 we decided to test the viability of 107 and its analogs as drug candidates. 
During the preparation of this thesis, Toru and co-workers reported the synthesis of 20-
fluorocamptothecin starting from 20-deoxyCPT68 by the electrophilic fluorination of 20-
deoxycamptothecin using selectfluor (not shown). 
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 5.2. Synthesis and Biological Evaluation of Analogs of 20-Fluorocamptothecin 
Beginning with the known propargylated pyridone 108 (see Scheme 1.3, Chapter 1, R7 = 
H), we synthesized a few analogs of 107 (Scheme 5.3). Thus, 108 was treated with DAST at −78 
°C to afford fluoropyridone 109 in 96% yield. Pyridone 109 was reacted with p-fluoro (110a) 
and 3,4-methylenedioxy isonitriles (110b) under the standard radical cyclization conditions to 
afford the corresponding camptothecins 111a-c in moderate yields. The reaction with isonitrile 
110b produces a separable mixture of the 9,10- (111b) and the 10,11-substituted (111c) 
fluorocamptothecins in the ratio of 1:2.5 respectively. The assignment of the isomers was made 
based on the splitting pattern in the aromatic region of the 1H NMR spectrum. 
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Scheme 5.3 Synthesis of Analogs of 20F-CPT 
 
20F-DB67 112 was synthesized in a semi-synthetic fashion from DB67 upon treatment 
with DAST at −78 °C in a 61% yield (Scheme 5.4). Fortunately, the TBS group at the C7 
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 position remained unaffected under these conditions. The structure of 112 was confirmed by 
NMR and MS techniques. 
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Scheme 5.4 Reaction of DAST with DB67 
 
Fluorocamptothecins 107, 111a-c and 112 were sent for biological tests in the 
topoisomerase inhibitory assay. The assay conditions were identical to those described in 
previous chapters. The results of the assay showed that compounds 111a-c were not active at 
concentrations ranging from 0.1 µM to 100 µM. However, compounds 107 and 112 showed only 
traces of activity at 100 µM. We hypothesized that the lack of activity was due to the “R” 
stereochemistry of the C20 stereocenter. If the fluorination reaction proceeded with inversion of 
configuration at C20, then the resulting (20R)-fluorocamptothecin would be inactive. A total 
synthesis of both the enantiomers and the racemate of 107 was undertaken to confirm the 
hypothesis.  
 
5.3. Stereoselective Total Synthesis of 20S and 20R-Fluorocamptothecin 
The synthesis of (20R)- and (20S)-fluorocamptothecins commences with the previously 
introduced aldehyde 28b (see Scheme 2.7, Chapter 2) as shown in Scheme 5.5. A reductive 
etherification reaction69 of 28b with crotyl alcohol, Et3SiH and TFA provided the crotyl ether 
113 in 63% yield. Iodide 113 was subjected to an intramolecular Heck reaction in the presence of 
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 Pd(OAc)2, K2CO3 and Bu4NBr to afford the enol ether 114. After an aqueous workup, the crude 
enol ether 114 was subjected to dihydroxylation under Sharpless’ conditions but with DABCO in 
place of the chiral ligand70 to afford the corresponding racemic diol (not shown). 
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Scheme 5.5 Synthesis of 20-Fluorocamptothecin 107 
 
After purification by column chromatography, this diol was oxidized to the lactone 115 
on treatment with I2 and CaCO3 in an overall yield of 20% for the three steps. To access both the 
enantiomers of 115, racemic alcohol 115 was separated into its constituent enantiomers (S)-115 
and (R)-115 in 100% ee as determined by semi-preparative HPLC using (S,S) WHELK O 1 
chiral column under isocratic elution (95:5 hexanes/isopropanol) conditions. The retention time 
of (S)-115 under these conditions at the rate of 1 mL/min was 7.5 min and that of (R)-115 was 
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 10.5 min. When 68 mg of the racemic alcohol 115 was loaded on the HPLC with semi-
preparative column in three injections, 21 mg each of the R and S enantiomers could be isolated.  
The key fluorination reactions of (S)-115 and (R)-115 with DAST were carried out at −78 
°C to afford the fluoropyridines (R)-116 and (S)-116 respectively in 86% and 76% yields with 
good chiral transfer in 91% and 93% ee respectively as shown by HPLC analysis using (S,S) 
WHELK O 1 chiral column under isocratic elution (95:5 hexanes/isopropanol) conditions. The 
retention time of (S)-116 under these conditions at the rate of 1 mL/min was 10.6 min and that of 
(R)-116 was 18.0 min. The stereochemical assignment of fluoropyridines 116 will be described 
later. Pyridine lactone 115 was identified as a suitable intermediate for performing the 
fluorination reaction after it provided the best yield and cleaner reaction in comparison to other 
intermediates in the synthesis.71 In a comparison study between DAST and the other well-known 
fluorinating agent Deoxofluor [(CH3OCH2CH2)2NSF3],72 in which the temperature, time of the 
reaction and the equivalents of the fluorinating agent were varied, we discovered that the 
reactions with DAST afforded cleaner products, better yields and conversions and were 
completed in shorter times (Table 5.1). 
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 Table 5.1 Comparison of DAST and Deoxofluor for the Fluorination of 108 
 
NI O
OF
O
109
NI O
OHO
O
108
Fluorinating agent
temperature
 
  
Fluorinating Agent 
Entry Temperature Rxn. time 
DAST (pdt. yield) Deoxofluor (pdt. yield) 
1. 
2. 
3. 
Room temp. 
−40 °C 
−78 °C 
30 min 
1.5 h 
5 h 
109 (25%) 
109 (67%) 
109 (96%) 
109 (23%) 
109 (60%) 
109/108 (3:2, 25%) 
   
Pyridine lactones 116 were converted to the pyridones 109 in three steps. First, an 
iododesilylation reaction using ICl afforded the corresponding enantiomeric iodides. Second, a 
demethylation reaction of these iodides with in situ generated TMSI gave the corresponding 
pyridones. Third, the pyridones were alkylated with propargyl bromide in the presence of NaH 
and LiBr to give both enantiomers of 109 in overall yields of 33% and 25% for three steps. We 
were pleased to observe good yields with the iododesilylation reaction of 116 (59% and 65%) 
which, with most other similar substrates, was a low-yielding step. 
The key radical cyclization was carried out with the propargylated pyridones 109 and 
phenyl isonitrile in the presence of (Me3Sn)2 under photo-irradiation conditions to give both the 
enantiomers of 20-fluorocamptothecin (R)-107 and (S)-107 in 11% and 14% yields after 
purification by flash column chromatography. The purity of fluorocamptothecins 107 was 
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 confirmed by NMR and MS techniques. Also, the 1H and 13C NMR spectra of these samples 
matched with that of 107 made via the semisynthesis route (see Scheme 5.2). Racemic 107 was 
synthesized following the reaction sequences described in Scheme 5.3 starting from racemic 108. 
The three samples, (R)-107, (S)-107 and (±)107, were sent for the preliminary biological 
evaluation and the results from this are shown in Figure 5.1. 
  
  
Figure 5.1 Results of the Topo I Inhibitory DNA Cleavage Assay of Derivatives (S)-107, (R)-107 and rac-107 
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 The first two lanes in the gel display show the controls DNA and topo I in the absence of 
CPT. As expected, no cleavage products were observed. The next set of four lanes shows CPT 
control and the cleavage products are clearly observed. Each of these four lanes refers to the 
concentrations 0.1 µM, 1 µM, 10 µM and 100 µM respectively. The next three sets of lanes show 
the assay results of (S)-107, (R)-107 and (±)107 in that order. The DNA cleavage products are 
indicated by the arrow in Figure 5.1. 
The electrophoresis experiments showed that both the enantiomers of 107 showed 
activity at a concentration of 10 µM. We assigned the compound with the highest intensity to be 
(S)-107 and the less intense one (R)-107 based on the known premise that only (S)-
camptothecins are biologically active (see Section 1.3, Chapter 1). Tracing backwards in the 
reaction sequence, we determined that (S)-107 was obtained from (S)-116 which in turn was 
obtained from the fluorination of (R)-115. Thus, the reaction with DAST had occurred with an 
inversion of configuration. Racemic 107 also showed some weak activity at 10 µM 
concentration. The small selection of analogs presented in Section 5.2 had, therefore, been 
synthesized in the “wrong” configuration. Resynthesis and biological reevaluation of these 
analogs is currently in progress in our laboratories to confirm the configuration of the 
biologically active enantiomer of 107. 
The fluorocamptothecins can also be envisioned as good substrates for the determination 
of the function of the lactone moiety in DNA/Topo I interactions by using high-field 19F NMR 
spectroscopy. This allows the study of the dynamics of the ternary complex possible without 
isotopic labeling the protein. Studies using this technique in combination with computational 
modeling are currently in progress. 
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 5.4. Summary 
This chapter described the accidental discovery of the 20-fluorocamptothecins (20F-
CPTs) that were synthesized from their alcohol counterparts upon reaction with DAST. A small 
assortment of analogs of 20F-CPT was synthesized. However, these compounds showed no 
activity in the topoisomerase inhibitory assay. The two enantiomers of 107 have also been 
synthesized and submitted for biological testing. It was found that (S)-107 displayed activity at 
10 µM concentration while the R enantiomer showed no activity. Further research in the 
synthesis and biological studies of additional analogs of 20F-CPT with S configuration at the 
C20 position is underway. 
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 6. TOTAL SYNTHESIS OF LUOTONIN A AND ITS ANALOGS USING CASCADE 
RADICAL CYCLIZATION 
 
6.1. Introduction 
In 1997, Nomura and coworkers reported the isolation of a pyrroloquinazolinoquinoline 
alkaloid, luotonin A, extracted from the Chinese medicinal plant Peganum nigellastrum.73 The 
structure of luotonin A bears striking similarities to the well-studied topo I poison, camptothecin 
(Figure 6.1). 
 
N
N
N
O
N
N
O
O
OHO
Camptothecin, CPT
A B C
D
EE
D
CB A
Luotonin A  
Figure 6.1 Structures of Luotonin A and Camptothecin 
 
The structural similarities are in the rings A-C which are identical in luotonin A and CPT. 
The differences are in the D-ring in which pyrimidone moiety replaces the pyridone in CPT and 
the E-ring in which the lactone moiety, thought to be crucial for the biological activity of CPT, is 
absent in luotonin A. The lack of any functionality in the E-ring of luotonin A is interesting in 
light of several reports that modifications in the E-ring resulted in either diminishing or 
destroying CPT’s activity (see Section 1.3, Chapter 1).  
Furthermore, recently Hecht and coworkers reported that luotonin A mediates 
topoisomerase I-dependent cytotoxicity much like CPT. It was demonstrated that despite the lack 
of lactone moiety and the tertiary alcohol stereocenter in the E-ring, luotonin A stabilizes the 
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 human DNA- topo I covalent binary complex forming a ternary complex. Luotonin A was found 
to be cytotoxic towards the murine leukemia P-388 cell line with an IC50 of 1.8 µg/mL. It was 
also observed that luotonin A displays identical sequence selectivity of DNA cleavage by topo I 
to that of CPT in the electrophoresis experiments. With its similarities in structure and function 
to CPT, luotonin A was an attractive synthetic target to many research groups.   
 
6.2. Synthetic Approaches to Luotonin A 
A brief summary of the five distinct synthetic approaches to luotonin A reported thus far 
is shown in Scheme 6.1. Ihara reported a synthesis employing an intramolecular hetero Diels-
Alder reaction74 with a suitable aza-diene and cyano group as the dienophile. Harayama used an 
alkylation followed by an intramolecular Pd-assisted biaryl coupling in the presence of 
tricyclohexylphosphine as the ligand and KOAc as the base to afford the desired luotonin A.75   
The classical Friedlander condensation of the dihydropyrroloquinolinone with 2-
aminobenzoate was the method of choice of Hecht.76 Several other research groups employed the 
Friedlander condensation in their synthesis of luotonin A.77 The key difference in these syntheses 
is the choice of the aniline derivative for the condensation. Nomura reported the reaction of the 
pyrroloquinazoline derivative with N-(2-aminobenzylidene)-p-toluidine in the presence of 
pTsOH.68
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Scheme 6.1 Synthetic Approaches to Luotonin A 
 
While many of these syntheses are elegant, they are not sufficiently flexible to allow the 
ready functionalization of the parent luotonin A. Our approach (shown in the box in Scheme 
6.1), on the other hand, is modular in nature and facilitates quick access to several derivatives of 
luotonin A, particularly the A,B-ring analogs. In addition, the mild conditions of the radical 
reaction make it possible to tolerate a wide variety of functional groups.  
 
6.3. Total Synthesis of Luotonin A 
The synthesis of luotonin A commenced with the synthesis of dibromoquinazoline 117 as 
shown in Scheme 6.2. Commercially available benzoylene urea was treated with POBr3 and N,N-
dimethylaniline under solvent-free conditions at 105 °C to afford the quinazoline 117 in 52% 
yield. This use of solvents (such as CH2Cl2, CH3CN) in the dibromination reaction led to either 
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 poor yields of the desired product or recovery of starting material. Diiodoquinazoline 118 is a 
better substrate in this synthetic scheme that could be carried over to luotonin A since iodides are 
better radical precursors than bromides. Despite several attempts at the synthesis of 118, we were 
unsuccessful starting either from benzoylene urea (using PPh3, I2, Et3N) or from the dichloride 
119 (Bu4NI/THF; NaI/CH3CN; aq. HI) or any of its derivatives due to either the formation of 
multiple products or unreactive starting material.  
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Scheme 6.2 Total Synthesis of Luotonin A 
 
Dibromoquinazoline 117 was then subjected to monohydrolysis on treatment with 1N 
NaOH to afford the bromoquinazolinone 120 as the sole product in quantitative yield as 
indicated by 1H NMR, 13C NMR and MS analysis. A short reaction time (~ 2 h) is essential to 
avoid nonselective hydrolysis resulting in a complex mixture. Quinazolinone 120 was next 
treated with propargyl bromide in the presence of NaH to effect N-alkylation affording 
propargylated quinazolinone 121 in 66% yield. Under these reaction conditions, no O-alkylation 
product was observed as indicated by 1H and 13C NMR analysis. Bromide 121 was then 
converted to luotonin A 122 under photoirradition conditions upon treatment with phenyl 
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 isonitrile in the presence of (Me3Sn)2 in 47% yield after purification by flash column 
chromatography. The structure of 122 was confirmed by NMR and MS techniques and the data 
matched that reported in the literature.68
 
6.4. Synthesis of Analogs of Luotonin A 
Although luotonin A has been the subject of many syntheses, there is very limited 
knowledge about the effect of different substitution patterns in terms of the biological activity. 
Recently, Hecht reported a series of E-ring derivatives of luotonin A and evaluated them for topo 
I inhibitory activity (Figure 6.2). E-ring analogs 124, 125 and 127 have shown good DNA-topo I 
stabilization. Among luotonins 123, 17-chloroluotonin A (R1 = R3 = H, R2 = Cl) displayed good 
biological activity. 
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Figure 6.2 Hecht's E-ring Analogs of Luotonin A 
 
The modular nature of our synthesis, in addition to its conciseness, presents a good 
opportunity to synthesize several analogs in a quick manner. In a complementary fashion to 
Hecht’s synthesis of E-ring derivatives, our strategy could be used to synthesize a library of A, 
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 B-ring derivatives thus building a more complete SAR profile of luotonin A. The planned 
synthesis of the 4 x 8 library of luotonins is shown in Scheme 6.3. 
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Scheme 6.3 Synthesis of Library of Luotonin A Analogs 
 
Prior to undertaking the library synthesis, 1.4 g of the key bromoquinazolinone 
intermediate 120 was synthesized according to the chemistry described in Scheme 6.2. All the 
reactions leading to the final luotonins were performed using standard laboratory techniques in a 
serial fashion. The requisite building blocks for the library synthesis are shown in Table 6.1. 
Four propargyl bromides 128{a-d}, that were chosen based on previous experience in our 
laboratories, were synthesized according to literature procedures.52
The isonitriles were chosen based on their electron-withdrawing character (110{2} and 
110{3}), electron-donating character (110{4}, 110{5} and 110{8}) and hydrogen bond donor 
capacity (110{6} and 110{7}). All the isonitriles were synthesized following previously reported 
procedures.44
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 Table 6.1 Building Blocks for the Luotonin Library 
 
R8
Br R
10
R11 NC
R9
128 110  
 
Propargyl bromides  Isonitriles 
R8 Entry  R9 R10 R11 Entry 
H 
TBS 
Et 
CH2CH2TMS 
128{a} 
128{b} 
128{c} 
128{d} 
 
 
 
 
 
 
 
 
H 
H 
H 
H 
H 
H 
H 
H 
H 
F 
CF3
Me 
OMe 
OAc 
NHBoc 
OCH2CH2O
H 
H 
H 
H 
H 
H 
H 
-- 
110{1} 
110{2} 
110{3} 
110{4} 
110{5} 
110{6} 
110{7} 
110{8} 
  
  
 
 
 
    
 
   
 
 
Quinazolinone 120 was reacted with four propargyl bromides 128{a-d} to afford four 
propargylated quinazolinones 129{a-d} in 54-66% yields. Each of the four bromides 129{a-d} 
was subjected to the radical cascade cyclization with eight isonitriles 110{1-8} under 
photoirradiation conditions in the presence of (Me3Sn)2 to afford 32 products 130{a-d, 1-8} in 
moderate to good yields (see Table 6.2). For the final radical cyclizations, groups of four 
reactions were irradiated simultaneously and each crude product was purified by a quick column 
chromatography to separate the excess tin and isonitrile derivatives from the desired product. In 
the case of the reaction of 129 with 3,4-ethylenedioxy isonitrile 110{8}, two regioisomeric 
products, 9,10-ethylenedioxy luotonin and the 10,11-ethylenedioxy luotonin,65 were obtained 
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 and could be separated only by a semi-preparative HPLC, the details of which are discussed later 
in this chapter.  
The compounds obtained after purification by column chromatography were analyzed by 
1H NMR spectroscopy and the structures of some of the compounds were confirmed. This 1H 
NMR analysis, however, revealed an unexpected problem with some of the products of the 
radical cyclization. Compounds 130{b,1-6} and 130{b,8}, expected to be luotonins, displayed 
fewer than expected aromatic resonances. The proton signals of the substituent R10 (see Scheme 
6.3) were completely absent in all the 1H NMR spectra. Also, an additional singlet proton 
resonance was observed at 9.79 ppm in addition to only four aromatic resonances (two doublets 
and two triplets). Based on this analysis by 1H NMR and MS techniques, it was concluded that 
the products 130{b,1-6} and 130{b,8} were all the same compound 131{b} obtained by the direct 
reduction of the bromide 129{b} under the reaction conditions (Scheme 6.4). The additional 
proton signal at 9.79 ppm is explained by the newly formed pyrimidinyl proton. 7-TBS-10-
NHBoc luotonin, 130{b,7} was the only luotonin recovered among 130{b,1-8}. The same 
reduction behavior was also observed with a few products formed from 129{d} (not shown). The 
reason for this premature reduction of the bromides 129{b} is still unclear especially because all 
the 32 radical cyclizations were conducted at the same concentration. 
 
N
N
N
O
TBSR9
R10
R11
N
N
O
TBS
Br (Me3Sn)2, hν
129{b} 130{b, 1-8}
110{1-8}
N
N
O
TBS
H
131{b}
NC
R9
R10
R11
Not Observed Observed  
Scheme 6.4 Unexpected Side Reaction of 129{b} 
90 
 Table 6.2 Luotonin Library - Compound Numbers and Isolated Yields from Column Chromatography 
 
R8 
R10 
H TBS Et CH2CH2TMS
 
H 
 
F 
 
CF3 
 
Me 
 
OMe 
 
OAc 
 
NHBoc 
 
OCH2CH2O 
(9,10 & 10,11) 
 
 
130{a,1} 
47% 
130{a,2} 
65% 
130{a,3} 
71% 
130{a,4} 
57% 
130{a,5} 
63% 
130{a,6} 
62% 
130{a,7} 
52% 
130{a,8} 
Uidf 
 
 
130{b,1} 
Red 
130{b,2} 
Red 
130{b,3} 
Uidf 
130{b,4} 
Red 
130{b,5} 
Red 
130{b,6} 
Red 
130{b,7} 
31% 
130{b,8} 
Red 
 
 
130{c,1} 
68% 
130{c,2} 
75% 
130{c,3} 
62% 
130{c,4} 
33% 
130{c,5} 
86% 
130{c,6} 
39% 
130{c,7} 
94% 
130{c,8} 
86% 
 
 
130{d,1} 
Uidf 
130{d,2} 
Red 
130{d,3} 
Uidf 
130{d,4} 
Uidf 
130{d,5} 
74% 
130{d,6} 
Red 
130{d,7} 
37% 
130{d,8} 
94% 
 
 
• Red - Reduced product (e.g., 131{b}, see Scheme 6.4) 
• Uidf - Unidentifiable product from 1H NMR analysis 
 
Studies in the field of camptothecins and homocamptothecins have shown that hydrogen 
bond donor substitution at the C10 (i.e., R10) has been beneficial to their biological activity. 
Owing to the similarities of luotonin A to CPT in its function as a topo I poison, we decided to 
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 synthesize luotonin derivatives (possessing OH and NH2 functionalities) that would address the 
effects of hydrogen bonding on the drug’s biological activity.  
To synthesize 10-hydroxy and 10-amino luotonins (130, R10 = OH and NH2 respectively, 
Scheme 6.3), deprotections of the previously synthesized 10-acetoxy and 10-Boc protected 
aminoluotonins were undertaken (Scheme 6.5). 
 
N
N
N
O
R8
BocHN
130{a-d, 7}
TFA, CH2Cl2
(see Table 6.2
    for yields)
N
N
N
O
R8
H2N
132{a-d}
N
N
N
O
R8
AcO
130{a,c, 6}
K2CO3, MeOH
(see Table 6.2
    for yields)
N
N
N
O
R8
HO
133{a,c}  
Scheme 6.5 Synthesis of 10-hydroxy and 10-aminoluotonins 
 
Four Boc-protected amines 130 {a-d,7} were treated with TFA in CH2Cl2 (1:2 v/v) at 
room temperature for 12 h allowing for the cleavage of the Boc group. The two acetates 
130{a,c,6} were also cleaved upon treatment with 4 equiv of K2CO3 in a 1:1 MeOH/H2O at room 
temperature for about 5 h. Unfortunately only one carbamate, 130{d,7}, could be successfully 
deprotected to afford amine 132{d} in 85% yield after purification by flash column 
chromatography. None of the other carbamates 130{a-c,7} or the acetates 130{a,c,6} the 
corresponding amines and alcohols as indicated by TLC. 1H NMR analysis showed only traces 
of the desired amines and alcohols. 
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 Ultimately, 22 luotonins were analyzed by HPLC with an analytical Novapak silica 
column employing isocratic elution with EtOAc/CH2Cl2 (2:98, 5:95, 8:92 or 15:85 depending 
upon the polarity of the luotonin). Nineteen compounds displayed good to excellent purities 
ranging from 75% to 95%. However, to guarantee high purity of the luotonins for biological 
testing, the products isolated from column chromatography were further purified by semi-
preparative HPLC using a Novapak silica column under solvent elution conditions employed for 
the analytical HPLC study. Following the purification by HPLC, all the luotonins were 
characterized by LC-MS using XTerra C18 reverse phase column for LC and EI detection for 
MS. Fourteen luotonins showed high purities ranging from 90-100% and the remaining five 
displayed purities ranging from 75%-85%. They also displayed the expected molecular ions (M+) 
along with higher peaks (i.e. M + H, M + Na).  
While the structures and purities of all the luotonins were confirmed by 1H NMR and LC-
MS, complete characterization of four of the luotonins, 130{a,1}, 130{c,8}, 130{a,3} and 
130{a,4}, was also carried out and is described in the experimental section. A table of the 
structures, amounts and purities of the final fourteen luotonins is shown in Figure 6.3. These 
luotonins are currently in the course of being tested for topoisomerase I inhibitory activity. 
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 N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
N
N
N
O
O
O
LCMS purity: 100% LCMS purity: 91%LCMS purity: 98%
LCMS purity: 100%
LCMS purity: 93% LCMS purity: 97%
LCMS purity: 100% LCMS purity: 90%
LCMS purity: 100%
O
O
TMS
Me AcO
F F3C BocHN
TMS
130{a,1} 130{c,8} 130{d,8}
130{c,1}130{a,6}130{a,4}
130{c,2} 130{a,3} 130{d,7}
Amount: 2.1 mg Amount: 2.0 mg Amount: 1.3 mg
Amount: 0.3 mgAmount: 1.0 mgAmount: 1.6 mg
Amount: 3.4 mg Amount: 3.6 mg Amount: 1.7 mg
N
N
N
O
N
N
N
O
N
N
N
O
LCMS purity: 97%LCMS purity: 100%LCMS purity: 100%
BocHN AcO BocHN
TBS
130{a,7} 130{c,6} 130{b,7}
Amount: 1.0 mg Amount: 0.3 mg Amount: 0.5 mg
N
N
N
O
N
N
N
O
LCMS purity: 87%LCMS purity: 85%
F MeO
130{a,2} 130{c,5}
Amount: 1.6 mg Amount: 3.9 mg  
Figure 6.3 Structures, Amounts and LCMS Purities of Luotonins 
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 6.5. Summary 
This chapter described the synthesis of a recently isolated topo I poison, luotonin A and 
its analogs. The striking similarities in structure and biological function of luotonin A to those of 
CPT made luotonin A an attractive target in the synthetic community. A concise, modular and a 
rapid synthesis of several analogs of luotonin A was also described. Biological evaluation of 
these analogs, currently underway, will provide more insight into the structure-activity 
relationships of luotonin A that could lead to a promising chemotherapeutic drug. 
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 7. SUMMARY AND CONCLUSIONS 
 
The central theme of the research presented in this thesis revolved around the synthesis of 
analogs of camptothecin differing mainly in the D and E rings of the pentacyclic skeleton. 
Accordingly, homocamptothecin, cyclic ether and enelactone derivatives, open-form analogs, 
fluorocamptothecins and luotonins were synthesized. Within each of these five modifications, 
the analogs differed in their A, B-ring substitution patterns. 
The biological activity of all these analogs was tested in two assays: topoisomerase I 
inhibitory DNA cleavage assay and the cell growth inhibition SRB assay. The topo I inhibitory 
assays revealed that non-lactone analogs (cyclic ethers) were not biologically active and 
enelactones 95a and 95b showed cleavage products only at a concentration of about 100 µM. 
The fluorocamptothecins, on the other hand, were weakly active. Among the parent 
fluorocamptothecin enantiomers, (S)-107 and (R)-107 showed cleavage products at 10 µM and 
100 µM concentrations and thus were weakly active. The racemate (±)-107 showed some weak 
activity. Luotonins are currently being biologically evaluated. 
With regards to the biological activity, the most interesting analogs in this research have 
been the E-ring open form analogs. Hydrazides 96 and 97 have shown DNA cleavage profiles 
comparable to that of camptothecin. Also, the cell growth inhibition studies indicated that the 
GI50 values of 96 and 97 were about 20 nM and 100 nM respectively. These values are 
comparable to those of CPT and DB67 which are about 10 nM. These compounds show promise 
and further development of these analogs is needed to understand the implications of open form 
analogs in the broad picture of analog development of camptothecin. The following is a tabular 
summary of all the biological results. 
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 Table 7.1 Summary of the Biological Results 
Entry Structure of the Analog Compd.no. 
GI50
(nM) 
DNA clvg. assay 
activity 
1. 
 
 
 
 
 
 
 
 
 
2. 
 
 
 
 
 
 
 
 
3. 
 
 
 
 
 
 
 
 
 
4. 
N
N
O
COOMe
O
R7
R10
 
 
 
N
N
O
R7
R10
O
O
 
 
 
N
N
O
NHNH2
O
HO
R7
R10
OH
 
 
N
N
COOH
O
HO
R7
R10
 
92a, R7 = H, 
        R10 = H 
92b, R7 = H, 
        R10 = F 
92c, R7 = TBS, 
        R10 = H 
92d, R7 = TBS, 
        R10 = F 
 
 
95a, R7 = H, 
        R10 = H 
95b, R7 = H, 
        R10 = F 
95c, R7 = TBS, 
        R10 = H 
95d, R7 = TBS, 
        R10 = F 
 
 
 
96, R7 = H, 
      R10 = H 
97, R7 = TBS, 
      R10 = OH 
 
 
 
 
 
101, R7 = H, 
        R10 = H 
102, R7 = TBS, 
        R10 = OH 
- 
 
- 
 
- 
 
- 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
20 
 
100 
 
 
 
 
 
 
- 
 
- 
− 
 
− 
 
− 
 
− 
 
 
 
+ 
 
+ 
 
− 
 
− 
 
 
 
 
++ 
 
++ 
 
 
 
 
 
 
− 
 
− 
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 Entry Structure of the Analog Compd.no. 
GI50
(nM) 
DNA clvg. 
assay activity 
5. 
 
 
 
 
 
 
6. 
 
 
 
 
 
 
 
7. 
 
 
 
 
 
 
 
8. 
 
 
 
 
 
 
       
N
N
O
O
O
F
 
 
   
N
N
O
O
O
F
R10
R11
R9
 
N
N
O
O
O
F
HO
TBS
 
 
N
N
N
OR
10
R8
 
 
 
rac-107 
 
(R)-107 
 
(S)-107 
 
 
 
111a, R9 = R11 = H 
111b, R9, R10 = 
OCH2O, R11 = H 
111c, R9 = H, 
     R10,R11 = OCH2O 
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130{a,1}, R8= R10= H
130{a,4}, R8 = H, R10 
= Me 
130{a,6}, R8 = H, R10 
= OAc 
130{c,1}, R8 = Et, 
R10 = H 
130{c,2}, R8 = Et, 
R10 = F 
130{a,3}, R8 = H, R10 
= CF3
130{d,7}, R8 = 
CH2CH2TMS, R10 = 
BocNH 
130{a,7}, R8 = H, R10 
= BocNH 
130{c,6}, R8 = Et, 
R10 = OAc 
130{b,7}, R8 = TBS, 
R10 = BocNH 
- 
 
- 
 
- 
 
 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
 
 
 
To be 
determined 
+ 
 
+ 
 
+ 
 
 
 
− 
 
− 
 
− 
 
 
 
 
− 
 
 
 
 
To be 
determined 
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Entry Structure of the Analog Compd.no. 
GI50
(nM) 
DNA clvg. 
assay activity 
 
9. 
 
N
N
N
O
R8
O
O
 
 
 
 
130{c,8}, R8 = Et 
130{d,8}, R8 = 
CH2CH2TMS 
 
 
 
 
To be 
determined 
 
 
 
 
 
 
To be 
determined 
 
− No or negligible activity 
+ Weakly active 
++ Moderate to good activity 
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 8. EXPERIMENTAL 
 
General Procedures 
All reactions were performed under argon atmosphere unless otherwise noted. Air and 
moisture sensitive chemicals were handled by using standard syringe techniques. THF and 
diethyl ether were either distilled from sodium/benzophenone under argon or were dried by 
activated alumina according to literature procedure.78 Dichloromethane was distilled from 
calcium hydride under argon or dried by activated alumina according to the above reference. 
DMSO and acetonitrile were used from a Sure/SealTM bottle purchased from Aldrich. 
Diisopropylamine was distilled from NaOH under argon immediately prior to use. LiCl was 
predried under vacuum at 120 °C for 24 h before use. 4Å molecular sieves were predried under 
vacuum at 150 °C for 24 h before use. All other chemicals and solvents were purchased from 
chemical companies and used without purification unless otherwise stated.  
Experimental procedures and spectroscopic data for new compounds other than the 
library members are reported in this experimental section. All library compounds have been 
characterized by 1H NMR and MS or LCMS. 1H, 19F and 13C spectra were recorded on Bruker 
models Avance DPX 300 (300 MHz), Avance DRX 500 (500 MHz) NMR spectrometers. 19F 
spectra were recorded with CFCl3 as the reference solvent. Chemical shifts (δ) are reported in 
ppm. In reporting data, the following abbreviations were used: s = singlet, br s = broad singlet, d 
= doublet, t = triplet, q = quartet, dd = doublet of doublet, ddd = doublet of doublet of doublet, dt 
= doublet of triplet, dq = doublet of quartet, tq = triplet of quartet, tt = triplet of triplet and m = 
multiplet. Coupling constants (J) are reported in Hertz (Hz). IR spectra were recorded as thin 
films on NaCl plates (unless otherwise noted) on an ATI Mattson Genesis Series FTIR 
spectrometer. The peaks are reported in wavenumbers (cm-1). Low resolution mass spectra were 
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 obtained on a Fisions Autospec in EI mode at 70 eV and are reported in m/z units. High 
resolution mass spectra were taken on a VG-Autospec double focusing spectrometer. Optical 
rotations were measured on a Perkin-Elmer 241 polarimeter at the Na D-line (λ = 589 nm) using 
a 1 dm cell. Analytical chiral HPLC analyses were conducted using either a Chiralcel-OD 
column (Daicel Chemical Industries) or an (S,S)-WHELK O 1 (Regis Technologies Inc.) column 
with a Waters model 440 UV detector at wavelengths 254 and 210 nm.  
Thin layer chromatography (TLC) was performed on silica gel 60 F254 glass backed 
plates with a layer thickness of 0.25 mm manufactured by E. Merck. TLC visualization was 
performed by illumination with a 254 nm UV lamp or by staining with phosphomolybdic acid or 
permanganate solution and subsequent heating. Flash chromatography was performed on silica 
gel (230 – 400 mesh ASTM) purchased from Sorbtech or Bodman. 
Caution: Camptothecin and its derivatives can be toxic. All experiments must be done in 
a well-ventilated hood. Gloves and goggles must be worn at all times. 
 
Chapter 2 
4-Iodo-2-methoxypyridine-3-carbaldehyde (28a): 
     
N O
O
H
I  
Methyllithium in diethyl ether (1.4 M, 24 mL, 33 mmol) was added to a solution of 2-
methoxypyridine (1.9 mL, 18 mmol) in THF (120 mL) at –40 oC. Diisopropylamine (0.13 mL, 
0.90 mmol) was added and the color changed from colorless to yellow-orange.  After warming to 
0 oC and stirring for 3 h, the mixture was cooled to –78 oC and N,N,N′-trimethyl-N′-
formylethylenediamine (2.6 g, 20 mmol) was added slowly.  The reaction was allowed to warm 
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 to –40 oC immediately. nBuLi in hexanes (1.6 M, 23 mL, 37 mmol) was added dropwise through 
a syringe and the mixture was stirred for 3 h at –30 oC.  A solution of I2 (11 g, 44 mmol) in THF 
(70 mL) kept at 0 oC in a jacketed dropping funnel was then added dropwise at –78 oC with 
vigorous stirring. After 30 min, the resulting mixture was allowed to warm slowly to 0 oC (1 h), 
poured into 5% Na2SO3 (250 mL) and extracted with Et2O (3 x 150 mL). The residue obtained 
after removal of the solvents was purified by flash column chromatography (95:5 hexanes/ethyl 
acetate) to provide 28a as a yellow oil (1.9 g, 40%): 1H NMR (300 MHz, CDCl3) δ  4.06 (s, 3H), 
7.54 (d, J = 5.3 Hz, 1H), 7.86 (d, J = 5.3 Hz, 1H), 10.21 (s, 1H); 13C NMR (75 MHz, CDCl3) δ  
54.6, 108.7, 119.4, 130.5, 151.0, 164.4, 190.4; IR (CH2Cl2, NaCl, cm-1) 1703, 1551, 1462, 1368, 
1298, 1265, 1017, 847, 736; HRMS (EI) m/z calcd for C7H6INO2 (M+)  262.9443, found 
262.9431; LRMS (EI) m/z  263 (M+, 100), 234 (80), 205 (30), 127 (30), 93 (28), 78 (72). 
 
(4-Iodo-2-methoxypyridin-3-yl)methanol (29a): 
     
N O
OH
I  
A solution of NaBH4 (0.14 g, 3.6 mmol) in EtOH (20 mL) was added slowly to a solution of 28a 
(1.9 g, 7.1 mmol) in EtOH (20 mL) at 0 oC. After stirring for 4 h at 0 oC, the reaction mixture 
was carefully quenched with an ice-cold brine solution and extracted with Et2O (3 x 30 mL). The 
combined organic extracts were dried over MgSO4 and solvents were removed under reduced 
pressure to afford 29a as a pale yellow oil (1.8 g, 97%). The crude product was used crude for 
the subsequent reaction:  1H NMR (300 MHz, CDCl3) δ  2.43 (t, J = 7.0 Hz, 1H), 3.99 (s, 3H), 
4.82 (d, J = 7.0 Hz, 2H), 7.35 (d, J = 5.4 Hz, 1H), 7.70 (d, J = 5.4 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ  54.3, 64.9, 112.1, 126.5, 128.1, 146.6, 161.7; IR (CH2Cl2, NaCl, cm-1) 3391, 2946, 
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 1561, 1459, 1380, 1019, 805; HRMS (EI) m/z calcd for C7H8NO2I (M+) 264.9600, found 
264.9598; LRMS (EI) m/z  265 (M+, 53), 250 (84), 138 (30), 84 (100), 78 (30). 
 
4-Iodo-2-methoxy-3-methoxymethoxymethylpyridine (30a): 
     
N O
O
I
O
 
Chloromethylmethyl ether (1.5 mL, 20 mmol) was added dropwise through a syringe to a 
solution of 29a (1.8 g, 6.7 mmol) and iPr2EtN (3.5 mL, 20 mmol) in dry CH2Cl2 (40 mL) kept in 
an ice-bath at 0 oC. The resulting mixture was allowed to warm to room temperature and stirred 
for 22 h at room temperature. The reaction was then quenched with 5% NaHCO3 solution and 
extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated under reduced pressure to afford 30a as an orange-yellow oil 
(2.1 g, 100%).  The crude product was used for the subsequent reaction: 1H NMR (300 MHz, 
CDCl3) δ  3.45 (s, 3H), 3.96 (s, 3H), 4.72 (s, 2H), 4.75 (s, 2H), 7.35 (d, J = 5.4 Hz, 1H), 7.71 (d, 
J = 5.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ  54.3, 55.8, 67.9, 96.7, 114.2, 124.0, 128.1, 
147.1, 162.4; IR (CH2Cl2, NaCl, cm-1) 2949, 1561, 1459, 1380, 1265, 1039, 741;HRMS (EI) m/z 
calcd for C9H12NO3I (M+) 308.9862, found 308.9860; LRMS (EI) m/z  309 (M+,19), 277 (20), 
264 (45), 248 (100), 218 (68), 152 (39), 92 (50), 79 (35). 
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 (E)-3-(2-Methoxy-3-methoxymethoxymethylpyridin-4-yl)-pent-2-enoic acid ethyl ester 
(32a):  
     
N O
O O
COOEt  
A round bottomed flask was charged with LiCl (0.82 g, 19 mmol) and dried with a heatgun 
under vacuum. After cooling to room temperature, CuCl (1.6 g, 16 mmol) and Pd(PPh3)4 (0.19 g, 
0.16 mmol) were added. The reaction vessel was then degassed (4 times) under vacuum with an 
argon purge. Dry DMSO (35 mL) was added with concomitant stirring, followed by addition of 
30a (1.0 g, 3.2 mmol) and ethyl (E)-3-(tributylstannyl)-2-pentenoate 31 (1.6 g, 3.9 mmol). The 
resulting mixture was degassed (3 times) by a freeze-thaw process. The reaction mixture was 
stirred at room temperature for 1 h and then at 60 oC for 17 h. This was then cooled to room 
temperature, diluted with Et2O (200 mL) and washed with a mixture of brine (265 mL) and 5% 
NH4OH (55 mL). The aqueous layer was further extracted with Et2O (2 x 100 mL). The 
combined organic layers were washed with water (2 x 250 mL) and then with brine (2 x 250 
mL), dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (95:5 hexanes/ethyl acetate) to afford 32a as a yellow oil (0.82 
g, 82%): 1H NMR (300 MHz, CDCl3) δ  0.99 (t, J = 7.6 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H), 2.99 
(q, J = 7.6 Hz, 2H), 3.43 (s, 3H), 4.01 (s, 3H), 4.21 (q, J = 7.0 Hz, 2H), 4.49 (s, 2H), 4.73 (s, 2H), 
5.81 (s, 1H), 6.69 (d, J = 5.0 Hz, 1H), 8.11 (d, J = 5.0 Hz, 1H);  13C NMR (75 MHz, CDCl3) δ  
12.5, 14.4, 26.6, 54.0, 55.6, 60.3, 62.0, 97.0, 116.3, 116.8, 120.0, 146.4, 153.3, 159.4, 163.4, 
165.9; IR (CH2Cl2, NaCl, cm-1) 2982, 1713, 1640, 1593, 1560, 1453, 1392, 1266, 1186, 1040, 
104 
 743; HRMS (EI) m/z calcd for C16H23NO5 (M+) 309.1576, found 309.1587; LRMS (EI) m/z  309 
(M+,32), 277 (42), 236 (100), 190 (84), 174 (73), 160 (22), 77 (10). 
 
(E)-3-(2-Methoxy-3-methoxymethoxymethylpyridin-4-yl)-pent-2-en-1-ol (33a): 
     
N O
O O
OH  
LAH in diethyl ether (1 M, 9.7 mL, 9.7 mmol) was slowly added to a solution of 32a (1.2 g, 3.9 
mmol) in Et2O (35 mL) kept in a dry ice-acetone bath at –78 oC. The resulting mixture was 
allowed to warm to 0 oC (~2 h) and quenched by adding an ice-cold solution of satd. aqueous 
sodium potassium tartrate. The aqueous layer was extracted with Et2O (3 x 25 mL). The 
combined organic extracts were washed with water (20 mL) and brine (20 mL), dried over 
MgSO4 and concentrated under reduced pressure to afford 33a as a pale yellow oil (0.84 g, 
81%). The crude product was used for the subsequent reaction: 1H NMR (300 MHz, CDCl3) δ  
0.92 (t, J = 7.6 Hz, 3H), 2.44 (q, J = 7.6 Hz, 2H), 3.44 (s, 3H), 4.00 (s, 3H), 4.33 (dd, J = 5.6 Hz, 
6.7 Hz, 2H), 4.55 (s, 2H), 4.70 (s, 2H), 5.63 (t, J = 6.8 Hz, 1H), 6.68 (d, J = 5.2 Hz, 1H), 8.07 (d, 
J = 5.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 13.2, 15.5, 25.4, 54.0, 55.6, 59.0, 61.8, 96.2, 
117.3, 129.4, 142.0, 146.1, 154.6, 163.6; IR (CH2Cl2, NaCl, cm-1) 3383, 2945, 1594, 1555, 1452, 
1391, 1320, 1268, 1148, 1038, 739, 541; HRMS (EI) m/z  calcd for C13H18NO3  236.1287, found 
236.1292; LRMS (EI) m/z  268 (M + H, 38), 249 (31), 236 (62), 190 (48), 176 (100), 160 (35), 
91 (16), 77 (15). Copies of spectral data can be found in the appendix section. 
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 (2S,3S)-(+)-[3-Ethyl-3-(2-methoxy-3-methoxymethoxymethylpyridin-4-yl)-oxiranyl] 
methanol (34a): 
     
N O
O O
OH
O
 
(L)-(+)-Diethyltartrate (0.1 mL, 0.6 mmol) and Ti(OiPr)4 (0.14 mL, 0.48 mmol) were added to a 
suspension of 33a (0.16 g, 0.60 mmol) and 4Å molecular sieves (48 mg) in dry CH2Cl2 (5.0 mL) 
kept in a dry ice-acetone bath at –20 oC and the mixture was stirred for 1 h. Then tBuOOH, pre-
dried over 4Å molecular sieves for 1 h (0.19 mL, 5.0-6.0 M in decane), was added and stirred at 
–20 oC for 24 h. The resulting mixture was then diluted with Et2O (1.0 mL) and quenched with 
satd.Na2SO4 solution (0.5 mL). The resulting heterogenous mixture was stirred until it warmed to 
room temperature (2 h). This was then filtered through a celite pad washing with hot ethyl 
acetate several times. The combined filtrates were concentrated under vacuum. The residue was 
dissolved in Et2O (2.5 mL) at 0 oC and a 1 N NaOH solution saturated with NaCl (1.6 mL) was 
added. The two-phase mixture was vigorously stirred at 0 oC for 1 h and then transferred to a 
separatory funnel. The aqueous layer was separated and extracted with EtOAc (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure to 
afford 34a as a yellow oil (0.14 g, 84%) with 96% ee. The crude product was used for the 
subsequent reaction.  However, for HPLC analysis, the crude product was filtered over a silica 
plug to remove solvent front and baseline impurities. Epoxide 34a was then analyzed for 
enantiomeric purity using a Chiralcel OD column with 98:2 hexane/iPrOH as the eluent using the 
racemate as the standard. The desired (2S,3S) enantiomer elutes first, (Rt = 23.1 min): 1H NMR 
(300 MHz, CDCl3) δ  0.92 (t, J = 7.6 Hz, 3H), 1.81 (dq, J = 7.4 Hz, 14.8 Hz, 1H), 2.01 (dq, J = 
106 
 7.6 Hz, 15.0 Hz, 1H), 3.24 (t, J = 5.8 Hz, 1H), 3.46 (s, 3 H), 3.90 (m, 2H), 3.99 (s, 3H), 4.71 (s, 
2H), 4.73 (s, 2H), 6.93 (d, J = 5.2 Hz, 1H), 8.12 (d, J = 5.2 Hz, 1H) (-OH proton resonance not 
detected); 13C NMR (75 MHz, CDCl3) δ  9.4, 25.7, 26.0, 54.1, 55.8, 60.8, 61.3, 63.7, 64.7, 96.7, 
116.5, 116.8, 146.6, 151.0, 163.1; IR (CH2Cl2, NaCl, cm-1) 3408, 2980, 1765, 1607, 1457, 1410, 
1393, 1266, 1040, 742, 546; HRMS (EI) m/z calcd for C14H22NO5 (M+H) 284.1498, found 
284.1507; LRMS (EI) m/z 284 (M + H, 58), 190 (100), 178 (73), 162 (27), 148 (27), 77 (13); 
[α]D23 = +65.6 (c = 0.25, CH2Cl2). 
 
(R)-(+)-3-(2-Methoxy-3-methoxymethoxymethylpyridin-4-yl)-pentane-1,3-diol (35a): 
     
N O
O O
OH
HO
 
LAH in diethyl ether (1 M, 2.5 mL, 2.5 mmol) was added to a solution of 34a (0.71 g, 2.5 mmol) 
in Et2O (50 mL) kept in an ice bath at 0 oC and allowed to warm to room temperature and stirred 
for 24 h. The reaction was quenched with a chilled solution of sodium potassium tartrate at 0 oC 
and the aqueous layer was extracted with Et2O (3 x 40 mL). The combined organic extracts were 
washed with water (2 x 25 mL) and brine (2 x 25 mL), dried over MgSO4 and concentrated 
under reduced pressure to afford 35a as a colorless oil (0.54 g, 76%).  The crude product was 
sufficiently pure for the subsequent reaction: 1H NMR (300 MHz, CDCl3) δ  0.79 (t, J = 7.3 Hz, 
3H), 1.91 (q, J = 7.3 Hz, 2H), 2.15 (m, 2H), 3.42 (s, 3H), 3.60 (m, 1H), 3.74 (m, 1H), 3.98 (s, 
3H), 4.71 (s, 2H), 4.89 (d, J = 10.7 Hz, 1H), 5.10 (d, J = 10.7 Hz, 1H), 6.77 (d, J = 5.5 Hz, 1H), 
8.05 (d, J = 5.5 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ  7.8, 36.6, 43.8, 54.1, 55.9, 60.2, 61.1, 
80.9, 96.5, 116.3, 117.9, 146.2, 156.4, 163.8; IR (CH2Cl2, NaCl, cm-1) 3391, 3056, 2984, 1593, 
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 1446, 1382, 1265, 1037, 743, 546; HRMS (EI) m/z calcd for C14H24NO5 (M+H) 286.1654, found 
286.1658; LRMS (EI) m/z  286 (M + H,39), 235 (23), 222 (86), 205 (52), 194 (74), 178 (100), 
150 (49), 92 (30), 77 (15); [α]D23 = +0.185 (c = 1.08, CH2Cl2). 
 
(R)-(−)-3-Hydroxy-3-(2-methoxy-3-methoxymethoxymethylpyridin-4-yl)pentanal (36a): 
     
N O
O O
CHO
HO
 
Dess-Martin periodinane (1.2 g, 2.9 mmol) was added to a solution of 35a (0.50 g, 1.8 mmol) in 
CH2Cl2 (20 mL). The mixture was stirred at room temperature for 3 h and then poured into a 
well-stirred mixture of satd. Na2S2O3 (10 mL) and satd. NaHCO3 (10 mL). After 30 min, the 
layers were separated and the aqueous layer was extracted with diethyl ether (3 x 15 mL).  The 
combined organic extracts were washed with satd. NaHCO3 and brine, dried over MgSO4, and 
concentrated under vacuum to give the crude aldehyde 36a (0.47 g, 89%) as pale yellow oil. The 
crude product was used for the subsequent reaction: 1H NMR (300 MHz, CDCl3) δ  0.82 (t, J = 
7.4 Hz, 3H), 1.91 (2 overlapping dqs, 2H), 2.85 (dd, J = 2.1 Hz, 16.4 Hz, 1H), 3.10 (dd, J = 2.2 
Hz, 16.3 Hz, 1H), 3.41 (s, 3H), 3.96 (s, 3H), 4.74 (s, 2H), 4.98 (q, J = 10.9 Hz, 2H), 6.74 (d, J = 
5.5 Hz, 1H), 8.06 (d, J = 5.5 Hz, 1H), 9.73 (t, J = 2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ  7.9, 
36.4, 54.2, 55.3, 56.0, 60.9, 77.9, 96.4, 115.8, 117.4, 146.5, 155.6, 163.8, 202.2; IR (CH2Cl2, 
NaCl, cm-1) 3380, 3057, 2982, 1763, 1655, 1596, 1422, 1264, 895, 735, 547; HRMS (EI) m/z 
calcd for C14H22NO5 (M+H) 284.1498, found 284.1498; LRMS (EI) m/z 284 (M + H, 15), 265 
(25), 192 (20), 178 (72), 148 (24), 84 (100), 57 (26); [α]D23 = −11.5 (c = 0.125, CH2Cl2). 
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 (R)-(+)-5-Ethyl-5-hydroxy-1-methoxy-5,6-dihydro-9H-8-oxa-2-aza-benzocyclohepten-7-one 
[(R)-18]: 
     
N O
O
O
HO
 
2-methyl-2-butene (2.1 mL) was added to a solution of the aldehyde 36a (0.13 g, 0.46 mmol) in 
tert-butyl alcohol (7.1 mL). A solution of sodium chlorite (0.37 g, 4.1 mmol) and sodium 
dihydrogen phosphate (0.44 g, 3.2 mmol) in H2O (3.8 mL) was added dropwise to this mixture 
through a syringe. The resulting mixture was stirred at room temperature for 36 h. Then the 
crude mixture was extracted with ethyl acetate (2 x 10 mL). The aqueous layer was then 
acidified (pH ~ 3.5) by dropwise addition of 5% HCl and subsequently washed with ethyl acetate 
(2 x 10 mL). If a yellow coloration was observed, the mixture was washed with 5% sodium 
sulfite solution prior to this ethyl acetate extraction. The combined organic extracts were washed 
with brine, dried over sodium sulfate and concentrated under vacuum to give the crude product 
37a (0.12 g, 84%) as a light green oil which was used immediately after the workup. 
 TFA (8.0 mL) was added to 37a (0.11 g, 0.38 mmol) at room temperature via a syringe. 
After stirring for 24 h, the mixture was neutralized with satd. NaHCO3 (pH ~ 8) and extracted 
with diethyl ether (3 x 6 mL). The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure to afford (R)-18 as a yellow-brown oil (72 mg, 80%) which 
was used crude for the subsequent reaction. When necessary, the crude product was purified by 
column chromatography (75:25 hexanes/ethyl acetate): 1H NMR (300 MHz, CD3OD) δ  0.84 (t, 
J = 7.4 Hz, 3H), 1.85 (q, J = 7.4 Hz, 2H), 3.01 (d, J = 13.9 Hz, 1H), 3.41 (d, J = 13.9 Hz, 1H), 
3.94 (s, 3H), 5.29 (d, J = 15.2 Hz, 1H), 5.44 (d, J = 15.2 Hz, 1H), 7.15 (d, J = 5.5 Hz, 1H), 8.13 
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 (d, J = 5.5 Hz, 1H); 13C NMR (75 MHz, CD3OD) δ  9.0, 38.5, 43.8, 55.0, 61.4, 62.7, 74.7, 117.1, 
147.8, 156.0, 161.9, 173.1; IR (MeOH, NaCl, cm-1) 3390, 2958, 1725, 1683, 1596, 1377, 1204, 
1140, 1041; HRMS (EI) m/z calcd for C12H15NO4 (M+) 237.1001, found 237.0996; LRMS (EI) 
m/z  237 (M+, 75), 208 (22), 166 (100), 136 (25), 106 (7), 77 (7); [α]D23 = +3.0 (c = 0.1, MeOH). 
 
(R)-(+)-5-Ethyl-5-hydroxy-2,5,6,9-tetrahydro-8-oxa-2-aza-benzocycloheptene-1,7-dione 
[(R)-19]: 
     
H
N O
O
O
HO
 
Sodium iodide (0.070 g, 0.49 mmol) was added to a solution of lactone (R)-18 (0.070 g, 0.30 
mmol) in dry acetonitrile (1.0 mL) followed by chlorotrimethylsilane (0.060 mL, 0.49 mmol).  
The resulting mixture was stirred at room temperature for 15 min. Then H2O (2.7 µL, 0.15 
mmol) was added and the reaction mixture was heated to 60 oC for 7 h.  The mixture was then 
poured into a 1:1 solution of 5% sodium sulfite/brine (7.0 mL) and then quickly extracted with 
ethyl acetate (4 x 5 mL).  The organic layer was dried over MgSO4 and concentrated under 
reduced pressure. The crude product was subjected to flash chromatography (5:95 
MeOH/CH2Cl2) to afford pure (R)-19 as pale yellow oil (10 mg, 16%): 1H NMR (300 MHz, 
CD3OD) δ  0.91 (t, J = 7.5 Hz, 3H), 1.82 (m, 2H), 3.10 (d, J = 13.8 Hz, 1H), 3.40 (d, J = 13.8 
Hz, 1H), 5.30 (d, J = 15.2 Hz, 1H), 5.46 (d, J = 15.2 Hz, 1H), 6.57 (d, J = 7.0 Hz, 1H), 7.35 (d, J 
= 7.0 Hz, 1H); 13C NMR (75 MHz, CDCl3/CD3OD) δ  6.8, 35.2, 41.5, 61.0, 72.4, 105.9, 122.4, 
132.8, 156.3, 161.6, 172.6; IR (MeOH, NaCl, cm-1) 3370(br), 1655, 1049, 1025, 823, 768; 
HRMS (EI) m/z calcd for C11H13NO4 (M+) 223.0845, found 223.0851; LRMS (EI) m/z 224 (M + 
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 H, 32), 195 (21), 163 (43), 153 (100), 91 (40), 77 (19), 55 (24); [α]D23 = +35.0 (c = 0.08, 
MeOH). Copies of spectral data can be found in the appendix section. 
 
Chapter 3 
(1-Ethyl-4-methoxy-6-trimethylsilanyl-1,3-dihydro-furo[3,4-c]pyridin-1-yl)acetic acid (87): 
     
N
O
COOH
TMS O
 
H2O2 (30% w/w, 1.8 mL, 16 mmol) was added to a solution of 71 (0.30 g, 1.0 mmol) in MeOH 
(10.5 mL) kept at 0 °C in an ice bath. A solution of NaOH (6 N, 0.55 mL, 3.3 mmol) was added 
dropwise to this mixture via a syringe at 0 °C. After the addition was complete (5 min), the 
reaction mixture was warmed to room temperature and stirred for 6 h. Water (15 mL) was added, 
the layers were separated and the aqueous layer washed with CH2Cl2 (2 x 15 mL). The aqueous 
layer was then acidified (pH ~ 3) by dropwise addition of 1 N HCl via a Pasteur pipet and 
subsequently washed with CH2Cl2 (2 x 10 mL). The combined organic extracts were dried over 
MgSO4 and concentrated under reduced pressure to afford 87 as a colorless oil (0.28 g, 88%). 
The crude product was sufficiently pure for the subsequent reaction: 1H NMR (300 MHz, 
CDCl3) δ 0.29 (s, 9H), 0.77 (t, J = 7.3 Hz, 3H), 1.87 (dq, J = 14.7 Hz, 7.4 Hz, 1H), 2.01 (dq, J = 
7.4 Hz, 14.6 Hz, 1H), 2.79 (d, J = 15.2 Hz, 1H), 2.81 (d, J = 15.2 Hz, 1H), 4.00 (s, 3H), 5.10 (d, 
J = 12.7 Hz, 1H), 5.12 (d, J = 12.8 Hz, 1H), 6.88 (s, 1H); 13C NMR (75 MHz, CDCl3) δ −1.8, 
7.9, 32.2, 44.4, 52.9, 71.1, 89.6, 115.1, 120.1, 151.8, 158.2, 165.6, 173.9; IR (CH2Cl2, NaCl, cm-
1) 2950, 2858, 1705, 1582, 1449, 1352, 1239, 1029; HRMS (EI) m/z calcd for C15H23NO4Si (M+) 
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 309.1396, found 309.1382; LRMS (EI) m/z 309 (M+, 17), 294 (27), 280 (62), 249 (65), 208 (20), 
162 (9), 117 (10), 89 (37), 73 (100). 
 
(1-Ethyl-4-methoxy-6-trimethylsilanyl-1,3-dihydrofuro[3,4-c]pyridin-1-yl)acetic acid 
methyl ester: 
     
N
O
COOMe
TMS O
 
TMSCHN2 (2 M solution in hexanes, 0.55 mL, 1.09 mmol) was added to a solution of 87 (0.26 
g, 0.84 mmol) in a mixture of methanol (1.5 mL) and benzene (5.3 mL) at room temperature. 
After stirring for 30 min at room temperature, the reaction mixture was concentrated under 
reduced pressure to afford the ester as a yellow oil (0.26 g, 98%). The crude product was 
sufficiently pure for the subsequent reaction: 1H NMR (300 MHz, CDCl3) δ 0.29 (s, 9H), 0.76 (t, 
J = 7.3 Hz, 3H), 1.88 (dq, J = 7.4 Hz, 14.8 Hz, 1H), 2.01 (dq, J = 7.4 Hz, 14.7 Hz, 1H), 2.78 (d, J 
= 14.4 Hz, 1H), 2.80 (d, J = 14.4 Hz, 1H), 3.59 (s, 3H), 4.00 (s, 3H), 5.03 (d, J = 12.7 Hz, 1H), 
5.05 (d, J = 12.7 Hz, 1H), 6.89 (s, 1H); 13C NMR (75 MHz, CDCl3) δ −1.8, 7.8, 32.5, 44.5, 51.4, 
52.8, 70.9, 89.7, 115.5, 120.8, 152.4, 158.2, 165.0, 170.2; IR (CH2Cl2, NaCl, cm-1) 2955, 2858, 
1777, 1741, 1593, 1460, 1362, 1034; HRMS (EI) m/z calcd for C16H25NO4Si (M+) 323.1553, 
found 323.1563; LRMS (EI) m/z 323 (M+, 43), 308 (40), 294 (65), 250 (100), 234 (42), 208 (46), 
84 (82). Copies of spectral data can be found in the appendix section. 
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 (1-Ethyl-6-iodo-4-methoxy-1,3-dihydrofuro[3,4-c]pyridin-1-yl)acetic acid methyl ester: 
     
N
O
COOMe
I O
 
A solution of ICl (0.42 g, 2.6 mmol) in CCl4 (1.82 mL) was added to a solution of the above 
ester (0.21 g, 0.65 mmol) in CH2Cl2 (2.6 mL) kept at 0 °C in an ice bath and allowed to warm to 
room temperature. After stirring for 14 h, the reaction mixture was poured into a chilled solution 
of 5% Na2SO3/brine (1:1, 40 mL) and extracted the mixture with ethyl acetate (3 x 30 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (5:95 ethyl acetate/hexanes) to afford the 
iodide as a pale yellow oil (0.1 g, 41%): 1H NMR (300 MHz, CDCl3) δ 0.60 (t, J = 7.2 Hz, 3H), 
1.73 (m, 2H), 2.60 (d, J = 15.0 Hz, 1H), 2.62 (d, J = 15.0 Hz, 1H), 3.44 (s, 3H), 3.79 (s, 3H), 
4.80 (d, J = 12.9 Hz, 1H), 4.82 (d, J = 12.9 Hz, 1H), 7.00 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 
7.6, 32.6, 51.5, 54.1, 70.5, 89.0, 111.3, 121.1, 121.4, 156.2, 157.5, 169.8; IR (CH2Cl2, NaCl, cm-
1) 2950, 2853, 2356, 2330, 1741, 1593, 1460, 1362, 1035, 850; HRMS (EI) m/z calcd for 
C13H16INO4 (M+) 377.0124, found 377.0129; LRMS (EI) m/z 377 (M+, 32), 348 (35), 303 (100), 
288 (23), 162 (28), 77 (20). 
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 (1-Ethyl-6-iodo-4-oxo-1,3,4,5-tetrahydro-furo[3,4-c]pyridin-1-yl)acetic acid methyl ester 
(90): 
     
H
N
O
COOMe
I O
 
Sodium iodide (29 mg, 0.20 mmol) was added to a solution of the above iodide (46 mg, 0.12 
mmol) in dry acetonitrile (1.2 mL) at room temperature. Chlorotrimethylsilane (25 µL, 0.20 
mmol) was then added and the reaction mixture was stirred for 15 min at room temperature. H2O 
(1.0 µL, 0.061 mmol) was added and the reaction mixture was heated at 60 °C for 22 h. The 
mixture was then poured into a solution of 5% Na2SO3/brine (1:1, 7.8 mL) and quickly extracted 
with ethyl acetate (4 x 10 mL). The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(2:3 ethyl acetate/hexanes) to afford 90 as a pale yellow solid (30 mg, 68%): 1H NMR (300 
MHz, CDCl3) δ 0.80 (t, J = 7.2 Hz, 3H), 1.86 (m, 2H), 2.75 (q, J = 14.8 Hz, 2H), 3.61 (s, 3H), 
5.01 (s, 2H), 6.66 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 7.7, 32.2, 43.8, 51.7, 71.8, 90.2, 94.0, 
113.2, 127.4, 155.8, 161.0, 169.8; IR (CH2Cl2, NaCl, cm-1); HRMS (EI) m/z calcd for 
C12H14INO4 (M+) 362.9968, found 362.9961; LRMS (EI) m/z 363 (M+, 22), 334 (31), 289 (100), 
274 (15), 163 (23), 78 (21). 
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 (1-Ethyl-6-iodo-4-oxo-5-prop-2-ynyl-1,3,4,5-tetrahydrofuro[3,4-c]pyridin-1-yl)acetic acid 
methyl ester (91a): 
     
N
O
COOMe
I O
 
NaH in mineral oil (60%, 1.5 mg, 0.036 mmol) was added to a solution of 90 (12 mg, 0.033 
mmol) in a mixture of DME (0.25 mL) and DMF (0.10 mL) at 0 °C under argon. After stirring 
this mixture for 10 min at 0 °C, LiBr (5.8 mg, 0.066 mmol) was added. The reaction mixture was 
allowed to warm to room temperature and stirred for 15 min. Propargyl bromide (80% w/w in 
toluene, 15 µL, 0.13 mmol) was then added via a syringe and the reaction mixture was heated in 
the dark at 65 °C for 7 h. The final solution was poured into brine (5 mL) and extracted with 
ethyl acetate (3 x 5 mL). The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(2:3 ethyl acetate/hexanes) to give 91a as a pale yellow foam (7.0 mg, 54%): 1H NMR (300 
MHz, CDCl3) δ 0.82 (t, J = 7.4 Hz, 3H), 1.78 (dq, J = 7.4 Hz, 14.7 Hz, 1H), 1.92 (dq, J = 7.4 Hz, 
14.7 Hz, 1H), 2.45 (t, J = 2.4 Hz, 1H), 2.75 (q, J = 14.8 Hz, 2H), 3.63 (s, 3H), 4.97 (s, 2H), 5.11 
(dd, J = 2.4 Hz, 17.2 Hz, 1H), 5.13 (dd, J = 2.5 Hz, 17.1 Hz, 1H), 6.77 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 7.8, 32.0, 43.4, 43.7, 51.8, 71.9, 73.2, 90.2, 98.8, 114.6, 128.4, 153.8, 157.4, 
170.0; IR (CH2Cl2, NaCl, cm-1) 3288, 2970, 2852, 2356, 2335, 1736, 1649, 1521, 1198, 1024; 
HRMS (EI) m/z calcd for C15H16INO4 (M+) 401.0124, found 401.0135; LRMS (EI) m/z 401 (M+, 
31), 372 (24), 345 (13), 327 (100), 245 (18), 206 (20), 162 (36), 77 (17). Copies of spectral data 
can be found in the appendix section. 
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 (5-[3-{tert-Butyldimethylsilanyl}prop-2-ynyl]-1-ethyl-6-iodo-4-oxo-1,3,4,5-
tetrahydrofuro[3,4-c]pyridin-1-yl)acetic acid methyl ester (91b): 
     
N
O
COOMe
I O
TBS
 
Following the above procedure, 90 (19 mg, 0.051 mmol) was alkylated with 3-tert-
butyldimethylsilyl propargyl bromide (24 mg, 0.10 mmol) in the presence of NaH in mineral oil 
(60%, 2.3 mg, 0.056 mmol) and LiBr (8.9 mg, 0.10 mmol) in a mixture of DME (0.39 mL) and 
DMF (0.15 mL). The crude product was purified by flash chromatography (1:4 ethyl 
acetate/hexanes) to afford 91b as a colorless oil (12 mg, 45%): 1H NMR (300 MHz, CDCl3) δ 
0.10 (s, 6H), 0.82 (t, J = 7.4 Hz, 3H), 0.93 (s, 9H), 1.78 (dq, J = 7.4 Hz, 14.7 Hz, 1H), 1.92 (dq, J 
= 7.3 Hz, 14.7 Hz, 1H), 2.75 (q, J = 14.7 Hz, 2H), 3.62 (s, 3H), 4.98 (s, 2H), 5.12 (d, J = 17.3 
Hz, 1H), 5.15 (d, J = 17.3 Hz, 1H), 6.76 (s, 1H); 13C NMR (75 MHz, CDCl3) δ −4.9, 7.7, 16.6, 
26.0, 32.1, 43.8, 51.7, 72.0, 89.0, 90.2, 98.8, 99.3, 114.5, 128.2, 153.5, 157.3, 170.0; IR (CH2Cl2, 
NaCl, cm-1) 2950, 2924, 2852, 2356, 2330, 1736, 1654, 1526, 1198, 1034; HRMS (EI) m/z calcd 
for C21H30INO4Si (M+) 515.0989, found 515.0999; LRMS (EI) m/z 515 (M+, 25), 458 (100), 441 
(58), 420 (22), 384 (54), 356 (17), 258 (11), 162 (12), 96 (58), 73(57). Copies of spectral data 
can be found in the appendix section. 
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 5-Ethyl-3-iodo-1-methoxy-9H-8-oxa-2-azabenzocyclohepten-7-one: 
     
N
O
I O
O  
ICl (1 M in dichloromethane, 10 mL, 10 mmol) was added to a solution of 71 (0.73 g, 2.5 mmol) 
in CH2Cl2 (12 mL) kept at 0 °C in an ice bath and then allowed to warm to room temperature. 
After stirring for 16 h, the reaction mixture was poured into a chilled solution of 5% 
Na2SO3/brine (1:1, 150 mL) and extracted the mixture with ethyl acetate (3 x 120 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (5:95 ethyl acetate/hexanes) to afford the 
iodide as a pale yellow oil (0.32 g, 38%): 1H NMR (300 MHz, CDCl3) δ 1.17 (t, J = 7.3 Hz, 3H), 
2.62 (dq, J = 1.3 Hz, 7.4 Hz, 2H), 4.02 (s, 3H), 5.06 (br s, 2H), 6.38 (s, 1H), 7.38 (s, 1H); 13C 
NMR (75 MHz, CDCl3) δ 12.4, 28.9, 54.9, 60.2, 114.6, 116.4, 122.5, 124.4, 148.2, 149.4, 160.3, 
167.3; IR (CH2Cl2, NaCl, cm-1) 2955, 2924, 2847, 1736, 1618, 1454, 1362, 1045; HRMS (EI) 
m/z calcd for C12H12INO3 (M+) 344.9862, found 344.9868; LRMS (EI) m/z 345 (M+, 100), 316 
(58), 302 (74), 288 (54), 218 (22), 188 (35), 159 (43), 130 (55), 77 (36). 
 
5-Ethyl-3-iodo-2,9-dihydro-8-oxa-2-azabenzocycloheptene-1,7-dione (93): 
     
H
N
O
I O
O  
Sodium iodide (0.15 g, 1.0 mmol) was added to a solution of the above iodide (0.12 g, 0.33 
mmol) in dry acetonitrile (3.3 mL) at room temperature. Chlorotrimethylsilane (0.13 mL, 1.0 
117 
 mmol) was then added and the reaction mixture was stirred for 15 min at room temperature. H2O 
(3.0 µL, 0.17 mmol) was next added and the reaction mixture was heated to 60 °C and stirred at 
that temperature for 21 h. The mixture was then poured into a solution of 5% Na2SO3/brine (1:1, 
20 mL) and quickly extracted with ethyl acetate (4 x 20 mL). The combined organic extracts 
were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (1:4 acetone/dichloromethane) to afford 93 as a pale yellow 
solid (36 mg, 33%): 1H NMR (300 MHz, CDCl3) δ 1.13 (t, J = 7.4 Hz, 3H), 2.60 (q, J = 7.2 Hz, 
2H), 4.99 (br s, 2H), 6.32 (s, 1H), 7.04 (s, 1H), 12.27 (br s, 1H); 13C NMR (75 MHz, CDCl3) δ 
12.0, 28.0, 29.0, 60.0, 122.2, 148.2, 149.3, 161.0, 166.7; IR (CH2Cl2, NaCl, cm-1) 3344, 2955, 
2837, 1710, 1629, 1583, 1444, 1014; HRMS (EI) m/z calcd for C11H10INO3 (M+) 330.9705, 
found 330.9717; LRMS (EI) m/z 331 (M+, 100), 302 (82), 288 (92), 274 (65), 174 (17), 160 (26), 
146 (18). 
 
5-Ethyl-3-iodo-2-prop-2-ynyl-2,9-dihydro-8-oxa-2-azabenzocycloheptene-1,7-dione (94a): 
     
N
O
I O
O  
NaH in mineral oil (60%, 7.2 mg, 0.18 mmol) was added to a solution of 93 (30 mg, 0.091 
mmol) in a mixture of DME (0.70 mL) and DMF (0.30 mL) at 0 °C under argon. After stirring 
this mixture for 10 min at 0 °C, LiBr (32 mg, 0.36 mmol) was added. The reaction mixture was 
allowed to warm to room temperature and stirred for 15 min. Propargyl bromide (80% w/w in 
toluene, 80 µL, 0.72 mmol) was then added via a syringe and the reaction mixture was heated in 
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 the dark at 65 °C for 14 h. The final solution was poured into brine (10 mL) and extracted with 
ethyl acetate (3 x 10 mL). The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(3:7 ethyl acetate/hexanes) to give 94a as a pale yellow oil (12 mg, 37%): 1H NMR (300 MHz, 
CDCl3) δ 1.17 (t, J = 7.3 Hz, 3H), 2.39 (t, J = 2.5 Hz, 1H), 2.55 (q, J = 7.4 Hz, 2H), 5.11 (s, 2H), 
6.41 (s, 1H), 6.88 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 12.4, 28.4, 44.7, 61.1, 73.5, 101.1, 
116.8, 123.8, 125.0, 148.0, 149.2, 159.8, 167.3; IR (CH2Cl2, NaCl, cm-1) 2909, 2842, 2361, 
2330, 1710, 1644, 1506, 1454, 1045; HRMS (EI) m/z calcd for C14H12INO3 (M+) 368.9862, 
found 368.9866; LRMS (EI) m/z 369 (M+, 37), 340 (35), 326 (12), 256 (12), 149 (30), 129 (30), 
73 (66), 57 (100). Copies of spectral data can be found in the appendix section. 
 
2-[3-(tert-Butyldimethylsilanyl)prop-2-ynyl]-5-ethyl-3-iodo-2,9-dihydro-8-oxa-2-
azabenzocycloheptene-1,7-dione (94b): 
     
N
O
I O
TBS
O  
Following the above procedure, 93 (32 mg, 0.097 mmol) was alkylated with 3-tert-
butyldimethylsilyl propargyl bromide (0.18 g, 0.77 mmol) in the presence of NaH in mineral oil 
(60%, 7.7 mg, 0.19 mmol) and LiBr (34 mg, 0.39 mmol) in a mixture of DME (0.75 mL) and 
DMF (0.31 mL). The crude product was purified by flash chromatography (1:4 ethyl 
acetate/hexanes) to afford 94b as a colorless oil (20 mg, 43%): 1H NMR (300 MHz, CDCl3) δ 
0.10 (s, 6H), 0.91 (s, 9H), 1.17 (t, J = 7.4 Hz, 3H), 2.55 (q, J = 7.6 Hz, 2H), 5.13 (s, 2H), 6.41 (s, 
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 1H), 6.88 (s, 1H); 13C NMR (75 MHz, CDCl3) δ −4.9, 12.4, 16.6, 26.1, 28.4, 45.1, 61.3, 89.5, 
98.5, 101.2, 116.7, 123.6, 124.9, 147.9, 149.4, 159.8, 167.4; IR (CH2Cl2, NaCl, cm-1) 2955, 
2847, 2248, 2176, 1726, 1649, 1511, 1265, 1035; HRMS (EI) m/z calcd for C16H17INO3Si (M − 
tBu) 426.0022, found 426.0023; LRMS (EI) m/z 426 (M−tBu, 25), 398 (19), 382 (22), 223 (10), 
127 (56), 96 (100), 75 (91). Copies of spectral data can be found in the appendix section. 
 
General procedure 3A: Radical Cascade Cyclization towards the Synthesis of Non-lactone 
Analogs 92a-d, 95a-d. 
A solution of iodopyridone (~ 6-11 mg) in benzene was taken up in a 15 x 45 mm 
cylindrical screw-cap glass vial and kept at room temperature. A solution of isonitrile (1 M in 
benzene) and then hexamethylditin were added at room temperature. The vial was capped and 
the reaction mixture was irradiated with a 275W GE sunlamp for 4 h. The solvent was then 
evaporated and the residue was purified by preparative thin layer chromatography (1:9 
acetone/dichloromethane). 
 
Methyl(3-ethyl-13-oxo-11,13-dihydro-1H,3H-furo[3′,4′:6,7]indolizino[1,2-b]quinolin-3-
yl)acetate (92a): 
    
N
N
O
COOMe
O
 
Following general procedure 3A, iodopyridone 91a (7.6 mg, 0.019 mmol) was reacted with 
phenyl isonitrile (1 M, 76 µL, 0.076 mmol) and hexamethylditin (11 µL, 0.028 mmol) in 
benzene (0.32 mL) to afford 92a, after purification, as a yellow solid (2.1 mg, 30%): 1H NMR 
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 (500 MHz, CDCl3) δ 0.86 (t, J = 7.3 Hz, 3H), 1.94 (dq, J = 7.2 Hz, 14.5 Hz, 1H), 2.05 (dq, J = 
7.5 Hz, 14.7 Hz, 1H), 2.89 (d, J = 14.7 Hz, 1H), 2.90 (d, J = 14.8 Hz, 1H), 3.63 (s, 3H), 5.17 (d, 
J = 13.5 Hz, 1H), 5.18 (d, J = 13.4 Hz, 1H), 5.30 (s, 2H), 7.21 (s, 1H), 7.66 (t, J = 7.2 Hz, 1H), 
7.83 (t, J = 7.1 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 8.39 (s, 1H); 13C 
NMR (151 MHz, CDCl3) δ 7.9, 32.9, 44.4, 49.7, 51.8, 72.5, 90.8, 95.4, 127.8, 128.2, 128.3, 
129.1, 129.2, 129.7, 130.6, 131.1, 147.2, 148.9, 152.9, 154.3, 157.1, 170.1; IR (CH2Cl2, NaCl, 
cm-1) 2919, 2842, 2356, 2325, 1731, 1654, 1603, 1439, 1224, 1024; HRMS (EI) m/z calcd for 
C22H20N2O4 (M+) 376 1423, found 376.1417; LRMS (EI) m/z 376 (M+, 6), 347 (6), 302 (39), 261 
(5), 137 (13), 97 (18), 81 (45), 69 (100). Copies of spectral data can be found in the appendix 
section. 
 
Methyl(3-ethyl-8-fluoro-13-oxo-11,13-dihydro-1H,3H-furo[3′,4′:6,7]indolizino[1,2-
b]quinolin-3-yl)acetate (92b): 
    
N
N
O
COOMe
OF
 
Following general procedure 3A, iodopyridone 91a (6.5 mg, 0.016 mmol) was reacted with p-
fluorophenyl isonitrile (1 M, 65 µL, 0.065 mmol) and hexamethylditin (9.0 µL, 0.024 mmol) in 
benzene (0.27 mL) to afford 92b, after purification, as a yellow solid (3.5 mg, 55%): 1H NMR 
(300 MHz, CDCl3) δ 0.86 (t, J = 7.3 Hz, 3H), 1.94 (dq, J = 7.5 Hz, 14.6 Hz, 1H), 2.05 (dq, J = 
7.8 Hz, 15.1 Hz, 1H), 2.89 (d, J = 14.7 Hz, 1H), 2.91 (d, J = 14.7 Hz, 1H), 3.63 (s, 3H), 5.17 (s, 
2H), 5.30 (s, 2H), 7.17 (s, 1H), 7.54-7.64 (m, 2H), 8.21 (dd, J = 5.3 Hz, 9.2 Hz, 1H), 8.33 (s, 
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 1H); 13C NMR (75 MHz, CDCl3) δ 7.8, 32.8, 44.3, 49.5, 51.8, 72.4, 90.7, 95.2, 111.3 (d, JCF = 
20.0 Hz), 121.0, 128.8 (d, JCF = 11.3 Hz), 129.1, 130.2 (d, JCF = 46.3 Hz), 132.0 (d, JCF = 7.5 
Hz), 145.9, 146.8, 152.4, 154.3, 157.0, 170.1; IR (CH2Cl2, NaCl, cm-1) 2909, 2847, 2351, 2340, 
1721, 1654, 1593, 1501, 1449, 1234, 1024; HRMS (EI) m/z calcd for C22H19FN2O4 (M+) 
394.1329, found 394.1326; LRMS (EI) m/z 394 (M+, 18), 365 (15), 337 (10), 320 (100), 293 
(14), 171 (20), 105 (30), 83 (33), 69 (52). 
 
Methyl{10-[tert-butyl(dimethyl)silyl]-3-ethyl-13-oxo-11,13-dihydro-1H,3H-
furo[3′,4′:6,7]indolizino[1,2-b]quinolin-3-yl)acetate (92c): 
    
N
N
O
COOMe
O
TBS
 
Following general procedure 3A, iodopyridone 91b (8.3 mg, 0.016 mmol) was reacted with 
phenyl isonitrile (1 M, 64 µL, 0.064 mmol) and hexamethylditin (9.0 µL, 0.024 mmol) in 
benzene (0.27 mL) to afford 92c, after purification, as a yellow solid (5.6 mg, 71%): 1H NMR 
(500 MHz, CDCl3) δ 0.71 (s, 6H), 0.86 (t, J = 7.3 Hz, 3H), 1.01 (s, 9H), 1.94 (dq, J = 7.3 Hz, 
14.6 Hz, 1H), 2.05 (dq, J = 7.3 Hz, 14.7 Hz, 1H), 2.89 (d, J = 14.7 Hz, 1H), 2.90 (d, J = 14.7 Hz, 
1H), 3.63 (s, 3H), 5.16 (d, J = 13.4 Hz, 1H), 5.18 (d, J = 13.4 Hz, 1H), 5.32 (s, 2H), 7.19 (s, 1H), 
7.61 (t, J = 7.3 Hz, 1H), 7.78 (t, J = 7.3 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.24 (d, J = 8.5 Hz, 
1H); 13C NMR (75 MHz, CDCl3) δ −0.5, 7.7, 19.2, 27.1, 32.7, 44.3, 51.7, 52.0, 72.5, 90.6, 94.7, 
126.7, 128.5, 129.5, 130.5, 132.7, 136.6, 143.0, 147.0, 148.0, 151.0, 154.1, 155.2, 156.8, 170.0; 
IR (CH2Cl2, NaCl, cm-1) 2960, 2852, 2361, 2340, 1741, 1659, 1598, 1557, 1214, 1024; HRMS 
122 
 (EI) m/z calcd for C28H34N2O4Si (M+) 490.2288, found 490.2293; LRMS (EI) m/z 490 (M+, 27), 
461 (15), 434 (10), 416 (100), 359 (14), 331 (7), 73 (8). 
 
Methyl{10-[tert-butyl(dimethyl)silyl]-3-ethyl-8-fluoro-13-oxo-11,13-dihydro-1H,3H-
furo[3′,4′:6,7]indolizino[1,2-b]quinolin-3-yl)acetate (92d): 
    
N
N
O
COOMe
O
TBS
F
 
Following general procedure 3A, iodopyridone 91b (7.7 mg, 0.015 mmol) was reacted with p-
fluorophenyl isonitrile (1 M, 60 µL, 0.060 mmol) and hexamethylditin (9.0 µL, 0.022 mmol) in 
benzene (0.25 mL) to afford 92d, after purification, as a yellow solid (5.0 mg, 66%): 1H NMR 
(300 MHz, CDCl3) δ 0.71 (s, 6H), 0.85 (t, J = 7.3 Hz, 3H), 1.01 (s, 9H), 1.94 (dq, J = 7.2 Hz, 
14.4 Hz, 1H), 2.05 (dq, J = 7.5 Hz, 14.9 Hz, 1H), 2.89 (d, J = 14.7 Hz, 1H), 2.90 (d, J = 14.7 Hz, 
1H), 3.63 (s, 3H), 5.16 (s, 2H), 5.31 (s, 2H), 7.16 (s, 1H), 7.56 (ddd, J = 2.7 Hz, 7.6 Hz, 10.1 Hz, 
1H), 7.87 (dd, J = 2.7 Hz, 11.1 Hz, 1H), 8.20 (dd, J = 6.0 Hz, 9.2 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ −0.7, 7.8, 19.2, 27.1, 32.8, 44.3, 51.8, 52.0, 72.5, 90.7, 94.8, 113.5 (d, JCF = 24.0 Hz), 
120.0 (d, JCF = 25.0 Hz), 128.6, 133.2 (d, JCF = 96.2 Hz), 137.5, 142.2, 145.1, 146.8, 150.7, 
154.2, 156.8, 170.1; IR (CH2Cl2, NaCl, cm-1) 2955, 2929, 2852, 2366, 2335, 1736, 1664, 1593, 
1501, 1219; HRMS (EI) m/z calcd for C28H33FN2O4Si (M+) 508.2194, found 508.2199; LRMS 
(EI) m/z 508 (M+, 22), 479 (14), 452 (10), 434 (100), 393 (13), 349 (6), 73 (5). Copies of spectral 
data can be found in the appendix section. 
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 5-Ethyl-1,13-dihydro-3H,15H-oxepino[3′,4′:6,7]indolizino[1,2-b]quinoline-3,15-dione (95a): 
    
N
N
O
O
O
 
Following general procedure 3A, iodopyridone 94a (7.2 mg, 0.020 mmol) was reacted with 
phenyl isonitrile (1 M, 78 µL, 0.078 mmol) and hexamethylditin (11 µL, 0.029 mmol) in 
benzene (0.33 mL) to afford 95a, after purification, as a yellow solid (2.0 mg, 41%): 1H NMR 
(300 MHz, CDCl3) δ 1.25 (t, J = 7.3 Hz, 3H), 2.81 (q, J = 7.3 Hz, 2H), 5.36 (s, 4H), 6.51 (t, J = 
1.4 Hz, 1H), 7.49 (s, 1H), 7.71 (t, J = 7.4 Hz, 1H), 7.88 (t, J = 6.9 Hz, 1H), 7.98 (d, J = 8.2 Hz, 
1H), 8.30 (d, J = 8.7 Hz, 1H), 8.47 (s, 1H); 13C NMR (151 MHz, CDCl3) δ 12.8, 29.3, 50.5, 61.0, 
123.1, 125.8, 128.3, 128.4, 128.9, 130.9, 149.0, 151.3, 159.6, 167.8; IR (CH2Cl2, NaCl, cm-1) 
2914, 2847, 2361, 2335, 1710, 1644, 1598, 1444, 1035; HRMS (EI) m/z calcd for C21H16N2O3 
(M+) 344.1161, found 344.1161; LRMS (EI) m/z 344 (M+, 55), 315 (70), 301 (45), 285 (35), 271 
(20), 242 (32), 129 (17), 91 (46), 55 (100). Copies of spectral data can be found in the appendix 
section. 
 
5-Ethyl-10-fluoro-1,13-dihydro-3H,15H-oxepino[3′,4′:6,7]indolizino[1,2-b]quinoline-3,15-
dione (95b): 
    
N
N
O
O
O
F
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 Following general procedure 3A, iodopyridone 94a (7.8 mg, 0.021 mmol) was reacted with p-
fluorophenyl isonitrile (1 M, 85 µL, 0.085 mmol) and hexamethylditin (12 µL, 0.032 mmol) in 
benzene (0.35 mL) to afford 95b, after purification, as a yellow solid (3.5 mg, 55%): 1H NMR 
(300 MHz, CDCl3) δ 1.25 (t, J = 7.3 Hz, 3H), 2.80 (q, J = 7.3 Hz, 2H), 5.34 (s, 4H), 6.51 (s, 1H), 
7.35 (s, 1H), 7.58 (dd, J = 2.5 Hz, 8.6 Hz, 1H), 7.61-7.65 (m, 1H), 8.24 (dd, J = 5.3 Hz, 9.2 Hz, 
1H), 8.38 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 12.7, 29.1, 50.3, 60.8, 97.8, 111.3 (d, JCF = 
22.5 Hz), 121.2 (d, JCF = 25.0 Hz), 123.1, 125.7, 129.0 (d, JCF = 10.0 Hz), 129.6, 130.5, 132.3, 
146.0, 146.3, 149.0, 151.1, 152.0, 159.5, 160.3, 162.3, 167.7; IR (CH2Cl2, NaCl, cm-1) 2914, 
2852, 2356, 2340, 1695, 1654, 1588, 1454, 1188, 1034; HRMS (EI) m/z calcd for C21H15FN2O3 
(M+) 362.1067, found 362.1068; LRMS (EI) m/z 362 (M+, 22), 333 (30), 319 (19), 289 (7), 236 
(7), 199 (12), 111 (25), 97 (46), 69 (75), 55 (100). 
 
12-[tert-Butyl(dimethyl)silyl]-5-ethyl-1,13-dihydro-3H,15H-oxepino[3′,4′:6,7]indolizino[1,2-
b]quinoline-3,15-dione (95c): 
    
N
N
O
O
O
TBS
 
Following general procedure 3A, iodopyridone 94b (11 mg, 0.023 mmol) was reacted with 
phenyl isonitrile (1 M, 91 µL, 0.091 mmol) and hexamethylditin (13 µL, 0.034 mmol) in 
benzene (0.38 mL) to afford 95c, after purification, as a yellow solid (4.0 mg, 39%): 1H NMR 
(300 MHz, CDCl3) δ 0.72 (s, 6H), 1.01 (s, 9H), 1.25 (t, J = 7.4 Hz, 3H), 2.81 (dq, J = 1.3 Hz, 7.4 
Hz, 2H), 5.36 (s, 4H), 6.50 (t, J = 1.4 Hz, 1H), 7.37 (s, 1H), 7.64 (ddd, J = 1.5 Hz, 6.8 Hz,  8.4 
125 
 Hz, 1H), 7.80 (ddd, J = 1.3 Hz, 6.8 Hz,  8.2 Hz, 1H), 8.24 (t, J = 8.6 Hz, 2H); 13C NMR (75 
MHz, CDCl3) δ −0.5, 12.7, 19.3, 27.2, 29.2, 52.8, 61.0, 97.5, 122.9, 125.1, 127.1, 129.6, 129.8, 
130.7, 133.0, 136.3, 143.4, 146.7, 148.1, 149.0, 150.6, 151.4, 159.4, 167.9; IR (CH2Cl2, NaCl, 
cm-1) 2914, 2842, 2351, 2335, 1726, 1649, 1598, 1465, 1045; HRMS (EI) m/z calcd for 
C27H30N2O3Si (M+) 458.2026, found 458.2028; LRMS (EI) m/z 458 (M+, 100), 429 (58), 401 
(47), 373 (63), 357 (46), 343 (16), 299 (7), 255 (7), 91 (8), 73 (15). 
 
12-[tert-Butyl(dimethyl)silyl]-5-ethyl-10-fluoro-1,13-dihydro-3H,15H-
oxepino[3′,4′:6,7]indolizino[1,2-b]quinoline-3,15-dione (95d): 
    
N
N
O
O
O
TBS
F
 
Following general procedure 3A, iodopyridone 94b (9.0 mg, 0.019 mmol) was reacted with p-
fluorophenyl isonitrile (1 M, 75 µL, 0.075 mmol) and hexamethylditin (11 µL, 0.028 mmol) in 
benzene (0.31 mL) to afford 95d, after purification, as a yellow solid (3.0 mg, 34%): 1H NMR 
(300 MHz, CDCl3) δ 0.72 (s, 6H), 1.01 (s, 9H), 1.25 (t, J = 7.4 Hz, 3H), 2.81 (dq, J = 1.3 Hz, 7.4 
Hz, 2H), 5.35 (s, 4H), 6.50 (t, J = 1.4 Hz, 1H), 7.34 (s, 1H), 7.59 (ddd, J = 2.7 Hz, 7.5 Hz,  9.3 
Hz, 1H), 7.89 (dd, J = 2.6 Hz, 11.0 Hz, 1H), 8.23 (dd, J = 6.0 Hz, 9.3 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ −0.7, 12.7, 19.2, 27.1, 29.2, 52.8, 60.9, 97.4, 113.2 (d, JCF = 23.8 Hz), 120.0 (d, 
JCF = 25.0 Hz), 123.0, 125.2, 133.0 (d, JCF = 102.5 Hz), 137.0, 142.5, 145.2, 146.4, 149.0, 150.3, 
151.2, 159.3, 159.7 (d, JCF = 26.2 Hz), 161.6, 167.8; IR (CH2Cl2, NaCl, cm-1) 2955, 2914, 2842, 
2361, 2330, 1716, 1659, 1593, 1214, 1040; HRMS (EI) m/z calcd for C27H29FN2O3Si (M+) 
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 476.1932, found 476.1929; LRMS (EI) m/z 476 (M+, 100), 447 (66), 433 (36), 419 (40), 391 
(57), 375 (42), 361 (15), 273 (7), 98 (10), 73 (18). Copies of spectral data can be found in the 
appendix section. 
 
Chapter 4 
(S)-2-Hydroxy-2-[8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-
yl]butanohydrazide (96): 
    
N
N
O
O
NHNH2
HO
OH
 
Hydrazine monohydrate (45 µL, 0.93 mmol) was added to a suspension of camptothecin (54 mg, 
0.15 mmol) in MeOH (0.62 mL) at room temperature. After stirring at the same temperature for 
8 h, the reaction mixture was concentrated under reduced pressure to afford 96 as a pale yellow 
solid (59 mg, 100%) which was sufficiently pure for further analysis: 1H NMR (300 MHz, 
CD3SOCD3) δ 0.85 (t, J = 7.0 Hz, 3H), 2.17 (d, J = 6.8 Hz, 2H), 4.29 (br s, 2H), 4.75 (dd, J = 5.7 
Hz, 11.5 Hz, 1H), 4.77 (dd, J = 5.5 Hz, 11.6 Hz, 1H), 5.00 (t, J = 5.6Hz, 1H), 5.23 (s, 2H), 6.40 
(br s, 1H), 7.46 (s, 1H), 7.69 (t, J = 7.4 Hz, 1H), 7.84 (t, J = 7.1 Hz, 1H), 8.10 (d, J = 8.1 Hz, 
1H), 8.17 (d, J = 8.5 Hz, 1H), 8.65 (s, 1H), 9.25 (br s, 1H); 13C NMR (75 MHz, CD3SOCD3) δ 
7.8, 31.8, 50.1, 55.3, 79.3, 99.3, 127.4, 127.7, 128.4, 128.8, 128.9, 129.7, 130.2, 131.3, 142.6, 
147.9, 152.8, 152.9, 160.9, 171.7; HRMS (EI) m/z calcd for C20H16N2O4 (M – N2H4) 348.1110, 
found 348.1100; LRMS (EI) m/z 378 (M+ − 2, 31), 348 (100), 319 (30), 289 (22), 248 (38), 219 
(34), 140 (15). Copies of spectral data can be found in the appendix section. 
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 (S)-2-[12-[tert-Butyl(dimethyl)silyl]-2-hydroxy-8-(hydroxymethyl)-9-oxo-9,11-
dihydroindolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanohydrazide (97): 
    
N
N
O
OH
TBS
HO
O
NHNH2
HO
 
Following the above procedure, 7-tert-butyldimethylsilyl-10-hydroxycamptothecin (24 mg, 
0.050 mmol) was reacted with hydrazine monohydrate (24 µL, 0.50 mmol) in MeOH (0.20 mL) 
to afford 97 as a yellow solid (25 mg, 99%) which was sufficiently pure for subsequent analysis: 
1H NMR (300 MHz, CD3SOCD3) δ 0.64 (s, 6H), 0.84 (t, J = 6.8 Hz, 1H), 0.93 (s, 9H), 2.15 (d, J 
= 6.9 Hz, 1H), 4.27 (br s, 2H), 4.67 (d, J = 11.6 Hz, 1H), 4.81 (d, J = 11.7 Hz, 1H), 5.16 (s, 2H), 
7.35-7.38 (m, 2H), 7.54 (d, J = 2.2 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H); 13C NMR (75 MHz, 
CD3SOCD3) δ −1.1, 7.9, 18.8, 27.1, 31.8, 48.6, 52.3, 79.3, 98.1, 110.8, 122.4, 127.5, 131.3, 
133.9, 137.1, 138.2, 142.1, 143.1, 147.8, 153.2, 156.9, 160.7, 171.9; HRMS (EI) m/z calcd for 
C26H30N2O5Si (M+ – N2H4) 478.1924, found 478.1906; LRMS (EI) m/z 478 (M+ − N2H4, 22), 
434 (59). 421 (23), 377 (100), 320 (11), 291 (13), 235 (6), 73 (17). 
 
(S)-2-[8-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-9-oxo-9,11-dihydroindolizino[1,2-
b]quinolin-7-yl]-2-hydroxy-N-methoxy-N-methylbutanamide (99): 
    
N
N
O
OTBS
O
N
HO
O
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 Trimethylaluminum (2 M in heptane, 0.52 mL, 1.0 mmol) was added dropwise via a syringe over 
3 - 4 min to a suspension of N,O-dimethylhydroxylamine hydrochloride (0.10 g, 1.0 mmol) in 
CH2Cl2 (5.4 mL) at −10 °C accompanied by the evolution of gas. The resulting colorless solution 
was stirred at room temperature for 30 min and recooled to 0 °C. A suspension of camptothecin 
(0.12 g, 0.34 mmol) in CH2Cl2 (1.5 mL) was then added and the resulting clear brown solution 
was stirred at room temperature for 22 h. NaHSO4 (1 M, 1.2 mL) was carefully added and the 
resulting mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
washed with brine (10 mL), dried over MgSO4 and concentrated under reduced pressure to 
afford 98 as a yellow solid (96 mg, 68%). The crude product was used in the subsequent reaction 
immediately after the workup. 
 Alcohol 98 (95 mg, 0.23 mmol) was added to a solution of tert-butylchlorodimethylsilane 
(53 mg, 0.35 mmol) and imidazole (44 mg, 0.64 mmol) in DMF (0.19 mL). The reaction mixture 
was heated to 35 °C and stirred for 24 h. The reaction mixture was diluted with water (5 mL) and 
then extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were washed with 
brine, dried over MgSO4 and concentrated under reduced pressure to afford the Weinreb amide 
99 as a pale yellow solid (0.11 g, 92%). The crude product was sufficiently pure for subsequent 
analysis. However, an analytical sample of 99 was prepared by purification of the crude product 
by flash column chromatography (step gradient elution 1:49, 1:19, 1:9 acetone/dichloromethane): 
1H NMR (300 MHz, CDCl3) δ 0.19 (s, 3H), 0.22 (s, 3H), 0.96 (s, 9H), 0.97 (t, J = 7.3 Hz, 3H), 
2.18 (dq, J = 7.4 Hz, 14.1 Hz, 1H), 2.44 (dq, J = 7.3 Hz, 13.9 Hz, 1H), 3.22 (s, 3H), 3.24 (s, 3H), 
5.01 (d, J = 10.6 Hz, 1H), 5.02 (d, J = 10.7 Hz, 1H), 5.26 (d, J = 19.0 Hz, 1H), 5.30 (d, J = 19.0 
Hz, 1H), 5.41 (br s, 1H), 7.37 (s, 1H), 7.65 (ddd, J = 1.1 Hz, 6.9 Hz, 8.1 Hz, 1H), 7.82 (ddd, J = 
1.4 Hz, 6.9 Hz, 8.4 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H); 13C 
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 NMR (75 MHz, CDCl3) δ −5.4, −5.2, 7.6, 18.5, 26.0, 31.4, 33.3, 50.1, 56.5, 59.9, 80.0, 99.4, 
127.5, 127.7, 128.0, 128.1, 128.8, 129.6, 130.4, 130.9, 143.8, 148.8, 152.9, 154.4, 161.3, 172.9; 
IR (CH2Cl2, NaCl, cm-1) 3370, 2929, 2847, 1659, 1603, 1465, 1398, 1250, 1055; HRMS (EI) m/z 
calcd for C28H37N3O5Si (M+) 523.2502, found 523.2477; LRMS (EI) m/z 523 (M+, 18), 508 (28), 
466 (100), 377 (98), 363 (28), 303 (60), 275 (15), 191 (7), 75(72). Copies of spectral data can be 
found in the appendix section. 
 
(S)-2-Hydroxy-2-(8-methyl-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl)butanoic acid 
methyl ester (103): 
    
N
N
O
COOMeHO
 
Triethylamine (0.17 mL, 1.2 mmol) was added to a solution of camptothecin (27 mg, 0.078 
mmol) in DMF (1.7 mL) under argon. Dry 10% palladium on activated carbon (5 mg) was 
carefully added to the reaction mixture and the dissolved oxygen was removed under vacuum. 
Then a balloon of hydrogen was mounted and the mixture was stirred vigorously for 24 h. The 
catalyst was removed by filtration of the reaction mixture through a pad of Celite. The filtrate 
was concentrated under reduced pressure to remove solvents and excess reagents. The crude 
product was purified by semipreparative HPLC using Symmetry C18 column under isocratic 
elution conditions (30:70 MeOH/H2O + 0.1% HCOOH) to afford acid 101 as a yellow solid (11 
mg, 40%). This was used immediately in the subsequent reaction. 
TMSCHN2 (2 M solution in hexanes, 20 µL, 0.041 mmol) was added to a solution of 101 
(11 mg, 0.031 mmol) in a mixture of methanol (0.10 mL) and benzene (0.21 mL) at room 
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 temperature. After 30 min, the reaction mixture was concentrated under reduced pressure. The 
crude product was purified by flash column chromatography (gradient elution 1:4 to 7:3 
acetone/dichloromethane) to afford the ester 103 as a pale yellow solid (8.6 mg, 76%): 1H NMR 
(300 MHz, CDCl3) δ 1.05 (t, J = 7.3 Hz, 3H), 2.31 (s, 3H), 2.37 (q, J = 7.5 Hz, 2H), 3.79 (s, 3H), 
5.24 (s, 2H), 7.57 (s, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.78 (t, J = 8.4 Hz, 1H), 7.82 (d, J = 8.2 Hz, 
1H), 8.17 (d, J = 8.5 Hz, 1H), 8.27 (s, 1H); HRMS (EI) m/z calcd for C21H20N2O4 (M+) 
364.1423, found 364.1406; LRMS (EI) m/z 364 (M+, 67), 346 (19), 305 (100), 276 (65), 248 
(35), 219 (45), 140 (13), 75 (15). 
 
(S)-2-{12-[tert-Butyl(dimethyl)silyl]-2-hydroxy-8-methyl-9-oxo-9,11-dihydroindolizino[1,2-
b]quinolin-7-yl}-2-hydroxybutanoic acid (102): 
    
N
N
O
COOHHO
HO
TBS
 
Triethylamine (98 µL, 0.70 mmol) was added to a solution of 7-tert-butyldimethylsilyl-10-
hydroxy camptothecin (21 mg, 0.044 mmol) in MeOH (0.98 mL) under argon. Dry 10% 
palladium on activated carbon (4 mg) was carefully added to the reaction mixture and the 
dissolved oxygen was removed under vacuum. Then a balloon of hydrogen was mounted and the 
mixture was stirred vigorously for 14 h. The catalyst was removed by filtration of the reaction 
mixture through a pad of Celite. The filtrate was concentrated under reduced pressure to remove 
solvents and excess reagents. The crude product was purified by preparative TLC under isocratic 
elution conditions (95:5:5 dichloromethane/methanol/water) to afford 102 as a yellow solid (17 
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 mg, 83%): 1H NMR (300 MHz, CD3SOCD3) δ 0.68 (s, 6H), 0.88 (t, J = 6.8 Hz, 3H), 0.98 (s, 
9H), 1.88-2.09 (m, 2H), 2.24 (s, 3H), 5.10 (s, 2H), 7.33 (dd, J = 2.4 Hz, 9.0 Hz, 1H), 7.45 (s, 
1H), 7.53 (d, J = 2.4 Hz, 1H), 7.99 (d, J = 9.1 Hz, 1H); 13C NMR (75 MHz, CD3SOCD3) δ −1.1, 
8.9, 13.9, 18.9, 27.1, 31.1, 52.1, 78.7, 99.1, 110.9, 121.8, 125.9, 131.3, 133.5, 137.0, 138.4, 
140.6, 142.3, 148.9, 153.7, 155.9, 161.1, 175.4. Copies of spectral data can be found in the 
appendix section. 
 
Chapter 5 
(R)-(−)-4-Ethyl-4-hydroxy-8-methoxy-6-(trimethylsilyl)-1,4-dihydro-3H-pyrano[3,4-
c]pyridine-3-one [(R)-115]: 
N
O
O
OTMS
HO
 
Enol ether 114 (1.1 g, 4.0 mmol) was added to a vigorously stirred solution of K3Fe(CN)6 (4.0 g, 
12 mmol), K2CO3 (1.7 g, 12 mmol), CH3SO2NH2 (74 mg, 7.8 mmol), (DHQ)2-PYR (89 mg, 0.20 
mmol) and OsO4 (0.25 mL of a 2.5w% in tBuOH, 0.5 mol%) in a 1:1 mixture of tBuOH/H2O (40 
mL) at 0 °C. After stirring at room temperature for 18 h, Na2SO3 (4.0 g) was slowely added and 
the resulting suspension stirred for a further 30 min. CH2Cl2 (50 mL) and H2O (50 mL) were 
added and the aqueous layer was further extracted with CH2Cl2 (3 x 25 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (5:1 dichloromethane/ethyl acetate) to afford the 
α-hydroxylactol as a white solid (0.96 g, 85%). 
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 N-Iodosuccinimde (3.3 g, 15 mmol) and tetrabutylammonium iodide (1.1 g, 3.0 mmol) 
were added to a solution of the α-hydroxylactol (0.88 g, 3.0 mmol) in CH2Cl2 (6.0 mL). The 
reaction mixture was stirred at room temperature in the dark for 3 h, 5% Na2SO4 (50 mL) was 
added and the biphasic solution further diluted with CH2Cl2 (50 mL). The organic phase was 
washed with H2O (3 x 30 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (1:4 ethyl acetate/hexanes) to afford the 
lactone (R)-115 as a clear oil (0.79 g, 90%, 96% ee); [α]D23 = −83.0 (c = 0.5, CHCl3). For this 
lactone, all spectral data matched that previously reported for the corresponding (S)-lactone.65 
 
(R)-(−)- and (S)-(+)-4-Ethyl-4-fluoro-8-methoxy-6-trimethylsilyl-1,4-dihydro-3H-
pyrano[3,4-c]pyridin-3-one (116): 
     
N
O
O
TMS O
F
 
Diethylamino sulfurtrifluoride (15 µL, 0.11 mmol) was added dropwise via a syringe to a 
solution of (R)-115 (31 mg, 0.10 mmol) in CH2Cl2 (0.27 mL) at −78 °C. After stirring for 2 h at 
−78 °C, the reaction mixture was quenched with water (1.0 mL) and warmed to room 
temperature. The resulting suspension was extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure to afford (S)-
116 as a yellow solid (22 mg, 76%). The crude product was sufficiently pure for subsequent 
reaction. Pyridine lactone (S)-116 was analyzed for enantiomeric purity using (S,S) WHELK O 1 
chiral column under isocratic elution with 5% isopropanol in hexanes. The enantiomeric excess 
(ee) was determined to be 93%. Following the same procedure, (S)-115 (36 mg, 0.12 mmol) was 
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 reacted with diethylamino sulfurtrifluoride (18 µL, 0.13 mmol) in CH2Cl2 (0.31 mL) to afford 
the product (R)-116 as a yellow solid (31 mg, 86%, 91% ee): 1H NMR (300 MHz, CDCl3) δ 0.31 
(s, 9H), 1.03 (t, J = 7.4 Hz, 3H), 2.01 (m, 2H), 4.01 (s, 3H), 5.21 (d, J = 15.9 Hz, 1H), 5.54 (d, J 
= 15.9 Hz, 1H), 7.25 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −164.3 (t, J = 22.6 Hz); 13C NMR 
(75 MHz, CDCl3) δ −2.0, 7.2 (d, J = 4.2 Hz), 30.3 (d, J = 27.0 Hz), 53.5, 65.5, 90.1 (d, J = 191 
Hz), 110.8 (d, J = 5.5 Hz), 116.9 (d, J = 5.3 Hz), 142.8 (d, J = 24.0 Hz), 157.9, 167.0, 167.9 (d, J 
= 22.0 Hz); IR (CHCl3, NaCl, cm-1) 2950, 2893, 1767, 1577, 1449, 1357, 1244, 1096; HRMS 
(EI) m/z calcd for C14H20FNO3Si (M+) 297.1197, found 297.1202; LRMS (EI) m/z 297 (M+, 32), 
282 (100), 269 (30), 254 (32), 238 (32), 213 (27), 162 (10), 84 (27), 77 (38); For “R” [α]D23 = 
−57.2 (c = 0.50, CH2Cl2), for “S” [α]D23 = +59.5 (c = 0.64, CH2Cl2). Copies of spectral data 
including the HMBC spectrum can be found in the appendix section. 
 
(R)-(−)- and (S)-(+)-4-Ethyl-4-fluoro-6-iodo-8-methoxy-1,4-dihydro-3H-pyrano[3,4-
c]pyridin-3-one: 
     
N
O
O
I O
F
 
ICl (1 M in dichloromethane, 1.2 mL, 1.2 mmol) was added to a solution of (S)-116 (92 mg, 0.31 
mmol) in CH2Cl2 (1.5 mL) at 0 °C in an ice bath and then allowed to warm to room temperature. 
After stirring for 16 h, the reaction mixture was poured into a chilled solution of 5% 
Na2SO3/brine (1:1, 24 mL) and extracted the mixture with ethyl acetate (3 x 30 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (step gradient elution 1:9 to 1:4 ethyl 
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 acetate/hexanes) to afford the corresponding (S)-iodide as a pale yellow oil (63 mg, 59%). 
Following the same procedure, (R)-116 (0.10 g, 0.35 mmol) was reacted with ICl (1.4 mL, 1.4 
mmol) in CH2Cl2 (1.8 mL) to afford the corresponding (R)-iodide as a pale yellow oil (80 mg, 
65%): 1H NMR (300 MHz, CDCl3) δ 1.02 (t, J = 7.3 Hz, 3H), 1.99 (m, 2H), 3.99 (s, 3H), 5.13 
(d, J = 15.8 Hz, 1H), 5.46 (d, J = 15.9 Hz, 1H), 7.50 (s, 1H); 19F NMR (282 MHz, CDCl3) δ 
−164.3 (t, J = 22.6 Hz); 13C NMR (75 MHz, CDCl3) δ 7.2, 30.1 (d, J = 26.3 Hz), 54.8, 64.8, 89.4 
(d, J = 192.9 Hz), 111.0 (d, J = 5.6 Hz), 113.3, 122.7 (d, J = 6.6 Hz), 146.0 (d, J = 23.6 Hz), 
157.7, 167.0 (d, J = 21.6 Hz); IR (CHCl3, NaCl, cm-1) 2980, 2950, 1772, 1582, 1460, 1362, 
1096; HRMS (EI) m/z calcd for C11H11FINO3 (M+) 350.9768, found 350.9769; LRMS (EI) m/z 
351 (M+, 100), 323 (6), 307 (55), 292 (44), 224 (27), 180 (45), 137 (24), 109 (19), 77 (13); For 
“R” [α]D23 = −39.3 (c = 0.70, CH2Cl2), for “S” [α]D23 = +38.9 (c = 2.80, CH2Cl2). 
 
(R)-(−)- and (S)-(+)-4-Ethyl-4-fluoro-6-iodo-1H-pyrano[3,4-c]pyridine-3,8(4H,7H)-dione: 
     
H
N
O
O
I O
F
 
Sodium iodide (81 mg, 0.54 mmol) was added to a solution of the above (S)-iodide (63 mg, 0.18 
mmol) in dry acetonitrile (2.4 mL) at room temperature. Chlorotrimethylsilane (68 µL, 0.54 
mmol) was then added and the reaction mixture was stirred for 15 min at room temperature. H2O 
(2.0 µL, 0.090 mmol) was next added and the reaction mixture was heated to 60 °C and stirred at 
that temperature for 14 h. The mixture was then poured into a solution of 5% Na2SO3/brine (1:1, 
17 mL) and quickly extracted with ethyl acetate (3 x 20 mL). The combined organic extracts 
were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
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 purified by flash chromatography (1:4 ethyl acetate/hexanes) to afford the corresponding (S)-
iodopyridone as a pale yellow solid (43 mg, 71%). Following the same procedure, (R)-iodide (80 
mg, 0.23 mmol) was reacted with sodium iodide (0.10 g, 0.68 mmol), chlorotrimethylsilane (87 
µL, 0.68 mmol) and H2O (2.0 µL, 0.11 mmol) in dry acetonitrile (3.0 mL) to afford the 
corresponding (R)-iodopyridone as a pale yellow solid (58 mg, 76%): 1H NMR (300 MHz, 
CDCl3) δ 1.06 (t, J = 7.2 Hz, 3H), 2.02 (dq, J = 7.2 Hz, 21.4 Hz, 2H), 5.11 (d, J = 16.2 Hz, 1H), 
5.54 (d, J = 16.3 Hz, 1H), 6.95 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −164.2 (t, J = 22.6 Hz); 
13C NMR (75 MHz, CDCl3) δ 7.3, 30.0 (d, J = 26.2 Hz), 65.3, 89.0 (d, J = 193.2 Hz), 95.4, 114.1 
(d, J = 5.3 Hz), 118.5, 147.2 (d, J = 23.4 Hz), 161.2, 166.5 (d, J = 21.8 Hz); IR (CHCl3, NaCl, 
cm-1) 3431, 3098, 2919, 2842, 1762, 1649, 1547, 1454, 1152; HRMS (EI) m/z calcd for 
C10H9FINO3 (M+) 336.9611, found 336.9613; LRMS (EI) m/z 337 (M+, 100), 309 (7), 293 (94), 
278 (56), 266 (23), 166 (38), 138 (28), 91 (35); For “R” [α]D23 = −45.2 (c = 0.21, CH2Cl2), for 
“S” [α]D23 = +46.7 (c = 0.15, CH2Cl2). 
 
(R)-(−)- and (S)-(+)-4-Ethyl-4-fluoro-6-iodo-7-prop-2-ynyl-1H-pyrano[3,4-c]pyridine-
3,8(4H,7H)-dione (109): 
     
N
O
OI
F
O  
NaH in mineral oil (95%, 3.5 mg, 0.14 mmol) was added to a solution of the above (S)-
iodopyridone (43 mg, 0.13 mmol) in a mixture of DME (0.40 mL) and DMF (0.13 mL) at 0 °C 
under argon. After stirring this mixture for 10 min at 0 °C, LiBr (22 mg, 0.25 mmol) was added. 
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 The reaction mixture was allowed to warm to room temperature and stirred for 15 min. Propargyl 
bromide (80% w/w in toluene, 42 µL, 0.38 mmol) was then added via a syringe and the reaction 
mixture was heated in the dark at 65 °C for 6 h. The final solution was poured into brine (5 mL) 
and extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (1:9 ethyl acetate/dichloromethane) to give (S)-109 as a white solid (28 mg, 
60%). Following the same procedure, (R)-iodopyridone (58 mg, 0.17 mmol) was alkylated with 
propargyl bromide (58 µL, 0.52 mmol) in the presence of NaH (4.8 mg, 0.19 mmol) and LiBr 
(30 mg, 0.34 mmol) in a mixture of DME (0.54 mL) and DMF (0.18 mL) to afford (R)-109 as a 
white solid (42 mg, 66%): 1H NMR (300 MHz, CDCl3) δ 1.05 (t, J = 7.5 Hz, 3H), 2.00 (m, 2H), 
2.40 (t, J = 2.5 Hz, 1H), 5.08 (dd, J = 1.4 Hz, 14.3 Hz, 1H), 5.11 (s, 2H), 5.48 (dd, J = 1.2 Hz, 
16.9 Hz, 1H), 7.06 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −164.4 (t, J = 22.6 Hz); 13C NMR (75 
MHz, CDCl3) δ 7.3, 30.0 (d, J = 26.5 Hz), 44.1, 65.9, 73.7, 88.6 (d, J = 192.7 Hz), 100.5, 115.1 
(d, J = 7.8 Hz), 119.3, 145.2 (d, J = 23.6 Hz), 157.5, 166.4 (d, J = 21.8 Hz); IR (CHCl3, NaCl, 
cm-1) 3257, 3083, 2909, 2115, 1762, 1654, 1419, 1526, 1132; HRMS (EI) m/z calcd for 
C13H11FINO3 (M+) 374.9768, found 374.9771; LRMS (EI) m/z 375 (M+, 100), 346 (8), 331 (20), 
248 (5), 122 (8), 75 (13); For “R” [α]D23 = −29.6 (c = 0.50, CH2Cl2), for “S” [α]D23 = +32.0 (c = 
0.35, CH2Cl2). Copies of spectral data can be found in the appendix section. 
 
General procedure 5A: Radical Cascade Cyclization towards the Synthesis of 20-
Fluorocamptothecins. 
A solution of iodopyridone 109 in benzene was taken up in a 15 x 45 mm cylindrical 
screw-cap glass vial and kept at room temperature. A solution of isonitrile and then 
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 hexamethylditin were added at room temperature. The vial was capped and the reaction mixture 
was irradiated with a 275W GE sunlamp for 5 h. The solvent was then evaporated and the 
residue was purified by flash column chromatography (1:9 acetone/dichloromethane). 
 
(R)-(−)- and (S)-(+)-20-Fluoro camptothecin (107): 
    
N
N
O
O
O
F
 
Following general procedure 5A, iodopyridone (S)-109 (10 mg, 0.027 mmol) was reacted with 
phenyl isonitrile (1 M in benzene, 0.13 mL, 0.13 mmol) and hexamethylditin (15 µL, 0.040 
mmol) in benzene (0.44 mL) to afford (S)-107, after purification, as a yellow solid (1.0 mg, 
11%). Following the same procedure, iodopyridone (R)-109 (12 mg, 0.033 mmol) was reacted 
with phenyl isonitrile (1 M in benzene, 0.17 mL, 0.17 mmol) and hexamethylditin (19 µL, 0.050 
mmol) in benzene (0.55 mL) to afford (R)-107, after purification, as a yellow solid (1.6 mg, 
14%): 1H NMR (300 MHz, CDCl3) δ 1.12 (t, J = 7.4 Hz, 3H), 2.14 (dq, J = 7.4 Hz, 22.2 Hz, 2H), 
5.28 (dd, J = 1.4 Hz, 15.3 Hz, 1H), 5.32 (s, 2H), 5.72 (dd, J = 1.2 Hz, 16.7 Hz, 1H), 7.54 (s, 1H) 
7.69 (ddd, J = 1.2 Hz, 6.9 Hz, 8.1 Hz, 1H), 7.86 (ddd, J = 1.5 Hz, 6.9 Hz, 8.4 Hz, 1H), 7.95 (d, J 
= 8.2 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.42 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −163.2 (t, J 
= 22.6 Hz); 13C NMR (75 MHz, CDCl3) δ 7.4, 30.1 (d, J = 14.7 Hz), 50.2, 66.1, 89.5 (d, J = 
193.7 Hz), 96.6 (d, J = 3.7 Hz), 119.5, 128.2, 128.4, 129.8, 130.8, 131.2, 146.4 (d, J = 14.3 Hz), 
146.9, 149.0, 152.1, 157.3, 167.3 (d, J = 11.3 Hz); IR (CHCl3, NaCl, cm-1) 2914, 2842, 2356, 
2335, 1767, 1649, 1603, 1454, 1157; HRMS (EI) m/z calcd for C20H15FN2O3 (M+) 350.1067, 
found 350.1055; LRMS (EI) m/z 350 (M+, 45), 307 (10), 291 (25), 266 (10), 129 (17), 97 (40), 
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 83 (50), 69 (69), 57 (100); For “R” [α]D23 = −76.2 (c = 0.08, CH2Cl2), for “S” [α]D23 = +74.4 (c = 
0.10, CH2Cl2). Copies of spectral data can be found in the appendix section. 
 
(R)-(−)-10,20-Difluorocamptothecin (111a): 
    
N
N
O
O
O
F
F
 
Following the general procedure 5A, iodopyridone (R)-109 (9.0 mg, 0.024 mmol) was reacted 
with p-fluorophenyl isonitrile (1 M in benzene, 0.12 mL, 0.12 mmol) and hexamethylditin (14 
µL, 0.036 mmol) in benzene (0.40 mL) to afford (R)-111a, after purification, as a pale yellow 
solid (2.0 mg, 23%): 1H NMR (300 MHz, CDCl3) δ 1.13 (t, J = 7.4 Hz, 3H), 2.14 (dq, J = 7.6 
Hz, 22.0 Hz, 2H), 5.28 (d, J = 17.3 Hz, 1H), 5.33 (s, 2H), 5.73 (d, J = 16.7 Hz, 1H), 7.53 (s, 1H), 
7.56-7.67 (m, 2H), 8.26 (dd, J = 5.4 Hz, 9.3 Hz, 1H), 8.38 (s, 1H); 19F NMR (282 MHz, CDCl3) 
δ −108.7 (dd, J = 8.5 Hz, 14.1 Hz), −161.6 (t, J = 22.6 Hz); IR (CH2Cl2, NaCl, cm-1) 3354, 2924, 
2858, 1762, 1664, 1603, 1495, 1465, 1229, 1060; HRMS (EI) m/z calcd for C20H14F2N2O3 (M+) 
368.0972, found 368.0973; LRMS (EI) m/z 368 (M+, 100), 340 (16), 325 (35), 309 (67), 297 
(72), 261 (19), 158 (19), 131 (17), 75 (20); [α]D23 = −10.0 (c = 0.005, CH2Cl2). 
 
(R)-(−)-20-Fluoro-9,10-methylenedioxy camptothecin (111b) and 20-Fluoro-10,11-
methylenedioxycamptothecin (111c): 
Following the general procedure 5A, iodopyridone (R)-109 (25 mg, 0.024 mmol) was reacted 
with 3,4-methylenedioxyphenyl isonitrile (49 mg, 0.33 mmol) and hexamethylditin (39 µL, 0.10 
mmol) in benzene (1.1 mL) to afford a separable 1:2.5 mixture of 9,10- and 10,11-
139 
 methylenedioxy isomers (R)-111b and (R)-111c, after purification, as a pale yellow solids (2.0 
and 5.0 mg respectively, 26%):  
    
N
N
O
O
O
F
O
O
 
1H NMR (300 MHz, CDCl3) δ 1.12 (t, J = 7.4 Hz, 3H), 2.13 (dq, J = 7.4 Hz, 21.6 Hz, 2H), 5.27 
(d, J = 16.5 Hz, 1H), 5.30 (s, 2H), 5.73 (d, J = 16.6 Hz, 1H), 6.29 (s, 2H), 7.49 (s, 1H), 7.53 (d, J 
= 8.8 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 8.38 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −163.5 (t, J 
= 22.0 Hz); IR (CH2Cl2, NaCl, cm-1) 3354, 2919, 2852, 2345, 2325, 1659, 1629, 1460, 1050; 
HRMS (EI) m/z calcd for C21H15FN2O5 (M+) 394.0965, found 394.0954; LRMS (EI) m/z 394 
(M+, 100), 365 (13), 323 (36), 310 (17), 153 (5); [α]D23 = −14.2 (c = 0.06, CH2Cl2). 
 
    
N
N
O
O
O
F
O
O
 
1H NMR (300 MHz, CDCl3) δ 1.12 (t, J = 7.4 Hz, 3H), 2.13 (m, 2H), 5.25 (s, 2H), 5.27 (d, J = 
16.4 Hz, 1H), 5.73 (d, J = 16.4 Hz, 1H), 6.21 (s, 2H), 7.17 (s, 1H), 7.45 (s, 1H), 7.50 (s, 1H), 
8.21 (s, 1H); 19F NMR (282 MHz, CDCl3) δ −163.6 (t, J = 22.0 Hz); IR (CH2Cl2, NaCl, cm-1) 
2919, 2842, 1654, 1465, 1255, 1157, 1111; HRMS (EI) m/z calcd for C21H15FN2O5 (M+) 
394.0965, found 394.0964; LRMS (EI) m/z 394 (M+, 100), 365 (13), 351 (17), 335 (60), 323 
(54), 310 (25), 207 (10), 105 (19), 64 (42); [α]D23 = −8.3 (c = 0.17, CH2Cl2). Copies of spectral 
data of both isomers can be found in the appendix section. 
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 (R)-(−)-7-tert-Butyldimethylsilyl-20-fluoro-10-hydroxy camptothecin (112): 
    
N
N
O
O
O
F
HO
TBS
 
Diethylamino sulfurtrifluoride (9.0 µL, 0.070 mmol) was added dropwise via a syringe to a 
solution of DB67 (31 mg, 0.064 mmol) in CH2Cl2 (0.21 mL) at −78 °C. After stirring for 2 h at 
−78 °C, the reaction mixture was quenched with water (1.0 mL) and warmed to room 
temperature. The resulting suspension was extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure to afford 112 
as a yellow solid (19 mg, 61%). The crude product was sufficiently pure for subsequent analysis: 
1H NMR (300 MHz, CD3SOCD3) δ 0.64 (s, 6H), 0.94 (s, 9H), 0.96 (t, J = 7.5 Hz, 3H), 2.07-2.22 
(m, 2H), 5.22 (s, 2H), 5.47 (d, J = 16.7 Hz, 1H), 5.50 (d, J = 16.4 Hz, 1H), 7.10 (s, 1H), 7.38 (dd, 
J = 2.4 Hz, 9.1 Hz, 1H), 7.56 (d, J = 2.5 Hz, 1H), 8.03 (d, J = 9.1 Hz, 1H); 19F NMR (282 MHz, 
CDCl3) δ −163.5; 13C NMR (150 MHz, CD3OD) δ −0.8, 7.7, 19.8, 27.6, 30.2 (d, J = 25.6 Hz), 
53.8, 66.7, 91.2 (d, J = 191.0 Hz), 95.7 (d, J = 8.4 Hz), 112.0, 119.2 (d, J = 4.5 Hz), 123.3, 
132.4, 135.6, 138.1, 140.9, 143.8, 147.3 (d, J = 24.0 Hz), 148.4 (d, J = 36.0 Hz), 157.6, 158.2, 
168.5 (d, J = 21.0 Hz); IR (CH2Cl2, NaCl, cm-1) 3380, 3242, 2929, 2858, 1767, 1659, 1588, 
1552, 1413, 1301, 1106; HRMS (EI) m/z calcd for C26H29FN2O4Si (M+) 480.1881, found 
480.1876; LRMS (EI) m/z 480 (M+, 31), 423 (40), 379 (20), 264 (43), 199 (12), 136 (13), 91 
(100), 73 (52); [α]D23 = −15.0 (c = 0.08, CH2Cl2). 
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 Chapter 6 
2,4-Dibromoquinazoline (117): 
     
N
N B
Br
r
 
A two-necked round bottomed flask charged with benzoylene urea (1.9 g, 12 mmol) was fitted 
with an overhead mechanical stirrer. Addition of phosphorus oxybromide (23 g, 80 mmol) was 
followed by a dropwise addition of N,N-dimethylaniline (0.75 mL, 5.9 mmol) via a syringe at 
room temperature. This mixture was heated to 105 °C in an oil bath and vigorously stirred for 4 
h. At this temperature, the reaction mixture forms a pale yellow slurry which, after the reaction is 
done, turns bright yellow. The reaction was then cooled to 0 °C in an ice bath and carefully 
quenched with chilled water. The resulting mixture was extracted with CH2Cl2 (3 x 100 mL). 
The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. 
The crude product was immediately purified by column chromatography using basic alumina as 
the immobile phase (gradient elution 15:85 to 3:2 ethyl acetate/hexanes) to afford 117 as a white 
solid (1.8 g, 52%): 1H NMR (300 MHz, CD3OD) δ 7.78 (ddd, J = 1.2 Hz, 7.0 Hz, 8.3 Hz, 1H), 
7.89 (dd, J = 0.5 Hz, 8.4 Hz, 1H), 8.01 (ddd, J = 1.4 Hz, 6.9 Hz, 8.4 Hz, 1H), 8.19 (dd, J = 1.3 
Hz, 8.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 124.8, 128.0, 128.3, 129.5, 136.0, 145.7, 151.8, 
157.6; HRMS (EI) m/z calcd for C8H479Br2N2 (M+ − 2) 285.8741, found 285.8750; LRMS (EI) 
m/z 286 (M+ − 2, 55), 288 (M+, 85), 290 (M+ + 2, 54), 207 (100), 209 (100), 128 (75), 102 (75), 
75 (50). 
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 2-Bromoquinazolin-4(3H)-one (120): 
     
NH
N B
O
r
 
Aqueous NaOH (1 N, 37 mL, 37 mmol) was added to a solution of 117 (1.8 g, 6.1 mmol) in THF 
(12 mL) at room temperature and the reaction mixture was stirred for 2 h. The reaction mixture 
was then acidified (pH ~ 5) with glacial acetic acid and extracted with CH2Cl2 (3 x 40 mL). The 
combined organic extracts were concentrated under reduced pressure. Small amounts of water 
were azeotropically removed by coevaporation with MeOH to afford 120 as a tan solid (1.4 g, 
100%): 1H NMR (300 MHz, CD3OD) δ 7.46 (ddd, J = 1.1 Hz, 7.2 Hz, 8.1 Hz, 1H), 7.54 (d, J = 
8.1 Hz, 1H), 7.73 (ddd, J = 1.5 Hz, 7.1 Hz, 8.5 Hz, 1H), 8.13 (dd, J = 1.5 Hz, 8.0 Hz, 1H); 13C 
NMR (75 MHz, CD3SOCD3) δ 114.4, 115.5, 122.5, 127.0, 135.1, 141.0, 150.4, 163.0; IR 
(CH2Cl2, NaCl, cm-1) 3385, 2909, 2847, 1700, 1669, 1593, 1449, 1296; HRMS (EI) m/z calcd for 
C8H579BrN2O (M+ − 2) 223.9585, found 223.9582; LRMS (EI) m/z 224 (M+ − 2, 27), 226 (M+, 
27), 203 (37), 183 (10), 145 (60), 91 (47), 71 (100). Copies of spectral data can be found in the 
appendix section. 
 
General Procedure 6A: N-Propargylation of Quinazolinone 120. 
 NaH (95% in mineral oil) was added to a solution of 120 in DMF at 0 °C under argon. 
After stirring this mixture for 10 min at 0 °C, propargyl bromide (80% w/w in toluene) was then 
added via a syringe and the reaction mixture was stirred at room temperature for 6.5 h. The final 
solution was poured into brine (10 mL) and extracted with ethyl acetate (3 x 10 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
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 crude product was purified by flash chromatography (1:4 ethyl acetate/hexanes) to give N-
propargylated quinazolinones in good yields. 
 
2-Bromo-3-prop-2-ynylquinazolin-4(3H)-one (121): 
     
N
N B
O
r
 
Following general procedure 6A, 120 (0.11 g, 0.47 mmol) was reacted with propargyl bromide 
(62 µL, 0.56 mmol) in the presence of NaH (13 mg, 0.51 mmol) in DMF (2.3 mL) to give 121 as 
a pale yellow solid (81 mg, 66%): 1H NMR (300 MHz, CDCl3) δ 2.35 (t, J = 2.5 Hz, 1H), 5.08 
(d, J = 2.5 Hz, 2H), 7.50 (ddd, J = 1.2 Hz, 7.4 Hz, 8.1 Hz, 1H), 7.62 (dd, J = 0.6 Hz, 8.2 Hz, 1H), 
7.75 (ddd, J = 1.6 Hz, 7.2 Hz, 8.3 Hz, 1H), 8.24 (dd, J = 1.2 Hz, 8.0 Hz, 1H); 13C NMR (75 
MHz, CDCl3) δ 38.2, 72.9, 76.8, 120.3, 126.9, 127.4, 127.7, 134.6, 135.1, 147.0, 160.5; IR 
(CH2Cl2, NaCl, cm-1) 3267, 2980, 2361, 2125, 1690, 1577, 1557, 1332, 1152; HRMS (EI) m/z 
calcd for C11H7BrN2O (M+ − 1) 261.9742, found 261.9747; LRMS (EI) m/z 262 (M+ − 1, 46), 
262 (M+ + 1, 46), 183 (100), 155 (20), 129 (31), 102 (19), 63 (14). Copies of spectral data can be 
found in the appendix section. 
 
2-Bromo-3-{3-[tert-butyl(dimethyl)silyl]prop-2-ynyl}quinazolin-4(3H)-one (129{b}): 
     
N
N
O
TBS
Br
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 Following general procedure 6A, 120 (0.31 g, 1.4 mmol) was reacted with 3-tert-
butyldimethylsilyl propargyl bromide (0.38 g, 1.6 mmol) in the presence of NaH (38 mg, 1.5 
mmol) in DMF (6.8 mL) to give 129{b} as a tan solid (0.29 g, 56%): 1H NMR (300 MHz, 
CDCl3) δ 0.1 (s, 6H), 0.93 (s, 9H), 5.12 (s, 2H), 7.53 (ddd, J = 1.3 Hz, 7.1 Hz, 8.3 Hz, 1H), 7.65-
7.69 (m, 1H), 7.78 (ddd, J = 1.6 Hz, 7.1 Hz, 8.6 Hz, 1H), 8.27 (ddd, J = 0.6 Hz, 1.5 Hz, 8.0 Hz, 
1H); 13C NMR (75 MHz, CDCl3 + CD3SOCD3) δ −5.6, 15.5, 25.1, 29.7, 84.0, 100.0, 113.1, 
114.6, 121.7, 126.9, 134.1, 138.6, 149.1, 160.8; IR (CH2Cl2, NaCl, cm-1) 2924, 2852, 1721, 
1669, 1449, 1244, 1019. Copies of spectral data can be found in the appendix section. 
 
2-Bromo-3-pent-2-ynylquinazolin-4(3H)-one (129{c}): 
     
N
N
O
Br
 
Following general procedure 6A, 120 (0.32 g, 1.4 mmol) was reacted with 1-bromopent-2-yne 
(0.18 mL, 1.7 mmol) in the presence of NaH (39 mg, 1.6 mmol) in DMF (7.1 mL) to give 129{c} 
as a tan solid (0.23 g, 56%): 1H NMR (300 MHz, CDCl3) δ 1.11 (t, J = 7.5 Hz, 3H), 2.18 (tq, J = 
2.2 Hz, 7.5 Hz, 2H), 5.03 (t, J = 2.5 Hz, 2H), 7.49 (ddd, J = 1.2 Hz, 7.2 Hz, 8.1 Hz, 1H), 7.61 (d, 
J = 7.8 Hz, 1H), 7.74 (ddd, J = 1.5 Hz, 7.2 Hz, 8.4 Hz, 1H), 8.23 (dd, J = 1.3 Hz, 8.0 Hz, 1H); 
13C NMR (75 MHz, CDCl3 + CD3SOCD3) δ 11.7, 13.3, 29.6, 74.0, 83.0, 113.5, 115.1, 122.1, 
127.2, 134.5, 139.1, 149.4, 161.1; IR (CH2Cl2, NaCl, cm-1) 3042, 2899, 1721, 1659, 1629, 1454, 
1342, 1142; HRMS (EI) m/z calcd for C13H1179BrN2O (M – 1) 290.0055, found 290.0065; LRMS 
(EI) m/z 290 (M+ − 1, 12), 290 (M+ + 1, 12), 277 (M+ − 1, 46), 277 (M+ + 1, 46), 213 (100), 146 
(47), 119 (25). Copies of spectral data can be found in the appendix section. 
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 2-Bromo-3-[5-(trimethylsilyl)pent-2-ynyl]quinazolin-4(3H)-one (129{d}): 
     
N
N
O
Br
TMS  
Following general procedure 6A, 120 (0.12 g, 0.54 mmol) was reacted with 5-trimethylsilyl 
propargyl bromide (0.14 g, 0.65 mmol) in the presence of NaH (15 mg, 0.60 mmol) in DMF (2.7 
mL) to give 129{d} as a pale yellow solid (0.10 g, 54%): 1H NMR (300 MHz, CDCl3) δ −0.02 (s, 
9H), 0.77 (t, J = 8.1 Hz, 2H), 2.21 (tt, J = 2.2 Hz, 7.9 Hz, 2H), 5.05 (t, J = 2.1 Hz, 2H), 7.50 (dt, 
J = 1.0 Hz, 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.75 (dt, J = 1.5 Hz, 8.3 Hz, 1H), 8.26 (dd, J = 
1.4 Hz, 8.0 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ −1.8, 13.3, 15.8, 30.7, 73.5, 85.1, 114.6, 
115.2, 123.5, 128.5, 135.1, 138.4, 151.4, 161.6; IR (CH2Cl2, NaCl, cm-1) 3057, 2950, 2909, 
1726, 1664, 1618, 1449, 1270, 1239. Copies of spectral data can be found in the appendix 
section. 
 
General procedure 6B: Radical Cascade Cyclization towards the Synthesis of Luotonins. 
A solution of N-propargylated quinazolinone in benzene was taken up in a 15 x 45 mm 
cylindrical screw-cap glass vial and kept at room temperature. The appropriate isonitrile 
followed by hexamethylditin were added at room temperature. The vial was capped and the 
reaction mixture was irradiated with a 275W GE sunlamp for 8 h. The solvent was then 
evaporated and the residue was purified by column chromatography (1:9 
acetone/dichloromethane or 1:9 ethyl acetate/dichloromethane) to give luotonins as pale yellow 
to tan solids. 
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 LC-MS analysis: All the luotonins were analyzed by LCMS using XTerra C18 analytical 
column at the wavelength of 254 nm under the following conditions: 5 µL injection in CH2Cl2, 
gradient CH3CN/H2O (25:75) to CH3CN/H2O (100:0) for 30 min, then isocratic CH3CN (100%) 
for 10 min at the rate of 0.4 mL/min. The peaks were detected by ESI-MS for the corresponding 
m/z ratios. 
 
Luotonin A (122): 
    
N
N
N
O
 
Following general procedure 6B, quinazolinone 121 (35 mg, 0.13 mmol) was reacted with 
phenyl isonitrile (1 M in benzene, 0.66 mL, 0.66 mmol) and hexamethylditin (77 µL, 0.20 mmol) 
in benzene (2.2 mL) to afford 122 (18 mg, 47%): 1H NMR (300 MHz, CDCl3) δ 5.37 (s, 2H), 
7.60 (dt, J = 1.1 Hz, 8.0 Hz, 1H), 7.71 (ddd, J = 1.1 Hz, 7.0 Hz, 8.1 Hz, 1H), 7.87 (dt, J = 1.3 Hz, 
7.1 Hz, 2H), 7.98 (d, J = 7.7 Hz, 1H), 8.14 (d, J = 8.1 Hz, 1H), 8.47 (t, J = 8.0 Hz, 2H), 8.48 (s, 
1H); 13C NMR (75 MHz, CDCl3) δ 47.3, 121.3, 126.4, 127.4, 128.0, 128.5, 128.8, 129.4, 130.7, 
131.6, 134.6, 149.3, 149.4, 151.1, 152.5, 160.7; IR (CH2Cl2, NaCl, cm-1) 2919, 2842, 2351, 
2335, 1669, 1623, 1454; HRMS (EI) m/z calcd for C18H11N3O (M+) 285.0902, found 285.0900; 
LRMS (EI) m/z 285 (M+, 50), 218 (47), 200 (100), 184 (20), 146 (69), 119 (45), 92 (43); LCMS 
[Rt = 13.5 min; 286 (M + H)]. Copies of 1H NMR spectrum and LCMS data can be found in the 
appendix section. 
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 8-Ethylluotonin A (130{c, 1}): 
    
N
N
N
O
 
Following general procedure 6B, quinazolinone 129{c} (13 mg, 0.043 mmol) was reacted with 
phenyl isonitrile (1 M in benzene, 0.26 mL, 0.26 mmol) and hexamethylditin (25 µL, 0.064 
mmol) in benzene (0.72 mL) to afford 130{c, 1} (9.2 mg, 68%): 1H NMR (300 MHz, CDCl3) δ 
1.47 (t, J = 7.7 Hz, 3H), 3.28 (q, J = 7.7 Hz, 2H), 5.34 (s, 2H), 7.60 (t, J = 7.1 Hz, 1H), 7.74 (dd, 
J = 5.5 Hz, 7.1 Hz, 1H), 7.83-7.90 (m, 2H), 8.13 (t, J = 8.3 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 
8.46 (dd, J = 1.9 Hz, 8.1 Hz, 1H), 8.51 (d, J = 8.6 Hz, 1H); LCMS [Rt = 16.8 min; 314 (M + H)]. 
 
10-Fluoroluotonin A (130{a, 2}): 
    
N
N
N
OF
 
Following general procedure 6B, quinazolinone 121 (12 mg, 0.046 mmol) was reacted with p-
fluorophenyl isonitrile (1 M in benzene, 0.23 mL, 0.23 mmol) and hexamethylditin (26 µL, 
0.068 mmol) in benzene (0.76 mL) to afford 130{a, 2} (9.0 mg, 65%): 1H NMR (300 MHz, 
CDCl3) δ 5.37 (s, 2H), 7.57-7.66 (m, 3H), 7.88 (ddd, J = 1.6 Hz, 7.2 Hz, 8.6 Hz, 1H), 8.13 (d, J 
= 8.3 Hz, 1H), 8.43-8.53 (m, 3H); LCMS [Rt = 14.6 min; 304 (M + H)]. 
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 8-Ethyl-10-fluoroluotonin A (130{c, 2}): 
    
N
N
N
OF
 
Following general procedure 6B, quinazolinone 129{c} (15 mg, 0.050 mmol) was reacted with p-
fluorophenyl isonitrile (1 M in benzene, 0.25 mL, 0.25 mmol) and hexamethylditin (29 µL, 
0.075 mmol) in benzene (0.84 mL) to afford 130{c, 2} (13 mg, 75%): 1H NMR (300 MHz, 
CDCl3) δ 1.45 (t, J = 7.6 Hz, 3H), 3.21 (q, J = 7.7 Hz, 2H), 5.33 (s, 2H), 7.57-7.65 (m, 2H), 7.76 
(dd, J = 2.7 Hz, 9.9 Hz, 1H), 7.87 (dt, J = 1.5 Hz, 8.6 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 8.45 (dd, 
J = 1.2 Hz, 8.0 Hz, 1H), 8.50 (dd, J = 5.6 Hz, 9.3 Hz, 1H); LCMS [Rt = 17.6 min; 332 (M + H)]. 
Copies of 1H NMR spectrum and LCMS data can be found in the appendix section. 
 
10-Trifluoromethylluotonin A (130{a, 3}): 
    
N
N
N
OF3C
 
Following general procedure 6B, quinazolinone 121 (11 mg, 0.043 mmol) was reacted with p-
trifluoromethylphenyl isonitrile (1 M in benzene, 0.22 mL, 0.22 mmol) and hexamethylditin (25 
µL, 0.065 mmol) in benzene (0.72 mL) to afford 130{a, 3} (11 mg, 71%): 1H NMR (300 MHz, 
CDCl3) δ 5.41 (s, 2H), 7.62 (t, J = 7.2 Hz, 1H), 7.89 (dt, J = 1.4 Hz, 8.4 Hz, 1H), 8.03 (dd, J = 
1.8 Hz, 8.9 Hz, 1H), 8.14 (d, J = 8.1 Hz, 1H), 8.30 (s, 1H), 8.46 (dd, J = 1.3 Hz, 8.0 Hz, 1H), 
8.58 (s, 1H), 8.61 (d, J = 9.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 47.3, 121.4, 125.4, 126.4, 
126.5, 127.7, 127.9, 128.9, 130.6, 131.9, 132.7, 135.0, 149.2, 150.3, 152.0, 153.5, 160.5; IR 
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 (CH2Cl2, NaCl, cm-1) 2914, 2842, 2351, 1680, 1629, 1362, 1280, 1122; HRMS (EI) m/z calcd for 
C19H10F3N3O (M+) 353.0776, found 353.0779; LRMS (EI) m/z 353 (M+, 100), 325 (10), 284 (8), 
140 (6), 77(25); LCMS [Rt = 17.9 min; 354 (M + H)]. Copies of 1H NMR spectrum and LCMS 
data can be found in the appendix section. 
 
8-Ethyl-10-trifluoromethylluotonin A (130{c, 3}): 
    
N
N
N
OF3C
 
Following general procedure 6B, quinazolinone 129{c} (13 mg, 0.045 mmol) was reacted with p-
trifluoromethylphenyl isonitrile (1 M in benzene, 0.23 mL, 0.23 mmol) and hexamethylditin (26 
µL, 0.068 mmol) in benzene (0.76 mL) to afford 130{c, 3} (11 mg, 62%): 1H NMR (300 MHz, 
CDCl3) δ 1.49 (t, J = 7.7 Hz, 3H), 3.32 (q, J = 7.7 Hz, 2H), 5.37 (s, 2H), 7.63 (t, J = 8.0 Hz, 1H), 
7.89 (dt, J = 1.5 Hz, 8.3 Hz, 1H), 8.02 (dd, J = 1.8 Hz, 8.9 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 
8.46 (s, 1H), 8.47 (dd, J = 1.5 Hz, 7.9 Hz, 1H), 8.62 (d, J = 8.8 Hz, 1H); LCMS [Rt = 20.4 min; 
382 (M + H)]. 
 
10-Methylluotonin A (130{a, 4}): 
    
N
N
N
OH3C
 
Following general procedure 6B, quinazolinone 121 (11 mg, 0.041 mmol) was reacted with p-
methylphenyl isonitrile (1 M in benzene, 0.21 mL, 0.21 mmol) and hexamethylditin (24 µL, 
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 0.062 mmol) in benzene (0.68 mL) to afford 130{a, 4} (7.0 mg, 57%): 1H NMR (300 MHz, 
CDCl3) δ 3.05 (s, 3H), 5.36 (s, 2H), 7.57-7.63 (m, 2H), 7.72 (d, J = 7.0 Hz, 1H), 7.82 (d, J = 8.2 
Hz, 1H), 7.87 (dt, J = 1.4 Hz, 8.4 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.44-8.47 (m, 2H); 13C NMR 
(75 MHz, CDCl3) δ 20.1, 50.7, 129.5, 134.5, 135.0, 136.0, 137.1, 137.5, 137.6, 137.7, 138.0, 
139.6, 140.6, 143.5, 148.5, 159.4; IR (CH2Cl2, NaCl, cm-1) 3272, 2919, 2852, 1680, 1629, 1598, 
1460, 1311, 1096; HRMS (EI) m/z calcd for C19H13N3O (M+) 299.1059, found 299.1053; LRMS 
(EI) m/z 299 (M+, 100), 150 (6), 77 (5); LCMS [Rt = 16.8 min; 300 (M + H)]. Copies of 1H 
NMR spectrum and LCMS data can be found in the appendix section. 
 
8-Ethyl-10-methylluotonin A (130{c, 4}): 
    
N
N
N
OH3C
 
Following general procedure 6B, quinazolinone 129{c} (11 mg, 0.037 mmol) was reacted with p-
methylphenyl isonitrile (1 M in benzene, 0.18 mL, 0.18 mmol) and hexamethylditin (21 µL, 
0.055 mmol) in benzene (0.61 mL) to afford 130{c, 4} (4.0 mg, 33%): 1H NMR (300 MHz, 
CDCl3) δ 1.45 (t, J = 7.6 Hz, 3H), 3.05 (s, 3H), 3.25 (q, J = 7.7 Hz, 2H), 5.32 (s, 2H), 7.55-7.64 
(m, 2H), 7.70 (d, J = 5.8 Hz, 1H), 7.87 (ddd, J = 1.5 Hz, 7.1 Hz, 8.4 Hz, 1H), 8.03 (d, J = 8.3 Hz, 
1H), 8.10 (d, J = 8.3 Hz, 1H), 8.46 (dd, J = 1.2 Hz, 7.9 Hz, 1H); LCMS [Rt = 20.0 min; 328 (M 
+ H)]. 
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 10-Methoxyluotonin A (130{a, 5}): 
    
N
N
N
OMeO
 
Following general procedure 6B, quinazolinone 121 (12 mg, 0.046 mmol) was reacted with p-
methoxyphenyl isonitrile (1 M in benzene, 0.23 mL, 0.23 mmol) and hexamethylditin (26 µL, 
0.068 mmol) in benzene (0.76 mL) to afford 130{a, 5} (9.1 mg, 63%): 1H NMR (300 MHz, 
CDCl3) δ 4.00 (s, 3H), 5.34 (s, 2H), 7.20 (d, J = 2.6 Hz, 3H), 7.51 (dd, J = 2.7 Hz, 9.4 Hz, 1H), 
7.58 (t, J = 7.9 Hz, 1H), 7.85 (dt, J = 1.4 Hz, 8.3 Hz, 1H), 8.11 (d, J = 8.3 Hz, 1H), 8.33 (s, 1H), 
8.38 (d, J = 9.4 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H); LCMS [Rt = 14.3 min; 316 (M + H)]. 
 
8-Ethyl-10-methoxyluotonin A (130{c, 5}): 
    
N
N
N
OMeO
 
Following general procedure 6B, quinazolinone 129{c} (14 mg, 0.048 mmol) was reacted with p-
methoxyphenyl isonitrile (1 M in benzene, 0.24 mL, 0.24 mmol) and hexamethylditin (30 µL, 
0.072 mmol) in benzene (0.80 mL) to afford 130{c, 5} (14 mg, 86%): 1H NMR (300 MHz, 
CDCl3) δ 1.44 (t, J = 7.7 Hz, 3H), 3.19 (q, J = 7.7 Hz, 2H), 4.00 (s, 3H), 5.27 (s, 2H), 7.31 (d, J 
= 2.6 Hz, 1H), 7.49 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.56 (dt, J = 1.1 Hz, 8.1 Hz, 1H), 7.85 (ddd, J = 
1.5 Hz, 7.2 Hz, 8.5 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 8.37 (d, J = 9.3 Hz, 1H), 8.42 (dd, J = 1.3 
Hz, 8.0 Hz, 1H); LCMS [Rt = 17.6 min; 344 (M + H)]. 
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 8-Trimethylsilylethyl-10-methoxyluotonin A (130{d, 5}): 
    
N
N
N
OMeO
TMS
 
Following general procedure 6B, quinazolinone 129{d} (12 mg, 0.033 mmol) was reacted with 
p-methoxyphenyl isonitrile (1 M in benzene, 0.16 mL, 0.16 mmol) and hexamethylditin (19 µL, 
0.050 mmol) in benzene (0.55 mL) to afford 130{d, 5} (10 mg, 74%): 1H NMR (300 MHz, 
CDCl3) δ 0.21 (s, 9H), 0.95-1.01 (m, 2H), 3.07-3.13 (m, 2H), 4.00 (s, 3H), 5.28 (s, 2H), 7.35 (d, 
J = 2.6 Hz, 1H), 7.50 (dt, J = 2.8 Hz, 9.3 Hz, 1H), 7.58 (dt, J = 1.0 Hz, 8.0 Hz, 1H), 7.85 (ddd, J 
= 1.5 Hz, 7.2 Hz, 8.5 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.38 (dd, J = 3.3 Hz, 9.3 Hz, 1H), 8.45 
(d, J = 8.0 Hz, 1H); LCMS [Rt = 25.3 min; 416 (M + H)]. 
 
10-Acetoxyluotonin A (130{a, 6}): 
    
N
N
N
OAcO
 
Following general procedure 6B, quinazolinone 121 (15 mg, 0.056 mmol) was reacted with p-
acetoxyphenyl isonitrile (1 M in benzene, 0.34 mL, 0.34 mmol) and hexamethylditin (33 µL, 
0.084 mmol) in benzene (0.94 mL) to afford 130{a, 6} (12 mg, 62%): 1H NMR (300 MHz, 
CDCl3) δ 2.42 (s, 3H), 5.37 (s, 2H), 7.58-7.63 (m, 2H), 7.76 (d, J = 2.5 Hz, 1H), 7.88 (ddd, J = 
1.5 Hz, 7.2 Hz, 8.5 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 8.44 (s, 1H), 8.46 (dd, J = 1.3 Hz, 8.0 Hz, 
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 1H), 8.51 (d, J = 9.2 Hz, 1H); LCMS [Rt = 13.6 min; 344 (M + H)]. Copies of 1H NMR 
spectrum and LCMS data can be found in the appendix section. 
 
10-Acetoxy-8-ethylluotonin A (130{c, 6}): 
    
N
N
N
OAcO
 
Following general procedure 6B, quinazolinone 129{c} (14 mg, 0.047 mmol) was reacted with p-
acetoxyphenyl isonitrile (1 M in benzene, 0.28 mL, 0.28 mmol) and hexamethylditin (27 µL, 
0.070 mmol) in benzene (0.78 mL) to afford 130{c, 6} (6.7 mg, 39%): 1H NMR (300 MHz, 
CDCl3) δ 1.45 (t, J = 7.6 Hz, 3H), 2.43 (s, 3H), 3.22 (d, J = 7.6 Hz, 2H), 5.33 (s, 2H), 7.57-7.62 
(m, 2H), 7.84-7.90 (m, 2H), 8.13 (d, J = 8.2 Hz, 1H), 8.46 (dd, J = 1.3 Hz, 8.0 Hz, 1H), 8.51 (d, J 
= 9.2 Hz, 1H); LCMS [Rt = 16.2 min; 372 (M + H)]. Copies of 1H NMR spectrum and LCMS 
data can be found in the appendix section. 
 
10-tert-Butyloxycarbonylaminoluotonin A (130{a, 7}): 
    
N
N
N
OBocHN
 
Following general procedure 6B, quinazolinone 121 (16 mg, 0.059 mmol) was reacted with p-
tert-butyloxycarbonylaminophenyl isonitrile (65 mg, 0.30 mmol) and hexamethylditin (34 µL, 
0.089 mmol) in benzene (0.99 mL) to afford 130{a, 7} (12 mg, 52%): 1H NMR (300 MHz, 
CDCl3) δ 1.59 (s, 9H), 5.34 (s, 2H), 6.83 (br s, 1H), 7.54-7.61 (m, 2H), 7.86 (dt, J = 1.5 Hz, 8.5 
154 
 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.31-8.40 (m, 3H), 8.45 (d, J = 7.9 Hz, 1H); LCMS [Rt = 18.1 
min; 401 (M + H)]. Copies of 1H NMR spectrum and LCMS data can be found in the appendix 
section. 
 
8-tert-Butyldimethylsilyl-10-tert-butyloxycarbonylaminoluotonin A (130{b, 7}): 
    
N
N
N
OBocHN
TBS
 
Following general procedure 6B, quinazolinone 129{b} (13 mg, 0.033 mmol) was reacted with 
p-tert-butyloxycarbonylaminophenyl isonitrile (36 mg, 0.17 mmol) and hexamethylditin (20 µL, 
0.050 mmol) in benzene (0.56 mL) to afford 130{b, 7} (5.3 mg, 31%): 1H NMR (300 MHz, 
CDCl3) δ 0.77 (s, 6H), 1.03 (s, 9H), 1.58 (s, 9H), 5.36 (s, 2H), 6.73 (br s, 1H), 7.47 (dd, J = 2.2 
Hz, 9.0 Hz, 1H), 7.57 (t, J = 7.2 Hz, 1H), 7.85 (dt, J = 1.4 Hz, 8.4 Hz, 1H), 8.12 (d, J = 8.1 Hz, 
1H), 8.38 (d, J = 9.1 Hz, 1H), 8.45 (dd, J = 1.3 Hz, 8.0 Hz, 1H), 8.78 (d, J = 1.5 Hz, 1H); LCMS 
[Rt = 28.1 min; 515 (M + H)]. Copies of 1H NMR spectrum and LCMS data can be found in the 
appendix section. 
 
10-tert-Butyloxycarbonylamino-8-ethylluotonin A (130{c, 7}): 
    
N
N
N
OBocHN
 
Following general procedure 6B, quinazolinone 129{c} (12 mg, 0.041 mmol) was reacted with p-
tert-butyloxycarbonylaminophenyl isonitrile (45 mg, 0.21 mmol) and hexamethylditin (24 µL, 
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 0.062 mmol) in benzene (0.69 mL) to afford 130{c, 7} (17 mg, 94%): 1H NMR (300 MHz, 
CDCl3) δ 1.46 (t, J = 7.6 Hz, 3H), 1.59 (s, 9H), 3.23 (d, J = 7.4 Hz, 2H), 5.31 (s, 2H), 6.83 (br s, 
1H), 7.58-7.62 (m, 2H), 7.86 (dt, J = 1.5 Hz, 8.4 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.38-8.47 (m, 
3H); LCMS [Rt = 20.5 min; 429 (M + H)]. 
 
10-tert-Butyloxycarbonylamino-8-trimethylsilylethylluotonin A (130{d, 7}): 
    
N
N
N
OBocHN
TMS
 
Following general procedure 6B, quinazolinone 129{d} (21 mg, 0.056 mmol) was reacted with 
p-tert-butyloxycarbonylaminophenyl isonitrile (62 mg, 0.28 mmol) and hexamethylditin (33 µL, 
0.085 mmol) in benzene (0.94 mL) to afford 130{d, 7} (10 mg, 37%): 1H NMR (300 MHz, 
CDCl3) δ 0.22 (s, 9H), 0.95-1.01 (m, 2H), 1.58 (s, 9H), 3.09-3.15 (m, 2H), 5.28 (s, 2H), 6.80 (br 
s, 1H), 7.55-7.62 (m, 2H), 7.85 (dt, J = 1.4 Hz, 8.4 Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 8.36-8.40 
(m, 2H), 8.44 (dd, J = 1.4 Hz, 8.0 Hz, 1H); LCMS [Rt = 27.9 min; 501 (M + H)]. Copies of 1H 
NMR spectrum and LCMS data can be found in the appendix section. 
 
8-Ethyl-9,10-ethylenedioxyluotonin A and 8-Ethyl-10,11-ethylenedioxyluotonin A (130{c, 
8}): 
Following general procedure 6B, quinazolinone 129{c} (18 mg, 0.063 mmol) was reacted with 
3,4-ethylenedioxyphenyl isonitrile (50 mg, 0.31 mmol) and hexamethylditin (36 µL, 0.094 
mmol) in benzene (1.0 mL) to afford a 2.5:1 mixture of 9,10- and 10,11-ethylenedioxy isomers 
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 130{c, 8} (20 mg, 86%) which was separated using HPLC with a semipreparative column under 
the same conditions as described in the general procedure 6B: 
    
N
N
N
O
O
O
 
1H NMR (300 MHz, CDCl3) δ 1.39 (t, J = 7.3 Hz, 3H), 3.39 (q, J = 7.4 Hz, 2H), 4.45 (s, 4H), 
5.29 (s, 2H), 7.41 (d, J = 9.2 Hz, 1H), 7.57 (t, J = 7.2 Hz, 1H), 7.84 (dt, J = 1.3 Hz, 8.4 Hz, 1H), 
8.02 (d, J = 9.2 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 8.43 (d, J = 7.9 Hz, 1H); LCMS [Rt = 17.1 
min; 372 (M + H)]. 
    
N
N
N
OO
O
 
1H NMR (300 MHz, CDCl3) δ 1.41 (t, J = 7.6 Hz, 3H), 3.14 (q, J = 7.6 Hz, 2H), 4.45 (s, 4H), 
5.26 (s, 2H), 7.51 (s, 1H), 7.57 (t, J = 7.3 Hz, 1H), 7.85 (dt, J = 1.4 Hz, 8.5 Hz, 1H), 7.91 (s, 1H), 
8.10 (d, J = 8.2 Hz, 1H), 8.43 (dd, J = 1.2 Hz, 7.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 13.9, 
22.9, 46.6, 64.5, 108.0, 109.5, 116.0, 121.2, 124.1, 126.2, 126.4, 127.1, 128.6, 134.5, 146.7, 
149.5, 150.1, 160.8; IR (CH2Cl2, NaCl, cm-1) 2919, 2873, 2361, 2340, 1675, 1618, 1501, 1460, 
1285, 1060; HRMS (EI) m/z calcd for C22H17N3O3 (M+) 371.1270, found 371.1267; LRMS (EI) 
m/z 371 (M+, 100), 342 (20), 177 (26), 105 (43), 77 (58); LCMS [Rt = 17.1 min; 372 (M + H)]. 
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 9,10-Ethylenedioxy-8-trimethylsilylethylluotonin A and 10,11-Ethylenedioxy-8-
trimethylsilylethylluotonin A (130{d, 8}): 
Following general procedure 6B, quinazolinone 129{d} (15 mg, 0.041 mmol) was reacted with 
3,4-ethylenedioxyphenyl isonitrile (33 mg, 0.21 mmol) and hexamethylditin (24 µL, 0.062 
mmol) in benzene (0.69 mL) to afford a 1:1 mixture of 9,10- and 10,11-ethylenedioxy isomers 
130{d, 8} (17 mg, 94%) which was separated using HPLC with a semipreparative column under 
the same conditions as described in the general procedure 6B: 
    
N
N
N
O
O
O
TMS
 
1H NMR (300 MHz, CDCl3) δ 0.16 (s, 9H), 0.91-0.97 (m, 2H), 3.29-3.34 (m, 2H), 4.44 (s, 4H), 
5.26 (s, 2H), 7.41 (d, J = 9.2 Hz, 1H), 7.57 (dt, J = 0.7 Hz, 7.0 Hz, 1H), 7.85 (ddd, J = 1.5 Hz, 
7.4 Hz, 8.4 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 8.10 (d, J = 8.1 Hz, 1H), 8.45 (dd, J = 1.2 Hz, 7.9 
Hz, 1H); LCMS [Rt = 25.7 min; 444 (M + H)]. 
    
N
N
N
OO
O
TMS
 
1H NMR (300 MHz, CDCl3) δ 0.19 (s, 9H), 0.91-0.97 (m, 2H), 3.01-3.07 (m, 2H), 4.45 (s, 4H), 
5.24 (s, 2H), 7.43 (s, 1H), 7.57 (dt, J = 1.1 Hz, 8.0 Hz, 1H), 7.85 (dt, J = 1.4 Hz, 8.5 Hz, 1H), 
7.91 (s, 1H), 8.11 (d, J = 8.3 Hz, 1H), 8.44 (dd, J = 1.2 Hz, 8.0 Hz, 1H); LCMS [Rt = 24.7 min; 
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 444 (M + H)]. Copies of 1H NMR spectrum and LCMS data can be found in the appendix 
section. 
 
10-Amino-8-trimethylsilylethylluotonin A (132{d}): 
    
N
N
N
OH2N
TMS
 
TFA (0.30 mL) was added to a solution of 130{d, 7} (5.0 mg, 0.010 mmol) in CH2Cl2 (0.60 mL) 
at room temperature. After stirring for 12 h, the reaction mixture was concentrated under reduced 
pressure and the residue was purified by flash column chromatography (1:9 
acetone/dichloromethane) to afford 132{d} as a light brown solid (3.4 mg, 85%): 1H NMR (300 
MHz, CDCl3) δ 0.19 (s, 9H), 0.92-0.98 (m, 2H), 2.99-3.05 (m, 2H), 4.22 (br s, 2H), 5.23 (s, 2H), 
7.05 (d, J = 2.4 Hz, 1H), 7.23-7.24 (m, 1H), 7.56 (t, J = 7.5 Hz, 1H), 7.84 (dt, J = 1.3 Hz, 8.3 Hz, 
1H), 8.09 (d, J = 8.1 Hz, 1H), 8.28 (d, J = 9.0 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H); LCMS [Rt = 
20.9 min; 401 (M + H)]. 
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 Figure A-1: 1H and 13C NMR spectra of compound 33a 
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 Figure A-2: 1H and 13C NMR spectra of compound (R)-19 
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 Figure A-3: 1H and 13C NMR spectra of compound “esterified 87” 
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 Figure A-4: 1H and 13C NMR spectra of compound 91a 
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 Figure A-5: 1H and 13C NMR spectra of compound 91b 
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 Figure A-6: 1H and 13C NMR spectra of compound 94a 
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 Figure A-7: 1H and 13C NMR spectra of compound 94b 
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 Figure A-8: 1H and 13C NMR spectra of compound 92a 
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 Figure A-9: 1H and 13C NMR spectra of compound 92d 
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 Figure A-10: 1H and 13C NMR spectra of compound 95a 
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 Figure A-11: 1H and 13C NMR spectra of compound 95d 
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 Figure A-12: 1H and 13C NMR spectra of compound 96 
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 Figure A-13: 1H and 13C NMR spectra of compound 99 
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 Figure A-14: 1H and 13C NMR spectra of compound 102 
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 Figure A-15: 1H and 13C NMR spectra of compound (S)-116 
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 Figure A-16: 1H and 13C NMR spectra of compound (S)-109 
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Figure A-17: 1H and 13C NMR spectra of compound (R)-107 
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 Figure A-18: HMBC spectrum of compound (R)-107 
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Figure A-19: 1H NMR spectra of compounds 111b and 111c 
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 Figure A-20: 1H and 13C NMR spectra of compound 121 
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 Figure A-21: 1H and 13C NMR spectra of compound 120 
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 Figure A-22: 1H and 13C NMR spectra of compound 129{b} 
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 Figure A-23: 1H and 13C NMR spectra of compound 129{c} 
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 Figure A-24: 1H and 13C NMR spectra of compound 129{d} 
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Figure A-25: 1H spectrum of compound 122 
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 Figure A-26: LCMS data of compound 122 
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 Figure A-27: 1H spectrum of compound 130{c,2} 
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 Figure A-28: LCMS data of compound 130{c,2} 
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 Figure A-29: 1H spectrum of compound 130{a,3} 
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 Figure A-30: LCMS data of compound 130{a,3} 
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 Figure A-31: 1H spectrum of compound 130{a,4} 
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 Figure A-32: LCMS data of compound 130{a,4} 
 
N
N
N
OMe
 
 
 
192 
 Figure A-33: 1H spectrum of compound 130{a,6} 
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 Figure A-34: LCMS data of compound 130{a,6} 
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 Figure A-35: 1H spectrum of compound 130{c,6} 
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 Figure A-36: LCMS data of compound 130{c,6} 
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 Figure A-37: 1H spectrum of compound 130{a,7} 
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 Figure A-38: LCMS data of compound 130{a,7} 
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 Figure A-39: 1H spectrum of compound 130{b,7} 
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 Figure A-40: LCMS data of compound 130{b,7} 
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 Figure A-41: 1H spectrum of compound 130{d,7} 
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 Figure A-42: LCMS data of compound 130{d,7} 
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 Figure A-43: 1H spectrum of compound 130{d,8} (9,10 isomer) 
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 Figure A-44: LCMS data of compound 130{d,8} (9,10 isomer) 
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Figure A-45: 1H spectrum of compound 130{d,8} (10,11 isomer) 
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 Figure A-46: LCMS data of compound 130{d,8} (10,11 isomer) 
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